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General introduction

Introduction 9
1. WhaT iS PhOTOdynaMiC ThEraPy?
Photodynamic therapy (PDT) is based on a photochemical reaction that involves three 
basic components: (1) a photosensitizer, which is a light-sensitive molecule that medi-
ates transfer of light energy to molecular oxygen; (2) light of the appropriate wavelength 
that is absorbed by the photosensitizer, and (3) molecular oxygen. These components 
interact with each other and with the surrounding tissue, creating the photodynamic 
effect. The photodynamic processes are based on quantum mechanical principles that 
are described below and schematically illustrated in figure 1.
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Figure 1. Quantum mechanical principles of PDT. The photosensitizer (PS) is excited by absorption of light 
energy. The excess energy is then released in various ways that include emission of fluorescent light and 
energy transfer to oxygen. This results predominantly in formation of the highly reactive singlet oxygen.
1.1. Quantum mechanics of PdT
Light is part of the electromagnetic spectrum and can be considered both as an elec-
tromagnetic wave and as consisting of separate particles of energy, called photons. The 
interaction between photons and molecules such as photosensitizers depends on the 
energy of the photon and the specific light absorption characteristics of the photosen-
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sitizer. A photon can interact with the electronic structure of the photosensitizer and 
transfer its energy to the photosensitizer. The photosensitizer is transformed from its 
stable, low-energy ground state to a higher energy singlet state. This singlet state is 
unstable and the photosensitizer transfers its excess energy back to the environment. 
Some of the energy is released as heat in a process termed internal conversion. Two 
other de-excitation pathways are possible: an electron returns to its ground state ac-
companied by the emission of a lower energy photon, termed fluorescence. Or energy 
is transferred in a process that involves electronic spin conversion, leading to formation 
of a triplet state photosensitizer. This triplet state is more stable than the singlet state, 
and has a longer lifetime but still loses its energy to the environment. This can occur in 
a similar way to fluorescence via the emission of a phosphorescent photon. This is an 
unfavourable spin forbidden transition and means that the triplet state is able to inter-
act with other molecules in the environment of the photosensitizer. Two triplet state 
interactions predominate and are termed type I and type II reactions. Type I reactions 
involve direct electron or hydrogen transfers with surrounding molecules, resulting in 
formation of free radicals or radical ions, which subsequently can react with oxygen to 
form several reactive oxygen species. Type II reactions are more likely to happen than 
type I reactions, and involve energy transfer between the photosensitizer triplet state 
and nearby oxygen to form singlet oxygen, which is highly reactive and causes damage 
to surrounding biomolecules.
Type I and II reactions result in photodynamic damage to cellular structures that can be 
used to destroy specific cells such as tumour cells. An important aspect of PDT is that sin-
glet oxygen has a short lifetime (~30-180 ns 1) and thus only damages molecules that are 
very close to the photosensitizer (within a distance of 10-55 nm 2). One of the molecules 
that is very close to site of the generation of singlet oxygen is the photosensitizer itself 
which, as a result, is also destroyed. This process termed photobleaching is important 
because it means that the amount of fluorescence from the photosensitizer can be used 
as an indirect measure for singlet oxygen formation and thus for PDT effect. The cellular 
distribution of photosensitizers and their distribution in tissue are critical factors related 
to the effectiveness of PDT. The topics of distribution of the photosensitizer in tissue and 
the use of fluorescence measurements to monitor the PDT process are important topics 
that will be explained in more detail. First the potential usefulness of PDT in general are 
introduced, followed by its specific use in dermatology.
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2. aPPliCaTiOnS OF PdT
The possible applications for PDT are widespread within and outside of medicine. For 
instance it can be used to kill micro-organisms without inducing resistance 3, which is an 
increasing problem with the widespread use of antibiotics. Contrary to antibiotics, PDT 
incorporates a physical way of inducing cell death: singlet oxygen formation that can-
not be circumvented by a biological mechanism. Such a PDT application could be very 
interesting for sterilization purposes such as water sterilisation 4 or to destroy bacterial 
biofilms 5. There are also attempts to use PDT to kill arthropods that pose a considerable 
health problem in certain areas of the world 6.
The main application of PDT is as a medical treatment. A general positive feature of PDT 
is its selectivity to the site where the light is applied, limiting systemic side effects. It can 
theoretically be used in any organ and for any cell type in the body, as long as they are 
accessible for light delivery. Since the dominant effect of PDT is photodynamic damage, 
its primary use is focused on destruction of diseased tissues. The typical case for this is 
cancer and examples that are being treated using PDT are cancers in the head and neck 
7, brain 8, gastrointestinal tract 9, urological tract, 10 and in the skin 11. Also non-malignant 
tissues can be targeted such as for instance the vasculature in age related macular 
degeneration or choroidal neovascularisation 12. This thesis will only focus on the use of 
PDT in the skin, the organ in which there is the most and highest level of evidence for 
its effectiveness 13.
3. PdT in dErMaTOlOgy uSing POrPhyrin PrECurSOrS
3.1. PdT applications
In dermatology, PDT is primarily used to treat actinic keratosis, superficial basal cell 
carcinoma and Bowen’s disease. Although PDT is one of several possible treatment 
options for these conditions, this thesis will only focus on PDT and does not concern 
comparing these different treatment options. Other, off-label applications for PDT are 
Paget’s disease, mycosis fungoides acne, psoriasis, lichen sclerosus, common warts and 
more 11, 14-16.
3.2. Porphyrin precursors and PpiX synthesis
In the vast majority of cases skin PDT involves topical application of a vehicle (i.e. a 
cream, gel or ointment) that contains porphyrin precursor molecules. Aminolevulinic 
acid (ALA), its methyl ester methylaminolevulinate (MAL) and its hexyl ester hexylami-
nolevulinate (HAL) are all three precursor drugs of the photosensitizer PpIX. ALA and 
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MAL are registered for the indications mentioned above, but HAL is not. It is registered 
for photodiagnosis of bladder cancer but there is on-going research to use HAL-PDT as 
a therapeutic agent for several indications in dermatology, gynaecology and urology.
After topical application the porphyrin precursors penetrate into the skin through diffu-
sion and active transport. After uptake, MAL and HAL are first cleaved into ALA and an 
alcohol after which a multi-step enzymatic cascade follows. This cascade is part of the 
heme biosynthesis pathway that starts in the cytosol and continues in the mitochondria. 
The last step in this pathway is iron chelation of PpIX to form heme. This step is relatively 
slow, which results in a temporary accumulation of PpIX within in the mitochondria. 
The process of penetration through the skin followed by uptake and PpIX synthesis 
is illustrated for ALA in figure 2. Typically, it takes 3-4 hours to reach maximum PpIX 
concentrations, at which time-point illumination takes place.
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Figure 2. Aminolevulinic acid (ALA) penetrates through the epidermis and is transported into the 
keratinocyte cytosol via the gamma-aminobutyric acid (GABA) transporter. Multiple enzymatic steps 
within the heme synthesis pathway lead to protoporphyrin IX (PpIX) accumulation in the mitochondrion.
3.3. illumination
Depending on the indication and on geographic differences in treatment protocols ei-
ther blue or red light is used, which are both based on peaks in the absorption spectrum 
of PpIX (figure 3). In this figure it can be seen that it is possible to choose a variety of 
wavelengths of light to excite PpIX, because PpIX has its major absorption peak around 
400nm (blue) and several smaller ones between 500 (green) and 630 nm (red). However, 
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blue and green light are also very much more strongly absorbed by other chromophores 
such as haemoglobin and melanin in skin (figure 4). Because of this and also because 
shorter wavelengths of light are scattered more, the bioavailability of blue and green 
light decreases with increasing depth compared with red light. For this reason in basal 
cell carcinoma red light is the preferred choice. Both red and blue light are used for 
actinic keratosis.
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Figure 3. The normalized absorption and emission spectra of protoporphyrin IX. Absorption is highest 
around 405 nm, with several smaller peaks at longer wavelengths. The emission peak is centred around 
635 nm.
0
0,2
0,4
0,6
0,8
1
400 450 500 550 600 650 700 750
N
or
m
al
iz
ed
 a
bs
or
pt
io
n 
Wavelength (nm) 
HbO2
Hb
Melanin
Figure 4. Normalized absorption spectra of three common chromophores in the skin: melanin, 
haemoglobin (HbO2) and deoxygenized haemoglobin (Hb). Absorption of light of these chromophores is 
higher in the blue region (around 400 nm) than in the red (around 600nm).
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3.4. responses to PdT
PDT occurs as soon as light, photosensitizer and oxygen are simultaneously present. 
Thus, illumination several hours after topical application of a porphyrin precursor initi-
ates the photodynamic process that leads to formation of singlet oxygen and ultimately 
cell death. However, cell death by singlet oxygen formation is a somewhat simplified 
representation of events. The response of tissue to PDT is more complex and can be 
divided in three main categories: cellular, immunological and vascular responses. A 
combination of these three ultimately results in an overall response to PDT that includes 
destruction of the target (e.g. tumor) tissue.
3.4.1. Cellular response to PDT
After PDT cells may either die by necrosis or the more controlled apoptosis, or by other 
pathways such as autophagy 17-20. Necrosis is the least controlled mechanism leading to 
cellular debris, whereas apoptosis is an ordered way for a cell beyond repair to dispose 
of itself. The process of autophagy involves phagocytosis and lysosomal breakdown of 
dysfunctional cellular components and it can act both as a death and survival mecha-
nism. The specifics of these cellular mechanisms are complex and beyond the scope of 
this thesis but the cellular response to PDT using porphyrin pre-cursors is dominated 
by apoptosis. This is because PpIX is predominately localised in the mitochondria at 
the time PDT is normally applied. Direct damage to mitochondrial proteins leads to the 
destruction of the mitochondrial membranes, the release of cytochrome c and caspase 
induction.
3.4.2. Immunological response to PDT
The absence of immunity has been shown to reduce PDT outcome, indicating an 
important role for the immune system 21,  22. After PDT a quick influx of neutrophils is 
observed, followed by mast cell and macrophage invasion to the treated site 23. Both 
this type of acute innate anti-tumor response and also adaptive immune responses are 
recognized to contribute to the overall PDT success 24. Although the complexity of the 
immune response to PDT is an interesting topic, its specifics are also beyond the scope 
of this thesis.
3.4.3. Vascular response to PDT
It is known that blood vessels can respond to PDT, primarily from what is known about 
PDT using systemic porphyrins in the late 1980s when constriction and destruction of 
the microvasculature have been reported 25-30. These vascular effects can work in both 
ways in terms of PDT effect. If vessels constrict too much during PDT, this will hamper 
the influx of blood, and thus of oxygen to the PDT site. This type of response will reduce 
the PDT effect. On the other hand, if vasoconstriction happens late (during or after PDT), 
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or if vessels are damaged, it can be beneficial because local ischemia may help destroy 
remaining cancer cells that would otherwise survive 31,  32. This in turn means that the 
ischemia cannot be too extensive or long-lasting because the normal tissue may die too, 
resulting in an inferior cosmetic or functional outcome. These effects suggest that there 
may be a delicate balance between causing too much and too little vascular damage, 
illustrating the potential importance of such vascular effects on PDT response 33.
For topical PDT such as is used in dermatology, it is however generally assumed that 
vascular effects either do not take place in human skin or are irrelevant, despite the fact 
that there is preclinical evidence to the contrary in the literature 34-36. It has also been 
reported that vessels can constrict during PDT due to release of vasoactive substances 
such as nitric oxide 37 or cyclooxygenase products 29. Despite the results of these stud-
ies the clinical effects and the extent of vascular responses of topical ALA-PDT remain 
unclear. In this thesis the study of these vascular processes during and after PDT is a 
recurring theme. To understand these vascular effects, one of the relevant factors is the 
distribution of PpIX within the vasculature. I will go into the details of the PpIX distribu-
tion below, but will first I will explain why further PDT research is necessary.
3.5. limitations of PdT
PDT in the skin is generally quite effective with 3 month complete response rates 
reported in meta-analyses varying from 69-96% for actinic keratosis 38 and 71-87% for 
superficial basal cell carcinoma 39. However, long term follow up is often not reported 
but will likely be lower, yet better reflect the real cure rate. For example 69% and 76% 
5 year response rates have been described for nodular bcc after debulking 40, 41 and the 
highest reported 5 year complete response is 88% for superficial basal cell carcinoma 42. 
Moreover, considering the patient selection bias in clinical trials the complete response 
in everyday practice is probably lower than reported in such studies.
Despite these -for cancer treatment- relatively high complete response rates there 
remain significant limitations to PDT. First, still about 1 in 4 or 5 patients ultimately does 
not respond to the treatment and it is not understood why particular patients fail to re-
spond. A second important current limitation of PDT is that it can be extremely painful, 
which is considered the most important potential side effect of PDT 43. However, despite 
pain being a frequently studied subject 44, it is also not well understood why this is vari-
able for individual patients. It is essential to understand such underlying mechanisms 
for further improvement of PDT.
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3.5.1. Personalized medicine
To try and understand individual treatment failures or side effects is where the concept 
of personalized medicine becomes an interesting subject. It is based on the observation 
that individual patients can respond quite different to any medical treatment. Potential 
reasons for these differences may vary from large scale (e.g. gender) to very small scale 
differences (e.g. genetic base) or anything in between. The concept of personalized 
medicine has gained attention over the past years mainly because of advances in genet-
ics. However, the main idea behind personalized medicine is to identify the causative 
factors for differences in response to optimize treatment on an individual basis.
For PDT, there is much to gain by applying this concept of personalized medicine. 
Currently, in everyday practice all patients receive the same treatment. However, we 
are unsure of the exact parameters that are responsible for treatment success on an 
individual basis. In order to be able to fine-tune PDT to the individual patient’s needs 
it is important to define characteristics that may be important for treatment outcome, 
measure them and evaluate their relevance. Knowledge derived in such a way can next 
be used to optimize and personalize treatment to achieve best therapeutic efficacy and 
least side effects. The consequential logical question that arises then is: what are the 
relevant measurable or controllable parameters that are related to PDT effectiveness 
and how do we gain insight in them?
3.6. relevant parameters for PdT outcome
Obviously the most important factors for PDT success are either related to: the PpIX 
concentration and its localisation in the skin; the oxygen supply to the target site; or 
the local amount of light that is available for the photodynamic process. As we will see, 
things are significantly more complicated but this is a useful starting point. Many param-
eters that may influence PDT outcome can be measured or controlled in the PDT process 
and this can be done at various time-points. Three important time periods that can be 
defined are either before, during or after the illumination. These three time periods will 
be discussed separately, and I will focus on the parameters that can be measured or 
controlled during PDT for reasons that will become clear.
3.6.1. Before PDT
Before PDT starts, the obvious measurement is the clinical evaluation which can be fol-
lowed by histological examination to determine the tumour type, its growth pattern 
and sometimes its thickness in order to decide if the lesion is eligible for PDT in the first 
place45. The thickness can be relevant because the availability of both PpIX and light 
are depth-dependent. Another thing that may be relevant is the status of the patient’s 
immune system. Considering the role of the immune system in the PDT response, immu-
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nosuppression is expected to decrease PDT efficacy. A significant effect was not found 
however in one study of PDT for basal cell carcinoma 46, but long term responses were 
lower for PDT of actinic keratosis in immunosuppressed patients 47. In practice however, 
the lesion type and growth pattern are generally all that is being measured before PDT. 
The main difficulty here is to identify which parameters may be relevant to predict PDT 
effectiveness and side effects.
It is interesting to philosophise on what other parameters can theoretically be measured 
before PDT that provide information on the likelihood of treatment success. Some 
lesions may contain cells that are particularly capable of surviving oxidative damage 
by some enhanced repair mechanism such as autophagy. Certain uptake transporters 
of ALA may be down-regulated in tumour cells; there may be small alterations in the 
heme synthesis pathway, or there may be an active pump mechanism that inhibits PpIX 
accumulation. Another possibility is that some tumour cells are living in hypoxic condi-
tions that leads to them being better protected against PDT, which requires oxygen. 
Mechanisms such as these potentially enhance tumour cell survival chances during or 
after PDT. They may have a genetic basis to them, or they may be related to endocrine 
or paracrine functions. It could be useful if they can be measured in the skin biopsy 
prior to PDT. Similarly, there may be predispositions for experiencing increased pain 
which may vary from psychological to genetic factors. Be sure to note that these are just 
hypothetical examples of why some patients may respond differently to therapy than 
other and which could theoretically be taken into account before deciding upon PDT. 
The hypothetical and speculative nature of this paragraph shows that there is much 
more to explore.
3.6.2. During PDT
Currently the most interesting moment to perform measurement is during PDT. This 
monitoring of PDT is a prominent feature throughout this thesis, which is why I will 
discuss this in most detail here. Because the local photosensitizer, oxygen and light 
concentrations are the key ingredients for effective PDT, these parameters and their 
interactions are the most obvious ones to measure. In addition to measuring effective-
ness, side effects can also be measured of which pain is the most important parameter.
3.6.2.1. Photosensitizer
An obvious but crucial aspect for PDT success is the availability of sufficient amounts of 
PpIX at the correct locations in the skin. This makes the distribution of PpIX in the skin 
critical. It depends on both the ability of the precursor molecule to penetrate the skin 
and to be taken up by the target cells. The ability to penetrate the skin is related to the 
lipophilicity, which is different for the precursors and related to the ester groups of MAL 
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and HAL. The cellular uptake of ALA, MAL and HAL is regulated by different transporter 
molecules 48-53. Because of these differences between ALA, MAL and HAL there is an 
on-going debate about which one is the “best” PpIX precursor. Part of this debate is 
also concerned with potential differences in selectivity for cancerous tissue between 
them. Both the increased metabolic rate of neoplastic cells and the enhanced penetra-
tion through a disrupted stratum corneum in (pre)cancerous skin conditions have been 
attributed to such differences 54.
Because ALA, MAL and HAL are very small molecules they are very hard to detect and 
when detectable markers are added to them, their biochemical behaviour will change. 
An interesting solution for this problem would be to use radioactive 14C isotopes of them, 
but this has not been extensively employed. Instead, the resulting PpIX concentration 
is normally determined. PpIX is easily detectable because it fluoresces and the fluores-
cence intensity can potentially be used as a measure for the PpIX concentration. Hence, 
optical measurements of PpIX fluorescence provide valuable insight into the PDT pro-
cess. Indeed, it has been shown that the PpIX fluorescence intensity before start of PDT 
and the photobleaching percentages during PDT are valuable tools to predict treatment 
outcome 55-60. For this reason we also measured PpIX fluorescence in the majority of the 
studies in this thesis. It is however important to realize that there are limitations to such 
measurements. Because of the very useful nature of measuring PpIX fluorescence I will 
explain more on the limitations of measurement techniques and the physics involved in 
separate sections later in this introduction.
3.6.2.2. Oxygen
Not only the photosensitizer is photobleached, oxygen is also consumed during PDT. 
This means that oxygen needs to be constantly supplied and that lack of oxygen will 
inhibit the PDT process 61. A consequence of this is that when sufficient light and pho-
tosensitizer are present, the availability of oxygen can be deducted from the efficiency 
of PpIX photobleaching 37. This again highlights the importance of monitoring PpIX 
fluorescence during PDT. Another way to measure oxygen consumption and monitor 
the PDT process would be to measure the singlet oxygen luminescence 1. This is possible 
but is technologically challenging and is far from being applied in routine clinical treat-
ments. Yet another method to study the oxygen availability at the site of PDT is to study 
the blood supply from nearby blood vessels. Blood flow, constriction of blood vessels, 
blood oxygenation and microvascular damage are important measurable parameters 
here.
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3.6.2.3. Light
Light has a somewhat different character in that it is not routinely measured during PDT 
in the skin, but it is one of the most obvious controllable parameters. It is possible to 
vary the wavelength, the dose and intensity as well as the light delivery scheme. Each of 
these will be discussed in detail below.
3.6.2.3.1. Light - wavelength
As described above, the wavelength needs to match the absorption spectrum of PpIX: 
Both blue and red light are used, depending on the indication and geographic differences 
in treatment protocols. Another factor to consider is whether the PpIX fluorescence can 
be monitored during PDT. When red excitation light is used, it is difficult to measure PpIX 
fluorescence because the main red emission peak of PpIX, is centred at 635 nm (figure 3). 
Therefore, when PpIX fluorescence measurements are concerned, blue excitation light 
allows for the easy separation of excitation and emission light. Finally, when choosing 
the wavelength of the excitation light it should be noted that the most controllable 
light source in terms of effective light dose is a laser. Laser light has a single wavelength, 
which enables to calculate how much light is effective at exciting the photosensitizer. 
Broad light sources have the drawback that each wavelength has different ability to 
excite the photosensitizer, making it difficult to define the deposited effective light dose 
with depth.
3.6.2.3.2. Light – dose and intensity
When the amount of light delivery is concerned, both the total light dose and the rate 
at which this dose is delivered are relevant. The light dose is usually given as the total 
fluence, expressed in J cm-2. The rate of light delivery is given by the fluence rate (defined 
inside the tissue being illuminated) or by the irradiance (defined at the tissue surface). 
Both fluence rate and irradiance are expressed in W cm-2, which equals Jcm-2 s-1. These two 
parameters have very different impacts on the PDT process but the distinction between 
them can be confusing. The total dose is related to the total singlet oxygen production, 
which can be chosen to be as high so that all available PpIX is photobleached. The fluence 
rate determines how fast singlet oxygen is produced and oxygen is consumed, which 
can be detected by measuring the rate of photobleaching. An interesting consideration 
is that a high fluence rate (>100 mW cm-2) can exceed the ability of the tissue to supply 
oxygen, resulting in an inefficient overall PDT process. A lower fluence rate on the other 
hand improves PDT efficiency by better utilizing available oxygen 57, 62-65. When the flu-
ence rate is chosen too low however, it may be that not enough singlet oxygen is formed 
per time unit to cause lethal cellular damage because the cell repair mechanisms are 
faster. Again there seems to be a delicate balance between choosing too high or too low 
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a fluence rate. Fluence and fluence rate combined also determine the total illumination 
time, which can have considerable practical consequences.
3.6.2.3.3. Light - delivery scheme
A final controllable parameter related to light delivery is whether to deliver the light 
continuously or fractionated. A quick on-off fractionated regime can be chosen to 
avoid depleting oxygen supply, which essentially has a comparable effect as delivery 
of a lower fluence rate. Particular attention within our research group has been paid to 
investigating the use of a completely different light fractionated scheme. In this scheme 
two (continuous) light fractions are delivered separated by a dark interval of two hours. 
This was based on the observation that after PDT again PpIX was resynthesized, which 
could be utilized again in a second light fraction increasing efficacy 66, 67. In several pre-
clinical mouse models it was concluded that the first light fraction needs to be relatively 
small and the dark interval relatively long (> 2 hours) for optimal results 68, 69. This series 
of preclinical studies has led to a clinical ALA-PDT treatment protocol that has proven to 
be beneficial 42, 70. It turned out that the total amount of PpIX that was photobleached 
was not the mechanism of action that explained the increase in efficacy, which led to 
additional studies to elucidate this mechanism. It was shown that, contrary to ALA, light 
fractionation did not increase the effect of MAL-PDT in mouse skin 71. Differences in local 
PpIX concentration and distribution were hypothesized to account for this, because of 
the different lipophilicity and uptake mechanisms. Subsequent studies confirmed that 
the distribution of PpIX in endothelial cells in vitro, in the vasculature and the vascular 
response are different for ALA and MAL 53, 72. From these studies it was concluded that 
the vasculature plays an important role in the mechanism behind light fractionation. 
An in-vitro study further showed that light fractionation was especially effective under 
low concentrations of PpIX 73. Such low concentrations are expected to be present in 
for example the vasculature, but also potentially in some areas of a tumour that would 
not respond to a single (but would to a fractionated) illumination. Using the knowledge 
from these previous studies we have continued to investigated the vascular effects of 
topical PDT in some chapters in this thesis. We focused on such effects of HAL-PDT and 
compared this with ALA and MAL to help optimize HAL-PDT before it is regularly applied 
in the clinic.
3.6.2.4. Pain
A final clinically important parameter to measure during PDT is pain. The pain typically 
starts shortly after start of illumination and either disappears quickly when the light 
is switched of, but it can also last for several hours afterwards. Pain can be measured 
during PDT simply by asking the patient how intense the pain is, which is generally 
scored using a Visual Analogue Scale (VAS). In addition to scoring the intensity of the 
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pain, both the temporal aspect of pain and the quality of the pain sensation (i.e. burn-
ing, stinging etc.) are interesting parameters to measure. This type of information may 
help understand the underlying mechanism of pain during PDT which is currently not 
well understood. Because ALA is taken up by GABA receptors 74, 75 it has been suggested 
that the pain is caused by direct PDT damage to nerve cell endings, but this would not 
explain why MAL-PDT is also painful. Pain may be caused by stimulation of specialized 
c-fibre nerve receptors, because patients experience intense burning heat although 
during PDT although the temperature hardly increases. So called transient receptor po-
tential vanilloid (TRPV) receptors are a family of receptors that generate a heat sensation 
upon stimulation. An example of such a receptor is the TRPV1 channel which is activated 
by capsaicin (the substance that makes chilli peppers hot), causing a warm, burning 
sensation. However, in a small pilot study there was no decrease in pain perception after 
desensitization using capsaicin cream during the week prior to PDT 76. It could therefore 
be interesting to measure the release of other substances during PDT that may activate 
any of the TRPV channels. A possible benefit of conducting such research is that it may 
be possible to selectively block the receptors responsible for PDT pain perception.
3.6.3. After PDT
When measuring anything after PDT it is of course already too late to use these mea-
surements to modify that particular treatment in the clinic. Such measurement can 
however be valuable for research purposes. For example, therapeutic effect can be 
used in combination with other parameters (measured during or before PDT) to help 
understand mechanisms such as biological pathways that contribute to the ultimate 
PDT response. Therapeutic effect can be determined over the short and long term by 
measuring complete disappearance of the lesion. Proxy measures of this may also be 
used such as tumour volume decrease, visual skin damage or histological evaluation 
of PDT damage. Visual skin damage of normal mouse skin is used in two studies in this 
thesis, because in the past this proved to a good translational model for clinical PDT 
response. On histology necrosis and apoptosis may be directly visible, while it may be 
helpful to measure biochemical markers to improve sensitivity or study other cellular 
pathways such as autophagy. Use of such immunohistochemistry can also be helpful 
to determine vascular damage and immunological response to PDT. In addition to 
measurements that inform on treatment efficacy, it can be valuable to score side effects 
such as swelling, redness, pain, cosmetic or functional outcome and patient satisfaction.
3.7. Optical measurements
Having defined the potential relevant parameters to measure and/or control I will 
focus on PpIX fluorescence measurements, because this is major theme throughout 
this thesis. To better understand the techniques used in the studies of this thesis I will 
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introduce how optical techniques can be used. Several optical fluorescence measure-
ment techniques exist that make use of light to excite the fluorophore after which the 
fluorescent light is detected. As simple as this may sound, it gets complicated when 
the light interacts with other components in the tissue. This is not a significant prob-
lem when for example relatively flat tissues such as histological sections are analysed. 
However, when tissue is optically sampled these interactions between excitation and 
emission light with tissue components become very important. The way in which PpIX 
fluorescence measurements are influenced by these interactions and how this problem 
can be overcome will become clear later. First it is helpful to introduce the dominant 
tissue light interactions: absorption, scattering and fluorescence. Then, the different 
optical measurement techniques are explained that involve optical imaging and optical 
reflectance and fluorescence spectroscopy.
3.7.1. Absorption
Photons that propagate through tissue can collide with tissue constituents whereafter 
light energy is transferred (mostly to electrons) and quickly released as heat. This process 
is called absorption. The molecules that absorb the light are called chromophores. The 
major chromophores in skin that absorb light in the visible wavelength region are hae-
moglobin, deoxy-haemoglobin and melanin (figure 4). Bilirubin and beta-carotene are 
other chromophores that, under normal circumstances, are also present in the skin but as 
much lower concentrations. Each chromophore has a specific absorption spectrum, in-
dicating which wavelengths are best absorbed. Because of this, the wavelength-specific 
fraction of light that returns to a collector (when a wide range of wavelengths is used to 
illuminate the skin) can provide information on the type and amount of chromophores 
that are present. This is the basic principle for any reflectance spectroscopy technique. In 
addition to this absorption of light, another tissue-light interaction is scattering.
3.7.2. Scattering
Light scattering can be described in simple terms as the interaction of light with mat-
ter that results in a change of direction in which the light travels. The easiest way to 
think about this phenomenon is to visualize looking at a red laser beam from the side 
that is only visible when the light is scattered towards the retina by smoke or steam. 
In tissue such as the skin similar interactions occur. Macromolecules such as proteins 
and lipids have a higher molecular density than the cytosol. As a result, they have a 
different refractive index, indicating their capacity to scatter light in several directions 
77. Therefore, cellular structures with lipid membranes (e.g. nucleus, Golgi apparatus and 
mitochondria) or with high protein content (e.g. lysosomes) behave as strong scatter-
ing centres 78. When the light is scattered, the direction in which this happens depends 
-amongst others- on the relative size and distance between scattering particles and on 
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the angle and the wavelength of the incident light (shorter wavelengths scatter more). 
These scattering events in the skin also play an important role for optical measurements 
because light may or may not have returned to the collector due to it being scattered 
towards or away from it.
3.7.3. Fluorescence
Special types of chromophores called fluorophores absorb light energy and re-emit part 
of that energy as fluorescence. The quantum mechanics of this process have already 
been explained in the beginning of this introduction. As also mentioned earlier, the 
most important fluorophore for PDT in the skin is PpIX which is synthesized after the 
application of a precursor. There are however other fluorophores that are present in the 
skin also under normal conditions. Common fluorophores are collagen, NAD(H), FAD, 
flavins, and advanced glycation end-products 79, 80. The combined emission from all of 
these constitute the skin autofluorescence, which exhibits a characteristic bell-shaped 
emission peak centred around 480 nm after blue light excitation (the wavelength region 
that is commonly used to excite PpIX).
A critical aspect for fluorescence measurements of the skin is that both the excitation 
wavelength and the emission wavelength of the fluorophore are also absorbed and 
scattered before they can either excite the fluorophore or be collected by a detector. 
This means that the measured fluorescence intensity by any optical method will over or 
underestimate the intrinsic fluorophore concentration depending on the optical prop-
erties. Therefore it is necessary to correct for these absorption and scattering effects 
when quantitative measurements of fluorophore content are desired. Because PpIX 
fluorescence kinetics during PDT are helpful to predict PDT outcome, such accurate and 
quantitative PpIX fluorescence measurement are indeed desirable in PDT. Furthermore, 
optical properties are likely to change during the course of PDT, which will affect the 
temporal accuracy of PpIX fluorescence measurement when they are not corrected for 
optical properties. To perform adequate correction of any fluorescence measurement, 
the optical properties of the skin must first be measured. This is where reflectance spec-
troscopy comes into play.
4. rEFlECTanCE SPECTrOSCOPy
Reflectance spectroscopy involves the use of a broad wavelength light source that 
illuminates the tissue and a spectrometer that detects the reflected light over this 
wavelength range. Fiber optic reflectance spectroscopy uses optical fibers for light 
delivery from the light source to the tissue and light collection from the tissue to the 
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spectrometer. The reflectance spectrum is next analysed to extract the optical properties 
of the tissue. Reflectance spectroscopy can be very useful in itself because the optical 
properties provide information on the absorption and scattering characteristics of the 
tissue. The absorption properties can be used to calculate chromophore concentrations 
and blood oxygenation. The scattering properties may be used to detect nanoscale mor-
phological and architectural changes that occur during early carcinogenesis 81, 82. Several 
reflectance spectroscopic methods have been used and differences between them are 
generally dependent on the distribution and geometry of the delivery and collecting 
fibers. The most important consequence of various geometries are the differences in 
optically sampled volumes, which are determined by the photon path length.
4.1. Photon path length – isotropic and anisotropic light scattering
Both the amount of absorption and scattering events depend in the first place on the 
distance that the light has travelled in the tissue. This photon path-length determines 
the sampling volume –and depth- of a spectroscopic measurement. As mentioned 
above, it is mainly dependent on the geometry of the delivery and collection optical 
fibers. The further apart they are, the longer the photon path length. A longer photon 
path-length will result in more photons being absorbed and scattered. This in turn has 
important consequences for the average direction of light scattering. When the photon 
path length is relatively long (>0.5 mm sampling depth), the number of scattering 
events is very high. As a consequence, it can be assumed that the light does not have 
a preferred direction of scattering, but rather diffuses down a concentration gradient. 
This is termed diffuse or isotropic scattering 83. Conversely when the photon path 
length is short, light scattering becomes anisotropic. This means that the direction in 
which the light is scattered becomes critical for the amount of photons returning to the 
spectrometer 84-86. The probability distribution of these scattering angles is determined 
by a parameter called the phase function which can take complicated (in some cases 
unknown) forms, depending on the scattering constituents of the tissue. Unfortunately, 
reflectance spectroscopic measurements do not allow a complete determination of the 
phase function and assumptions have to be made. As will be explained soon, math-
ematical models have been developed to describe this phase function. Before we go 
there let’s first consider again the purpose for which we would like to utilise optical 
spectroscopy in this thesis: PDT.
4.2. Optimal sampling depth in PdT
When using reflectance spectroscopy in the skin for PDT purposes the optical sampling 
depth is a crucial factor. Because PpIX fluorescence comes mainly from the epidermis 
and because the oxygen necessary for PDT is supplied by blood vessels in the superficial 
dermis, the desired sampling depth is just into the superficial dermis. This has conse-
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quences for the choice of geometry used for spectroscopic measurements in the skin. 
A common technique such as diffuse reflectance spectroscopy samples both superficial 
and deep layers of the skin. As a result the sensitivity of measuring the optical properties 
of the superficial part of the skin decreases. This is why for PDT it is important to use 
reflectance spectroscopic techniques with a geometry that allow superficial sampling 
depths.
However, because of the anisotropic nature of light scattering in such superficial spec-
troscopic measurements it is not easy to account for these effects. During the course 
in which the studies in this thesis were carried out, methods to accurately quantify the 
optical properties of this superficial part of the skin were developed. We initially used 
diffuse reflectance spectroscopy (sampling deep into the skin). Later we used a tech-
nique termed differential pathlength spectroscopy (DPS) that allows determination of 
superficial absorption properties. The latest technique is termed multi-diameter single 
fibre reflectance (MDSFR) spectroscopy that allows a complete description of the optical 
properties in the superficially sampled volume.
4.3. differential path length spectroscopy
DPS involves taking a reflectance spectrum using two adjacent optical fibers with dif-
ferent diameters. that can be varied to accommodate the desired sampling depth 87, 88. 
Because one fiber collects and delivers light while the other only collects light, one fiber 
samples from both deep and superficial volumes while the other samples predominantly 
from deeper in the skin. Subtracting the signals yields information on the absorption 
characteristics of only the superficial layer. The influence of (differences) in scattering 
of the tissue have a small effect on the path-length of light in this superficial volume 
and DPS allows for the measurement of the blood volume fraction, the saturation, and 
the melanin, bilirubin and beta carotene content. We used this technique to monitor 
the superficial blood volume and saturation during PDT of human skin in one study in 
this thesis. The primary drawback of DPS is that it does not allow for a determination of 
the scattering properties of tissue. This is problematic since (1) the scattering properties 
are known to be diagnostically relevant and (2) without knowledge of the scattering 
properties of tissue it is impossible to correct the raw fluorescence for the influence of 
differences in optical properties.
4.4. Single fiber reflectance (SFr) spectroscopy
In SFR spectroscopy a single fiber is used for both delivery and collection of light 89-
91. The sampling depth is shallow and depends on the diameter of the fiber. From the 
measured reflectance spectrum the tissue absorption coefficient µa can be quantified 
(without prior knowledge of the scattering properties) 92. Decomposition of µa into the 
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constituent spectra of the chromophores present in the skin yields measurements of 
the blood volume, saturation, and melanin, bilirubin and beta-carotene concentrations. 
When more than one fiber with different diameters are used simultaneously it is possible 
to determine the scattering phase function parameter γ, which allows quantification of 
the tissue scattering properties that are given as the reduced scattering coefficient µs’. 
This use of more than one single fiber measurement is termed multi diameter single 
fiber (MDSFR) spectroscopy 93-95. In addition to measuring γ and µs’ , the slope of µs’ as a 
function of wavelength is also measured in MDSFR. This parameter is termed a2, or the 
scattering power. Where µs’ can be considered a measure of the density of scattering 
particles, a2 can be considered a measure of the relative size of these particles. Both 
these measures may be relevant if MDSFR spectroscopy is used for diagnostic purposes, 
for example to detect morphological changes in cellular architecture that may be altered 
in early carcinogenesis. In addition to the possible use of MDSFR as a diagnostic tool, its 
primary use for PDT is that the optical properties derived from MDSFR spectra can be 
used to correct fluorescence measurements 96.
5. SinglE FibEr FluOrESCEnCE (SFF) SPECTrOSCOPy
In fluorescence spectroscopy light with a defined wavelength is used to excite a fluoro-
phore (e.g. PpIX) and a spectrometer collects light above this wavelength emitted by the 
fluorophore. As explained, the optical properties of the sampled volume are important 
for the probability of both the excitation light to excite the fluorophore and for emission 
light to reach the spectrometer. In single fiber fluorescence (SFF) spectroscopy one of 
the fibers of the MDSFR spectroscopy measurement is used to acquire a fluorescence 
spectrum. Combining the information of the MDSFR and the SFF measurements enables 
to correct fluorescence spectra for the optical properties of the same sampling volume 
97-99. This is the topic of the last study in this thesis.
6. ThiS ThESiS OuTlinE
In short, the major topics that are included in this thesis are focused on monitoring rel-
evant parameters during PDT and to use this information to improve our understanding 
of PDT. Ultimately this type of information will be necessary in order to understand and 
predict individual treatment failures and to optimize and personalize treatment in terms 
of maximizing effectiveness and minimizing side effects. One of the main parameters 
that is being monitored in this thesis is the PpIX fluorescence. Different fluorescence 
measurement methods are used to investigate PpIX concentration and localisation 
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within the tissue, with a focus on the distribution of PpIX in the vasculature in some 
chapters. In addition, PpIX photobleaching kinetics are monitored during PDT that 
inform on oxygen consumption, which is also related to the vascular response to PDT. 
Because PpIX fluorescence is so informative for monitoring PDT, it is essential that ac-
curate fluorescence measurements are performed. As explained above it is necessary to 
measure the optical properties of the sampled skin volume first, so this information can 
be used to correct fluorescence measurements. Measuring the optical properties can 
also be useful to monitor changes is blood volume and saturation during PDT which in 
turn are related to vascular responses. Furthermore, quantifying optical properties may 
also be valuable for diagnostic purposes.
In chapter 2 a major limitation of PDT is introduced: pain. In a clinical investigation, char-
acteristics that may predict severe pain during PDT are measured and their influence is 
evaluated. This knowledge may add to a more personalized approach to PDT. A potential 
solution to decrease pain during PDT is described in Chapter 3. In a mouse model the 
effect of low fluence rate PDT on photobleaching kinetics and PDT efficacy is studied.
Chapters 4 and 5 focus on the vascular distribution of PpIX and the vascular effects of 
topical PDT in mouse models using different porphyrin precursors. PpIX fluorescence 
is measured in histological sections and in subcutaneous blood vessels in a skin fold 
chamber model in which these vessels are directly visible. The distribution of PpIX in 
the vasculature and the vascular response to PDT are measured which may be relevant 
for the oxygen supply during PDT and ultimately for the success or failure of individual 
treatments. In chapter 6 the knowledge from chapters 4 and 5 is used to investigate the 
effect of light fractionation on PDT efficacy for HAL. The rationale is that the vasculature 
is believed to play a role in the mechanism behind light fractionation. In this study the 
relation between PpIX fluorescence kinetics and PDT efficacy is again investigated .
In chapter 7 the clinical importance of monitoring optical properties of the skin during 
PDT for individual patients is introduced. DPS is introduced as a new optical technique 
that allows superficial measurements of absorption parameters during PDT such as the 
blood content and saturation. In chapter 8 the clinical use of MDSFR spectroscopy is 
introduced in human skin which measures not only the absorption but also the scatter-
ing characteristics. It is described how this complete determination of optical properties 
can be used in combination with single fiber fluorescence spectroscopy to correct the 
measured fluorescence. The importance to do this for individual patients undergoing 
PDT is described. Chapter 9 provides a general discussion of the results of the studies 
presented in this thesis, and how they contribute to the optimization of photodynamic 
therapy. It concludes with a brief discussion of future perspectives.
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abSTraCT
In PDT the clinical relevance of predictors for increased pain is unclear and the effect on 
patient satisfaction unknown. We identified risk factors associated with severe pain and 
patient dissatisfaction in ALA-PDT for actinic keratosis field cancerisation using multivari-
ate binary logistic regression. Treatment area size was the only significant predictor for 
severe pain and patient dissatisfaction. In our largest treatment area group (85-190 cm2) 
severe pain was reported by 81% of patients, clearly illustrating the need for adequate 
pain control. A way to decrease pain is low fluence rate PDT, of which daylight PDT is a 
popular recent example.
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TEXT (lETTEr TO ThE EdiTOr)
Treatment of actinic keratosis field cancerization poses an increasing challenge to the 
dermatologist. Photodynamic therapy (PDT) using aminolevulinic acid (ALA) or its meth-
yl ester is an attractive treatment modality for this indication because it is an effective, 
single day procedure with excellent cosmetic results. The main disadvantage of PDT is 
that it can be painful, limiting its applicability. Many factors influencing pain have been 
described in the literature: PpIX concentration; fluence rate; wavelength; treatment area 
size; localization; use of ALA or its methyl ester; sex; skin type; lesion redness; age; and 
lesion type 1-6, but results are inconsistent.
Moreover, an important consideration is that the outcomes are often difficult to interpret 
clinically. Pain is typically measured using a visual analogue scale. One approach has 
been to identify risk factors for pain using linear regression, resulting in beta coefficients 
that predict higher VAS scores. Another approach has been to compare the mean VAS 
score between two randomized groups. Both the beta coefficients and the magnitude of 
the mean difference can be difficult to interpret, due to the non-linear nature of the VAS 
score, and may not represent a clinically relevant association or difference.
Therefore, in this prospective study we chose severe versus non-severe pain as binary 
outcome, which is clinically relevant and easy to understand. In addition, patient satis-
faction was studied, which is becoming an increasingly important endpoint of clinical 
studies but which is not well studied in PDT. Our aim was to identify risk factors for 
severe pain, measure patient satisfaction and investigate the influence of severe pain 
on satisfaction. The study was approved by the local ethical committee, is in accordance 
with the declaration of Helsinki and all patients gave written informed consent prior to 
inclusion.
We included 48 patients that were treated with fractionated ALA-PDT for actinic field 
cancerization of at least 25 cm2 in the face, scalp or back of hands. The light fractionated 
treatment protocol is the standard treatment in our university hospital. It involves deliv-
ery of 20 J cm-2 in the first illumination after 4 hours of 20% ALA gel application under 
occlusion, followed by a dark interval of two hours and delivery of an additional 80 J 
cm-2 in a second illumination. We used a Waldmann PDT 1200L lamp, with an emission 
peak around 635 nm and a spectrum of 600-730 nm. The following characteristics were 
collected: age (older or younger than the mean), sex (m/f ), hair color (red/other), skin 
type (I-III) and the size of the treatment area (divided into three equal categories based 
on the data’s tertiles). Pain was scored immediately after the first and after the second 
illumination using a VAS score (scale 0-10) with 0 representing no pain and 10 the worst 
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pain imaginable. Severe pain was defined as a VAS score ≥ 7. If necessary, patients 
received local infiltrative or nerve block anesthesia. Treatment satisfaction was scored 
after three months using the Dutch version of the Treatment Satisfaction Questionnaire 
for Medication (TSQM) 7. This questionnaire has four domains: effectiveness, side effects, 
convenience, and global satisfaction (scale 0-100). A score ≥ 70 was considered “satis-
fied” and lower scores as “dissatisfied”. Predicting variables associated with severe pain 
and those associated with dissatisfaction were analyzed using univariate and multivari-
ate binary logistic regression.
In total 58% (28/48) of patients reported severe pain at any time point during the treat-
ment (i.e. either during the first or second illumination). All patients that experienced 
severe pain requested and received anesthesia, which reduced the reported median VAS 
from 9 to 5 in those patients. However, 7 of them still considered their pain as severe 
Table 1. Predicting variables for reporting severe pain at any time-point during PDT, using a univariate 
and multivariate binary logistic regression model (n=48). The odds ratios presented are relative to their 
baseline, indicated by the number 1.
 
 
univariate analysis Multivariate analysis *
Or (95% Ci) P-value Or (95% Ci) P-value
Sex
female 1 1  
male 2.48 (0.65-9.40) 0.18 0.57 (0.10-3.15) 0.52
hair color
red 1 n.a.  
other 1.47 (0.27-8.17) 0.66 n.a.  
Fitzpatrick skin type
1 1 1  
2 or 3 3.57 (0.77-16.54) 0.13 3.35 (0.54-20.72) 0.19
Treatment area size (cm2) 
25-54 1 1  
55-85 2.12 (0.52-8.81) 0.29 4.3 (0.73-25.40) 0.11
85-190 7.22 (1.44-36.22) 0.02 9.70 (1.43-65.58) 0.02
Pain medication use
no 1 n.a.  
yes 1.30 (0.38-4.43) 0.68 n.a.  
location 
hand 1 1  
face/scalp 2.57 (0.62-10.71) 0.19 3.15 (0.55-17.91) 0.20
Abbreviations: OR, Odds Ratio; CI, Confidence Interval; n.a. not applicable
* P-values< 0.20 were added to the multivariate analysis
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after anesthesia, and two of these patients did not complete treatment due to pain 
severity. The only significant predictor for severe pain was treatment area size (Table 1). 
Severe pain was reported by 38%, 56% and 81% of patients in respectively the smallest, 
middle and largest size categories (the total treatment area range was 25-190 cm2). The 
TSQM questionnaire was completed by 44 patients. Most patients that did not experi-
ence severe pain were satisfied for all domains, whereas most patients that experienced 
severe pain were dissatisfied for the domains effectiveness, convenience and global 
satisfaction (Table 2). Severe pain was a significant predictor for dissatisfaction on the 
TSQM convenience domain after adjusting for size (OR 6.8, 95% CI 1.4-33, P=0.02). Treat-
ment area size was a significant predictor for dissatisfaction on the TSQM effectiveness 
domain after adjusting for pain (OR 8.1,95% CI 1.4-50, P=0.02).
Table 2. Treatment satisfaction: TSQM domain scores for all patients (Total) and stratified for severe pain 
(VAS≥7) versus non-severe pain (VAS<7).
TSQM domain
Total VaS<7 group VaS≥7 group P-value
n=44 n=18 n=26 (Mann-Whitney test)
effectiveness (median, IQR) 67 (56-78) 72 (61-83) 67 (50-72) 0.12
side effects (median, IQR) 100 (90-100) 100 (98-100) 100 (69-100) 0.32
convenience (median, IQR) 53 (39-72) 72 (50-79) 47 (33-56) 0.01
global satisfaction (median, IQR) 61 (38-79) 71 (57-79) 50 (29-71) 0.02
Abbreviations: TSQM, Treatment Satisfaction Questionnaire for Medication; VAS, Visual Analogue Scale; IQR, 
InterQuartile Range
This study shows that PDT for large areas of actinic field cancerization is limited due to 
severe pain. This is a clinically relevant short term complication that also reduces long 
term patient satisfaction. Our finding that only size of the treatment area is a predictor 
for severe pain differs from other studies that have found other pain predictors, but 
match the conclusions from a review on this topic 6. Our limited sample size may have 
resulted in insufficient power to detect weaker predictors for severe pain. However, 
it is uncertain if these weaker predictors will have any clinical relevance. The results 
indicate that there is need for adequate pain control when treating large fields. Infiltra-
tive lidocain and nerve block anesthesia are considered effective in reducing pain8, but 
have their own side effects. Moreover, in our study a considerable number of patients 
still reported severe pain after local or nerve block anesthesia. Therefore, future stud-
ies that focus on other solutions to decrease pain are needed. Data from the literature 
suggest that lowering the fluence rate may be the most interesting option to decrease 
pain 2, 9. The mechanism behind this is not clear, but possibly the lower rate at which 
singlet oxygen is produced plays a role. Lowering the fluence rate utilizes oxygen more 
efficiently, so a lower total light dose can be sufficient to deliver the same effective PDT 
dose (which can be measured by monitoring protoporphyrin IX fluorescence). Fluence 
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rate, length of illumination, pain and clinical efficacy may need to be carefully weighed 
against each other. An increasingly popular example of low-dose, very low fluence rate 
PDT is daylight PDT which is indeed less painful but still effective 10.
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abSTraCT
Photodynamic therapy (PDT) for actinic field cancerization is effective but painful. Pain 
mechanisms remain unclear but fluence rate has been shown to be a critical factor. 
Lower fluence rates also utilize available oxygen more efficiently. We investigated PDT 
effect in normal SKH1-HR mice using low and high fluence rate aminolevulinic acid (ALA) 
PDT and a fractionated illumination scheme. Six groups of six mice with different light 
treatment parameters were studied. Visual skin damage was assessed up to 7 days post 
PDT. Fluorescence and reflectance spectroscopy during illuminations provided us with 
real time information about PpIX photobleaching. A novel dosing approach was intro-
duced in that we used a photobleaching percentage instead of a pre-set fluence. Data 
show similar total and maximum damage scores in high and low fluence rate groups. 
Photobleaching of PpIX in the low fluence rate groups shows a trend towards more ef-
ficient photobleaching. Results indicate that low fluence rate PDT is as effective as, and 
more efficient than high fluence rate PDT in normal mouse skin. Low fluence rate PDT 
light protocols need to be explored in human studies in search for an effective and well 
tolerated treatment for actinic field cancerization.
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inTrOduCTiOn
Non-melanoma skin cancer and precursor lesions are a steadily increasing health care 
problem 1-5. Especially extensive field cancerization necessitates the use of full field treat-
ment options, such as photodynamic therapy (PDT). PDT using topical aminolevulinic 
acid (ALA) or its ester derivates, such as methyl-ALA (Metvix®) is now well accepted and 
used for treating actinic keratosis (AK), Bowen’s disease (BD) and superficial basal cell 
carcinoma (sBCC). There is a consensus on the use of PDT for these indications, as pre-
sented in recent European guidelines 6, 7. Topically applied ALA is converted via the heme 
synthesis pathway resulting in the accumulation of the photosensitizer protoporphyrin 
IX (PpIX). Illumination with light of the appropriate wavelength leads to the generation 
of reactive oxygen species, notably singlet oxygen. This results in a range of tissue ef-
fects that include cell apoptosis, necrosis, vascular and immunological responses. The 
effectiveness of ALA-PDT is influenced by many variables such as fluence, fluence rate, 
light source, illumination scheme, the application time, the use of iron chelators and the 
use of penetration enhancers 8, 9.
Our group observed new formation of PpIX in time after single illumination in the past 
and subsequently investigated this in various animal models 10-12. A two-fold illumination 
scheme, separated by a substantial dark interval and a small first light fraction, increased 
response to PDT. We tested this light fractionated scheme in a clinical setting in sBCC’s 
and found a significant improvement in response compared to single illumination. One 
year response rates in fractionated ALA PDT were 97% 13 and in another study with 
different light treatment parameters, 5 year response rate was 84% 14. This approach 
appears to compare favourably with the results for methyl aminolevulinate (Metvix ®), 
where two-year response rates for primary ‘difficult to treat’ BCC are 76% 15 and 78% for 
patients prone to complications and poor cosmetic outcome with conventional treat-
ment 16.
The main disadvantage of PDT is that it is often a painful treatment 17, limiting the 
suitability of PDT as a treatment of first choice. Patients report a burning or tingling 
sensation that sometimes leads to need for local anaesthesia or termination of therapy. 
Especially treating extensive field cancerization with actinic keratosis in the face and 
scalp region is painful for the patient 17, 18. The exact mechanism underlying the pain is 
unclear. Some authors suggested that pain increases with higher PpIX concentrations, 
although results are conflicting 17, 19, 20. It has also been proposed that the methyl ester 
(Metvix ®) produces less pain than ALA 21. Recently a number of authors have reported 
significantly less pain during PDT using lower fluence rates 22-24 with low VAS scores at 
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20 mW cm-2. Besides the advantage in pain perception, it is well documented that using 
lower fluence rates results in more efficient usage of the available oxygen in tissue 25-30.
We would like to incorporate the use of low fluence rate to light fractionated ALA-PDT to 
maintain effectiveness while minimizing pain. Therefore we designed the present study 
comparing high and low fluence rate PDT and several illumination schemes in hairless 
mouse skin. These schemes were in part the same as used in previous studies from our 
group at 50 mW cm-2 and new groups were introduced using 20 mW cm-2. We delivered 
a cumulative total fluence (first + second light fraction) of 100 J cm-2 and lowered this to 
50 J cm-2 since this is the range of fluence that was studied previously and to minimize 
treatment time.
There are some obstacles that must be overcome when using lower fluence rate PDT. 
At 20 mW cm-2 treatment time will be 2.5 times longer compared to 50 mW cm-2 when 
the total fluence is kept constant. For clinical purposes short treatment times are strived 
for. As mentioned before, low fluence rate PDT leads to more efficient use of available 
oxygen. This indicates that less fluence is needed at 20 mW cm-2, which as a result may 
keep treatment times constant 19. Here a question arises as to how much less fluence 
needs to be delivered to achieve the same effect. This is an issue for both the first and 
second illumination. Especially dosing of the relatively small first light fraction is critical 
for maintaining PDT efficacy, as we showed previously 11, necessitating us to employ 
more accurate dosing than using a predetermined fluence.
Therefore, a novel dosing method for the first light fraction was adopted, making use of 
PpIX fluorescence measurements. During the photodynamic process, PpIX is destroyed 
by singlet oxygen, in a process termed photobleaching. In ALA-PDT the rate of PpIX 
photobleaching is directly related to the amount of singlet oxygen produced and can 
potentially be used as a predictor of PDT induced response. In normal mouse skin, in 
which the variations in the amount of PpIX are relatively small, the normalised extent of 
photobleaching can be used as a predictor of the PDT dose deposited 27, 31. In the present 
study we have used a fixed photobleaching percentage to determine when to stop the 
first illumination.
Our goal was to investigate if the animals that were illuminated at 20 mW cm-2 would 
react in a similar way to fractionated ALA-PDT as the animals that were illuminated at 50 
mW cm-2 with respect to PpIX fluorescence kinetics and damage response. Visual dam-
age to normal hairless mouse skin was used as a measure for efficacy. We hypothesized 
that 20 mW cm-2 is as effective as 50 mW cm-2 in inducing visually assessed skin damage.
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MaTErialS and METhOdS
animals
Thirty-six female albino hairless mice (SKH1 HR) were included in this experiment, di-
vided into 6 groups that received different treatment parameters as described below. 
Animals were put on a chlorophyll-free diet two weeks prior to treatment to remove 
autofluorescence from pheophorbide-a. The study was approved by the animal experi-
mental committee of the Erasmus University Medical Centre.
ala application
Animals were anesthetized with ketamine and valium before the application of 20% 
5-aminolevulinic acid (ALA, Medac, Hamburg, Germany), dissolved in 3% carboxy-
methylcellulose and NaOH in water (pH =4) to the skin using a 7mm round gauze, and 
occluded with a semi occlusive dressing (Tegaderm ®). A spot on the left thigh of the 
mice was chosen as the illumination area. There was a four hour interval between ALA 
application and the delivery of the first light fraction. Prior to and during illumination 
animals were again anesthetized using 2-3% Isoflurane in 100% oxygen.
groups of animals and light treatment parameters
We used six different illumination schemes (n=6 animals in each group). For delivered 
fluences per group see also table 1. Groups 1-3 served as control groups for comparison 
with experiments performed previously at 50 mW cm-2, while groups 4-6 were illumi-
nated at 20 mW cm-2. Group 1 received 100 J cm-2 in a single illumination at 50 mW cm-2. 
All other groups received two light fractions, separated by a dark interval of two hours. 
The exact duration of the illuminations in the first light fraction in groups 2-6 was based 
on the extent of PpIX fluorescence photobleaching measured during PDT in individual 
Table 1. Delivered fluences and treatment times per group for both light fractions.
group mW cm-2
delivered fluence ± Sd (J cm-2) Expected fluence (J cm-2)
Total time1st fraction 2nd fraction 1st fraction 2nd fraction
1 50 100.00 100 33 min. 20 sec.
2 50 4.44 ± 0.45 95.56 5 95 33 min. 20 sec.
3 50 5.20 ± 1.06 44.80 5 45 16 min. 40 sec.
4 20 3.67 ± 0.34 96.33 2 98 83 min. 20 sec.
5 20 3.74 ± 0.42 46.26 4 48 41 min. 40 sec.
6 20 + 50 4.28 ± 0.86 45.72 +50 2 48+50 58 min. 20 sec.
Fluence values represent means ± standard deviation (SD). For the first light fraction less fluence 
was needed to bleach 52% of PpIX in the 20 mW cm-2 groups compared to the 50 mW cm-2 groups. 
Illumination times for the first illumination were approximately two times longer in the low fluence rate 
groups.
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animals. This individualisation of the first light fraction is described in more detail in the 
data analysis section below. Each animal received a fluence that was needed to bleach 
52% of initial PpIX in the first light fraction, with an additional fluence during the second 
light fraction to reach various total fluences. Groups 2 and 3 were illuminated at 50 mW 
cm-2 to a total dose of 100 and 50 J cm-2 respectively. Groups 4 and 5 were illuminated at 
20 mW cm-2 to a total dose of 100 and 50 J cm-2 respectively. Group 6 received the same 
treatment scheme as group 5 immediately followed by 50 J cm-2 at 50 mW cm-2. This was 
based on a recent study, investigating the use of low fluence rates for the treatment of 
sBCC where PpIX photobleaching measurements were used as a method of determining 
the point during therapy where the fluence rate could be increased without inducing 
pain 23.
PdT light delivery
The experimental set-up was adapted from that which we used previously 32, to maxi-
mize the amount of fluorescence light collected from the tissue and facilitate spectral 
fitting of the data. Figure 1 shows a schematic overview of the setup. During PDT, an 
Argon Ion laser (514 nm) was used as the treatment light source with fluences of either 
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Figure 1. Experimental setup. During PDT, laser light was focused on the mouse skin treatment area and 
fluorescence emission, induced by the treatment light, was collected using a spectrograph. Reflectance 
was measured using a halogen lamp light source and the same spectrograph. A CCD camera was used for 
focusing and relocation purposes.
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20 or 50 mW cm-2. Light was delivered via a 400 micrometer optic fibre and focused to 
a homogenous 7 mm treatment area on the mouse skin via a dichroic mirror using a 
micro lens (QLT, Vancouver, BC, Canada) and a single biconvex lens. A charged coupled 
device (CCD) camera (ORCA-ER, Hamamatsu, Japan) was used for taking fluorescence 
images, to relocate the area of interrogation and maintain a constant distance between 
the mouse skin and the head of the spectrograph.
Fluorescence measurements
Fluorescence intensity was used as a measure of the PpIX concentration in the tissue. 
Fluorescence emission was collected from the illuminated area and focused into a 1 mm 
optical fibre coupled to a spectrograph (USB4000, Ocean Optics, Duiven, The Nether-
lands) via a 50/50 beam-splitter. Fluorescence spectra were taken continuously during 
the first and second illumination with integration times of 1000 ms and 2000 ms for 50 
mW cm-2 and 20 mW cm-2 respectively, without interrupting PDT light delivery. Scattered 
excitation light was blocked using a long-pass filter (570 nm, Melles Griot, Zevenaar, The 
Netherlands), placed in the optical path.
During the first light fraction, spectra were analyzed in real-time as described below 
to calculate the percentage of photobleaching and the illumination was terminated 
automatically when the extent of PpIX fluorescence photobleaching had reach 52% 
of its initial value. This value was based on highest damage scores with this bleaching 
percentage in previous experiments 10.
reflectance spectroscopy
Reflectance spectra were obtained before and immediately after illumination for correct-
ing the fluorescence spectra for changes in tissue optical properties in the fluorescence 
emission band. Light from a halogen lamp (0.15 mW cm-2, Stortz, Tutlingen, Germany) 
was filtered with a long-pass filter (OG 530, Melles Griot, Zevenaar, the Netherlands) to 
minimize fluorescence excitation of the tissue during reflectance measurements, and 
delivered via another optical fibre and focussed on the same 7 mm treatment area using 
a second 50/50 beam splitter. Reflected light was collected using the same system as 
the fluorescence emission. This enables fluorescence and reflection measurements be-
ing acquired using the same source-detection geometry. A white plastic reference card 
(Vink, Didam, The Netherlands) was used to correct spectra for small changes in light 
intensity and spectral output.
data analysis
The reflectance spectra before and after illumination were corrected for changes in light 
intensity, spectral lamp output and background with the use of the reference card. These 
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spectra can be used to detect changes in tissue optical properties during illumination 
and correct the PpIX fluorescence intensity for this with a method first suggested by 
Wu et al 33. Fluorescence spectra were analyzed in real-time during the first illumina-
tion. Spectra were analyzed as a linear combination of the basis fluorescence spectra 
of normal mouse skin, autofluorescence and hydroxyaldehyde chlorin photoproduct of 
PpIX, using a single value decomposition (SVD) algorithm. The output of this analysis 
yields information on the PpIX fluorescence intensity. The decrease of PpIX fluorescence 
intensity over time was used to determine the rate and the extent of PpIX photobleach-
ing. The first illumination was terminated when the PpIX fluorescence was decreased by 
52% of its original value. The spectra acquired during the first and second illumination 
were analyzed more extensively after the end of therapy. The fitted PpIX intensity values 
were corrected for different integration times and laser light intensities for accurate 
comparison and if necessary corrected for changes in tissue optical properties. These 
fluorescence intensities were normalized to 100% at the start of the first illumination 
using a second-order-decay fit 27. The fluorescence intensity at the start of the second 
light fraction was either again normalized to 100%, or presented as a percentage of the 
fluorescence intensity at the start of the first illumination.
damage score
Damage scoring was performed daily up to 7 days post PDT by 2 investigators blinded 
from the treatment schemes (by HdeB and AvdP). We used a visual scoring system, 
that we have described previously 27, with a zero to five-point scale: grade 0 means no 
damage; 1 = minimal erythema; 2 = moderate erythema; 3 = severe edema or a white 
blister; 4 = thin crust and 5 = thick crust. The severity and extent of PDT response was 
measured and scored where different levels of severity were considered within each 
treatment field. The overall damage score was calculated according to the damage and 
the relative contribution of each region. Means were calculated per group of mice and 
plotted against time. The distribution of maximum damage score per group over time 
was evaluated using daily photographs.
Statistics
In a previous experiment 11 we measured a cumulative damage score (see section 2.7) 
of 17 ± 4SD (n=19) for control group 1 and 25 ± 4SD (n=15) for control group 2. Since 
we expect 20 mW cm-2 to be as effective in inducing skin damage as 50 mW cm-2, the 
expected skin damage for group 4 would be equal to group 2. A power analysis with α 
= 0.05 and β = 0.80 results in 6 animals needed per group. For calculating differences 
in total damage scores between groups Student-Newman-Keuls multiple comparisons 
testing was performed, after calculating the total area under the curve (AUC) for subse-
quent daily damage scores.
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reflectance measurements
Figure 2 shows the average reflectance spectra measured immediately before and 
after the first light fraction for animals treated in groups 2 and 3 (at 50 mW cm-2). Both 
spectra show the absorption features that are expected from tissue in this region of the 
spectrum (560-860 nm). Mice from all other groups showed the same response. There 
is very little change in the absorption of mouse skin before and after illumination when 
reflectance is measured in this geometry. Therefore, the PpIX fluorescence intensities 
shown in this study are not corrected for changes in tissue optical properties.
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Figure 2. Reflectance intensity before and after PDT in the range of 560-860 nm. Reflectance is shown as 
arbitrary units. The grey line represents measurement before and the black line after PDT.
delivered fluence in first light fraction
Delivered fluences in the first and second illumination and treatment times per group 
are shown in Table 1. Less fluence was needed in the low fluence rate groups and treat-
ment times were longer.
PpiX fluorescence during illumination
Figure 3 shows the mean normalized PpIX fluorescence intensity during a two fold il-
lumination in which a total dose of 100 J cm-2 was delivered 4 and 6 hours after ALA 
application at a fluence rate of 50 mW cm-2 (group 2). Data from the first light fraction 
(panel a) and second light fraction (panel b) are separated by a two hour dark interval. 
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The first illumination was terminated when the intensity of PpIX fluorescence had 
bleached by 52%. In the 2-hour dark interval PpIX fluorescence increased to over 80% of 
the initial value. This increase was subject to large variation, as indicated by large error 
bars. For both illuminations the first 6 J cm-2 is shown for clarity: the second light fraction 
continued on to a total of 100 J cm-2, after which approximately 3,2% of the initial PpIX 
intensity at the start of the first light fraction remained.
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Figure 3. Mean normalized PpIX photobleaching in the first (panel a) en second (panel b) illumination 
in groups 2 and 3 (50 mW cm-2), separated by a dark interval of 2 hours. Error bars indicate one standard 
deviation.
Figure 4 shows the mean normalized PpIX photobleaching for the first illumination to 
illustrate differences with respect to fluence rate. The 20 mW cm-2 groups (4, 5 and 6) 
showed more efficient photobleaching than the 50 mW cm-2 groups (2 and 3). At lower 
fluence rates, less fluence was needed to bleach 52% of available PpIX (P=0.002). For 
clarity only the first 6 J cm-2 is shown.
Figure 5 shows the mean normalized PpIX photobleaching for the second illumination 
for different fluence rates. The 20 mW cm-2 groups again showed a non-significant trend 
towards faster bleaching than the 50 mW cm-2 groups. In group 6, (50 J cm-2 at 20 mW 
cm-2 using a fractionated illumination, followed by 50 J cm-2 at 50 mW cm-2), no change 
in bleaching rate was observed when the fluence rate was increased from 20 to 50 mW 
cm-2 (data not shown).
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Figure 4. Mean normalized PpIX photobleaching for the first illumination for different fluence rates. The 
full squares indicate averages at 50 mW cm-2 (groups 2 and 3). The open squares indicate averages at 
20 mW cm-2 (groups 4, 5 and 6). At 20 mW cm-2 less fluence was needed to bleach 52% of available PpIX 
(P=0.002). Error bars indicate one standard deviation.
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Figure 5. Mean normalized PpIX photobleaching for the second illumination for different fluence rates. 
The open squares represent averages of the 20 mW cm-2 groups and full squares averages of the 50 mW 
cm-2 groups.
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damage score
One day after PDT severe edema or white blister formation was visible, while damage 
increased over time up to day 4 when highest damage scores were observed.
Figure 6 shows the mean damage scores for each group of animals, calculated as the 
area under the curve (AUC) for subsequent daily damage scores.
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Figure 6. Mean damage score for 7 days after PDT for each group of animals, calculated as the area under 
the curve for subsequent daily damage scores. Group 1: 100 J cm-2 at 50 mW cm-2 (this is the only group 
with a single illumination, groups 2-6 received a fractionated illumination). Group 2: 100 J cm-2 at 50 mW 
cm-2. Group 3: 50 J cm-2 at 50 mW cm-2. Group 4: 100 J cm-2 at 20 mW cm-2. Group 5: 50 J cm-2 at 20 mW cm-
2. Group 6: 50 J cm-2 at 20 mW cm-2 followed by 50 J cm-2 at 50 mW cm-2. Differences between groups are 
illustrated by arrows and P-values (Student-Newman-Keuls test).
All fractionated groups had higher total damage scores than the single illumination 
group and statistical differences are indicated by arrows with their P-values (ANOVA, 
Student-Newman-Keuls test).
In figure 7 the maximum score reached at any time point within the treated area is 
shown per group of 6 mice. Only in group 1, where a single illumination to 100 J cm-2 
at 50 mW cm-2 is delivered, 3 mice had maximum scores of only 3, representing severe 
edema or a white blister. In all other groups all mice reached maximum scores of either 
4 or 5, representing a thin or thick crust respectively.
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diSCuSSiOn
This study was designed to investigate the efficacy of low fluence rate ALA-PDT in normal 
mouse skin. Our primary outcome was visual skin damage and this model has previously 
succesfully been used as an indicator for clinical PDT efficacy. Our results show that low 
fluence rate ALA-PDT is as effective as high fluence rate PDT in inducing skin damage in 
normal mouse skin. We used real-time PpIX fluorescence spectroscopy to provide us with 
more insight into the complex mechanisms and interactions of light, PpIX formation and 
depletion, oxygen consumption, and photoproduct formation during PDT. Results are in 
line with the concept that low fluence rate ALA-PDT results in more efficient use of avail-
able oxygen. An important and novel modification in the present study was the use of a 
fixed PpIX photobleaching percentage for the first illumination, instead of using a fixed 
fluence. In normal mouse skin using the light treatment parameters we have chosen in 
the present study, the percentage photobleaching is likely to be well correlated to the 
amount of singlet oxygen formed, and therefore to the PDT dose delivered in a single 
light fraction. When using a fixed fluence scheme there is risk of delivering too much 
or too little fluence during the first light fraction due to inter-individual variations in 
photobleaching rate. Previously we have shown that this results in less PDT damage 11. 
For this reason we used real-time fluorescence measurements to determine PpIX pho-
tobleaching as a way of standardizing the effective PDT dose for the first illumination 
in both high and low fluence rate groups. We stress the importance of monitoring PpIX 
photobleaching during illumination since it makes comparing the different illumination 
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Figure 7. The maximum score reached (regardless of day or size) per group of mice. Only in group 1 
(single illumination group) no higher damage score than 3 was observed. Groups 2-6 appear to be similar 
to each other with minimum scores of either 4 or 5 (5=maximum possible score).
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schemes more reliable. We chose to deliver as much fluence as needed to bleach 52% of 
available PpIX for the first illumination, based on previous experiments in normal mouse 
skin. It is important to note that the normalization step should be made with care. 
The fluorescence intensity variations in the skin of normal hairless mice are relatively 
small and on the order of 25% of the average initial PpIX intensity before the first light 
fraction. To accommodate large variations in the initial PpIX concentration in skin that 
may be present in other (clinical) lesions would require a more thorough analysis of PDT 
dose deposition so that the treatment parameters could be changed accordingly. It is 
probable that the ‘optimal’ bleaching dose may be different or variable for individual 
patients and lesions and for different dermatological conditions, which could differ in 
intrinsic response to PDT, blood supply and thickness of the lesion. It should also be 
noted that this photobleaching method is only valid for photosensitizers that undergo 
photobleaching mediated by singlet oxygen alone. For instance, the hematoporphyrin 
derivative Photofrin® can also be bleached by other mechanisms. 34
We also measured reflectance spectra before and after PDT. Previously, we always cor-
rected the PpIX fluorescence measurements for possible changes in optical properties 
of the tissue layer the emitted PpIX fluorescence has to travel through. It is reasonable 
to assume that the tissue absorption will change, due to PDT-induced changes in blood 
flow and saturation. Any change in absorption of this tissue layer will bias the PpIX fluo-
rescence intensity measurements at the skin surface. The results from our reflectance 
measurements, as illustrated in figure 2, indicate that correcting is not necessary when 
using our measurement method. This does not necessarily mean that the tissue optical 
properties in the superficial skin layer do not change; it is possible that other measure-
ment methods could reveal such changes. The measurement volume over which the 
reflectance measurements are taken is much deeper than the superficial treatment 
effect of PDT. The influence of this dimension mismatch will be the scope of future 
investigation.
We were able to reproduce the results that we have found previously. The PpIX photo-
bleaching kinetics for the two-fold illumination schemes at 50 mW cm-2, as illustrated in 
figure 3, show a similar photobleaching rate as previous studies 10, 11, 27 during the first 
and second illumination as well as a comparable increase in PpIX fluorescence to around 
80% of the initial value during the dark interval and subsequent bleaching to under 5% 
at the end of the second illumination. These groups of animals (groups 2 and 3) and their 
results therefore serve as controls for the 20 mW cm-2 groups.
In accordance to several previous studies, we found that illuminating at lower fluence 
rates (20 mW cm-2) results in more efficient PDT than at higher fluence rates (50 mW cm-2), 
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as is illustrated in figure 4 and table 1. Using higher fluence rates causes depletion of 
available oxygen during PDT, interrupting the continuous PpIX photobleaching process. 
The treatment time for the first illumination is approximately two times longer in the 20 
mW cm-2 groups than in the 50 mW cm-2 groups, instead of 50/20 = 2.5 times as would 
be the case if the photobleaching rate were the same. However, the amount of fluence 
needed (and as a result also treatment time) does not decrease proportionally with de-
creasing fluence rate. The consequence of this is that treatment times remain longer at 
lower fluence rates if the same amount of total photobleaching is desired. Our choice of 
low fluence rate in the present study was based on our wish to minimize pain in clinical 
PDT. Since it may be possible to further reduce the pain associated with the illumina-
tion by further reducing the fluence rate, it is interesting to consider the relationship 
between fluence rate and the fluence needed to achieve a fixed photobleaching per-
centage. In previous studies, we and others 26, 27 have shown that the efficiency of PpIX 
photobleaching was even higher when the fluence rate is reduced to 5 mW cm-2 and 
lower for fluence rates above 50 mW cm-2. Finlay et al 26 have shown that the efficiency 
of photobleaching increases even further for lower fluence rates in rat skin. Theoretically 
there will be a maximum efficiency of photobleaching below 1 mW cm-2, where PDT 
efficiency is optimal. The practical value of delivering PDT at these very low fluence rates 
remains unclear, since treatment times will likely be very long at very low fluence rates.
For the second illumination we also observed a trend to faster photobleaching in the 
20 mW cm-2 groups compared to the 50 mW cm-2 groups, as is shown in figure 6. This 
indicates that also for the second illumination, which is longer than the first, low fluence 
rate photobleaching occurs somewhat more efficiently. In the first illumination the dif-
ference is much more obvious however. This may be explained by vasodilatation after 
the first illumination, increasing oxygen availability during the second illumination.
When comparing damage scores between groups, figures 6 and 7 illustrate different 
methods of damage scoring. Groups 1-3 are illumination schemes that we have used in 
previous experiments and skin damage scores are consistent to the results from these 
previous experiments, while groups 4-6 were the low fluence rate groups. As is shown in 
figure 6, the single illumination group 1 has the lowest total damage score. All the other 
groups have higher scores with the highest in group 2 (100 J cm-2 at 50 mW cm-2). Our 
special interest was whether the low fluence rate groups (4, 5 and 6) would score signifi-
cantly better than the single group and not significantly worse than the control group 2. 
All low fluence rate groups have a significant higher total damage score compared to the 
single illumination group. Groups 4 and 6 (100 J cm-2 total) are not statistically different 
from group 2, but only group 5 (50 J cm-2 in total) is borderline statistically worse than 
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group 2. Total differences between all fractionated groups are small however. A small, 
but statistical difference may not necessarily represent a clinically relevant difference.
We used damage to normal mouse skin as a substitute for clinical effect, because this 
model previously proved to be a good translational model 10, 11, 13, 27. In the present study 
we extended the previously used model by measuring maximum damage, which is likely 
to be also indicative of PDT effect. It is important however to realize that in a clinical 
setting, PDT effect is based on destruction of dysplastic tissue instead of normal tissue 
and in human skin instead of mouse skin.
From figure 7 it is clear that in the single illumination (group 1) maximum scores were 
more shifted towards lower scores than in the fractionated groups 2-6, while there is 
no apparent difference in score between these fractionated groups. A difference in the 
results in this scoring method and the one illustrated in figure 6 is that group 5 (50 
J cm-2) has three animals with highest maximum damage scores and doesn’t appear 
to be worse than any other group. Combining the different damage scoring methods, 
there appears to be no difference between high and low fluence rate groups in terms of 
inducing visual skin damage.
Taking the results from this study into account when designing a clinical trial comparing 
low and high fluence rate light fractionated PDT, there are additional considerations. As 
is clear from our results there is no proportional relationship between fluence and flu-
ence rate for a fixed bleaching percentage. This means that treatment times will remain 
longer at lower fluence rates when the same amount of PpIX bleaching is used as a 
treatment metric.
The clinical implications of this are important because treatment times for the second 
illumination could be substantially longer using lower fluence rates. The duration of the 
first illumination is in the order of a few minutes so differences will be small and clinically 
irrelevant. In group 2 (100 J cm-2 at 50 mW cm-2) the second illumination takes 31 min-
utes and at the end on average 3,2% (SD 1,5) of initial PpIX is left. For group 5 (50 J cm-2 
at 20 mW cm-2) the second illumination takes 40 minutes, leaving 7,7% (SD 2,7) of PpIX. 
In group 6 (50 J cm-2 at 50 mW cm-2 followed by 50 J cm-2 at 50 mW cm-2) the second il-
lumination takes 56 minutes and 2,9% (SD 1,0) of PpIX is left. Interestingly, the bleaching 
rate does not change at the point when fluence rate is increased. Probably the amount 
of oxygen is no longer the limiting factor for PpIX photobleaching but the concentration 
of PpIX is. It is unclear however what the biological advantage is of illuminating tissues 
with very little PpIX content. An interesting extension of the present study would be to 
Low fluence rate ALA-PDT 59
use a fixed remaining PpIX percentage to stop the second illumination, but it will be 
difficult to determine this percentage.
It is also important to recognize that mouse skin is considerably thinner compared to 
human skin. Theoretically, deeper layers of skin may need higher total fluences since 
fluence rate decreases exponentially in tissue with increasing depth. Especially in the 
deeper bases of sBCC the fluence at depth may be an important consideration. Also 
the variation in vascularisation of tumor tissue results in variable light absorption and 
oxygen supply. Therefore it theoretically makes sense to have a clinical illumination 
scheme based on the illumination scheme of group 6 (50 J cm-2 at 20 mW cm-2 followed 
by 50 J cm-2 at 50 mW cm-2). Effectiveness is expected to be maintained, pain is expected 
to be minimal and treatment times remain relatively short.
In conclusion the present study shows that low fluence rate, light fractionated ALA-PDT 
appears to be as effective in inducing visual skin damage in mouse skin, while PpIX pho-
tobleaching occurs more efficiently. This in part limits the duration of therapy, although 
lower fluence rate PDT does result in longer illuminations when the same amount of 
photobleaching is desired. There is need for further investigations that should include 
a clinical trial investigating pain and clinical efficacy using low and high fluence rate 
fractionated PDT, while performing PpIX fluorescence measurements. Maintaining 
high efficacy of therapy should be the most important consideration, while pain and 
treatment time must be carefully weighed against each other. Thickness of lesions must 
be taken into account when interpreting the results from the present study because of 
differences in thickness between mouse and human skin.
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abSTraCT
Vascular responses to photodynamic therapy (PDT) may influence the availability of 
oxygen during PDT and the extent of tumor destruction after PDT. However, for topical 
PDT vascular effects are largely unknown. Arteriole and venule diameters were mea-
sured before and after hexylaminolevulinate (HAL) and aminolevulinic acid (ALA) PDT 
and related to the protoporphyrin IX (PpIX) concentration in the vessel wall. A mouse 
skin fold chamber model and an intravital confocal microscope allowed direct imaging 
of the subcutaneous vessels underlying the treated area. In both HAL and ALA groups 
over 60% of arterioles constricted completely, while venules generally did not respond, 
except for two larger veins that constricted partially. Arteriole vasoconstriction strongly 
correlated with PpIX fluorescence intensity in the arteriole wall. Total PpIX fluorescence 
intensity was significantly higher for HAL than ALA for the whole area that was imaged 
but not for the arteriole walls. In conclusion, complete arteriole vasoconstriction occurs 
frequently in both HAL and ALA based topical PDT, especially when relatively high PpIX 
concentrations in arteriole walls are reached. Vasoconstriction will likely influence PDT 
effect and should be considered in studies on topical HAL and ALA-PDT. Also, our results 
may redefine the vasculature as a potential secondary target for topical PDT.
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inTrOduCTiOn
In photodynamic therapy (PDT) sufficient amounts of photosensitizer, oxygen and light 
in tumor tissue lead to the generation of reactive oxygen species, notably singlet oxygen, 
and subsequent destruction of the tumor 1-3. The effectiveness of tumor destruction also 
depends on biological factors such as immunological responses and vascular effects 4, 5. 
The availability of oxygen during PDT as well as the oxygen supply to surviving tumor 
cells after PDT may be influenced by vascular effects 6. Previous in-vivo studies have 
shown that reduced oxygenation during PDT can lead to less efficient and less effec-
tive PDT 7-10. Vascular effects therefore may be very relevant to the efficiency of the PDT 
process. For this reason research has focused in the late 80’s and early 90’s on vascular ef-
fects of PDT. For systemic hematoporphyrin and aminolevulinic acid (ALA)-PDT vascular 
effects such as arteriole vasoconstriction, endothelial damage and reduced blood flow 
have been well documented 11-18.
For topical PDT with porphyrin precursors however, there is a limited amount of publica-
tions on vascular effects. Since topical PDT is used frequently (particularly in dermatol-
ogy), it is important to also investigate and understand the vascular mechanisms. In 
dermatology, ALA is used for treating non melanoma skin cancers, while HAL is currently 
registered for photodiagnosis of bladder cancer, but might also be used for therapeutic 
applications in the future. For topical ALA-PDT, some studies have focused on trans epi-
dermal spectroscopic measurements and found reduced blood flow 19, 20 and a decrease 
of intravasal fluorescein fluorescence, indicating vasoconstriction 21. In other studies, 
blood vessels were measured microscopically in a similar animal model as we have used 
for ALA in which vasoconstriction 22 and loss of functional vessels 23 were found. Only 
two studies describe the vascular effects of topical hexyaminolevulinate (HAL)-PDT. In 
both, a spectroscopic approach was used; in one to measure fluorescein fluorescence 
decrease in mouse skin vessels 24 and in the other to measure blood concentration in 
human skin, which increased after PDT 25.
An important underlying question is to try and understand why and in particular over 
what timescale vessels respond during and following PDT. It is logical to assume that 
constriction of blood vessels is related to the ability of the vessel wall to accumulate 
PpIX. In this respect it is important to consider the differences between the photosensi-
tizer precursors that we investigated. Both HAL and ALA lead to the intracellular forma-
tion and accumulation of the photosensitizer protoporphyrin IX (PpIX). Because ALA is 
a hydrophilic molecule it does not penetrate well through the lipophilic upper layers 
of skin, especially the stratum corneum 26. To overcome this, more lipophilic esters of 
ALA became commercially available, claiming deeper penetration and possibly higher 
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affinity for tumor cells. These esters, of which HAL is one example, enter cells by different 
uptake mechanisms than ALA. The uptake of ALA depends largely on active transport 
into cells through BETA transporters 27, 28, whereas ALA esters have been described to 
depend on PEPT1 or PEPT2 transporters 29. It was also concluded that for neither ALA or 
ALA esters, diffusion is responsible for cellular uptake, a conclusion based on oil-water 
distribution coefficients 30, 31. For the ability of the vessel wall to accumulate PpIX, these 
uptake mechanisms may be relevant with respect to the vascular response after HAL or 
ALA-PDT. Vascular endothelial cells have been demonstrated to accumulate PpIX after 
both HAL and ALA application in vitro 32 and for ALA it was demonstrated that vessel 
walls accumulate PpIX in vivo 33.
In summary the vascular effects of topical PDT, in particular of HAL-PDT are not well 
known, as well as the relation between the ability of the vessel wall to accumulate PpIX 
and the vascular response. Therefore we investigated the in vivo PpIX distribution in 
tissue including the vessel walls after topical HAL application in mice, the effect of PDT 
on the venule and arteriole diameters and compared this with ALA. We used a skin fold 
chamber model and intravital confocal microscopy. This geometry allowed us to inter-
rogate the vasculature directly without being hampered by overlying epidermis. This is 
different from previous studies that imaged through the epidermis as described above. 
Primary outcomes were vascular response, measured as change in vessel diameter and 
PpIX fluorescence intensity.
MaTErialS and METhOdS
Experimental setup
A dorsal skin fold mouse model was prepared as described in another study 22. The setup 
is schematically illustrated in Figure 1. On one side of the fold, the skin was completely 
removed up to the cutaneous muscular layer of the opposed skin. The fold was then 
fixed with light metal bolts and sutures and closed with a glass cover slide. The intact 
side was used to apply ALA or HAL to the skin and for PDT light delivery. The non-intact 
side was used to take transmission and fluorescence images using a confocal micro-
scope before and after PDT. Window chamber preparation, drug and light delivery, and 
image recording were all performed under general anaesthesia.
Treatment groups and drug delivery
Ten female albino hairless mice (SKH1 HR, Charles River, Someren, The Netherlands) 
were included in this experiment, divided in two groups of five mice. The mice were 
put on a chlorophyll-free diet two weeks prior to treatment to remove autofluorescence 
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from pheophorbide-a. The study was approved by the animal experimental committee 
of the Erasmus University Medical Center.
In one group of five mice 20% ALA (Fagron, Oud Beijerland, The Netherlands) in carboxy-
methylcelluse in water and NaOH (pH=4) and in the other group of five mice 5% HAL 
ointment (Photocure, Oslo, Norway) was applied to the skin. ALA and HAL were occluded 
in the dark for 4 hours before light delivery. In 3 mice from the ALA group and 5 mice 
from the HAL group, 0.2 mg fluorescein (FITC-BSA, Sigma) was injected intravenously 
directly after illuminations, to visualize delayed vascular response in a different way. In 
the remaining two ALA animals the fluorescein injection failed so for these animals no 
data for the fluorescein time-point were obtained.
Confocal imaging
Prior to ALA or HAL application autofluorescence spectra were obtained using an intra-
vital confocal microscope (Zeiss LSM510META, Carl Zeiss B.V., Sliedrecht, The Nether-
lands). Four hours after ALA or HAL application PpIX was excited using 514 nm laser light 
and fluorescence was recorded in lambda mode (695-681 nm) using a 10x objective 
and an optical slice thickness of 40 µm. Immediately hereafter transmission images of 
the same location were taken. For each mouse images were obtained from two or three 
confocal microscope 
(imaging pre and post PDT) 
laser  
(PDT light delivery) 
HAL or ALA 
630 nm 
514 nm 
fluorescence 
intact skin side removed skin side 
blood vessel 
epidermis subcutis 
Figure 1. Experimental setup. Schematic representation of the mouse skin fold model. Removing the skin 
on one side allowed detailed confocal imaging of the subcutaneous blood vessels and PpIX fluorescence 
before and after topical HAL or ALA based PDT.
68 Chapter 4
different representative locations at 100x magnification for all images, plus an overview 
image at 20x that was not included in later analysis. After PDT light delivery transmission 
images were taken again from the same location. Twenty minutes later transmission and 
fluorescein fluorescence images were recorded in some mice using 488 nm excitation 
light and a 505-515 nm band pass filter for detection.
PdT light delivery
All mice received a single dose of 100 J cm-2 at 65 mW cm-2, using a 630 nm laser (Visuals 
630, Carls Zeiss B.V., Sliedrecht, The Netherlands). Light was focused on a 7 mm diam-
eter area using a microlens. A fluence rate of 65 mW cm-2 was chosen to allow for the 
comparison of PDT performed previously at 50 mW cm-2 using 514 nm illumination. The 
rationale for this choice is discussed in a previous study from our group 22.
image analysis
The PpIX fluorescence intensity was corrected for autofluorescence as described previ-
ously 34.
A sequence of images taken from the same location was imported and analysed using 
ImageJ software (ImageJ 1.46, National Institute of Health, USA). Each sequence con-
sisted of a transmission image before PDT, a PpIX fluorescence image, a transmission 
image directly after PDT and transmission and fluorescein fluorescence images twenty 
minutes after PDT.
Two types of analysis were made: one to measure the vascular response to PDT and 
another to measure the distribution of PpIX fluorescence intensity in the tissue. The 
investigator was blinded for the treatment groups.
To measure the vascular response to PDT, venule and arteriole diameters were measured 
in the transmission images before and after PDT, and in the transmission image twenty 
minutes after PDT. Vasoconstriction was defined as: (1- vessel diameter after PDT / vessel 
diameter before PDT)* 100%.
To measure the PpIX distribution, regions of interest (ROIs) were drawn in the transmis-
sion image before PDT in different tissue types: adipose tissue, venule wall, venule centre 
and arteriole wall. For all tissue types ROIs from different locations were drawn. The PpIX 
fluorescence intensity of the ROIs was subsequently measured in the corresponding 
fluorescence image.
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Data were exported to Excel, Office Professional Plus 2010 and to IBM SPSS statistics 21 
and subsequently analysed.
Statistics
Vasoconstriction was descriptively analysed by means of medians and interquartile 
ranges. Each vessel measurement was considered as an independent variable, resulting 
in n=14 measurements in the HAL group and n=15 measurement in the ALA group. 
Non-parametric tests were used to compare differences within and between groups. 
PpIX distribution in tissue was analysed by means of descriptive statistics presented as 
means and standard deviations and a two-sided student’s t-test to test for statistical 
significance. A two-sided P-value of 0.05 was considered statistically significant.
rESulTS
Vascular response to PdT
The arteriole vascular response was similar for HAL and ALA. Complete vasoconstriction 
-i.e. no arteriole could be seen in the transmission image immediately after PDT- oc-
curred in 64% (9 out of 14) of arterioles for HAL and in 60% (9 out of 15) for ALA. Other 
arterioles constricted partially, except for two in the ALA group that dilated instead. 
Overall, the arteriole diameter after PDT was significantly lower than before PDT in both 
HAL and ALA groups (P=0.001 and P=0.003 respectively, Wilcoxon signed rank test). 
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Figure 2. Vascular response of arterioles at different time-points. For both HAL (black) and ALA (grey) 
median arteriole diameter decreased to zero immediately after PDT, indicating complete vasocontriction. 
Twenty minutes after PDT arterioles remained partly contricted. Error bars indicate the 75th percentile.
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Between the HAL and ALA groups there was no significant difference in vasoconstric-
tion after PDT (P=0.91, Mann-Whitney U test). In the subset of arterioles that received 
fluorescein and were imaged twenty minutes after PDT (n=11 for HAL and n=6 for ALA), 
arterioles frequently remained constricted, and this was still significantly different from 
before PDT in the HAL group. The fluorescein injection and subsequent proper imaging 
failed in a number of cases, which explains the lower numbers of arterioles included 
in this analysis. Figure 2 illustrates the vascular response of the arterioles at different 
time-points.
In contrast, the venules that were imaged at 100x magnification did not show constric-
tion after PDT. Only in the HAL group two larger (> 150 µm) feeder veins imaged at 20x 
magnification showed partial constriction at several sites along the vein.
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Figure 3. Relationship between PpIX fluorescence intensity and vasoconstriction. The relation 
between PpIX fluorescence intensity of individual arteriole walls and the arteriole vasocontriction 
immediately after PDT for HAL (a) and ALA (b). Relatively high PpIX fluorescence intensities resulted in 
100% vasoconsriction, while relatively low PpIX fluorescence intensities resulted in various degrees of 
vasoconstriction. This relation is similar for HAL and ALA.
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relation between vascular response and PpiX fluorescence intensity
The amount of arteriole vasoconstriction immediately after PDT strongly correlated with 
the PpIX fluorescence intensity in the arteriole wall for both HAL (Figure 3a) and ALA 
(Figure 3b). Spearman’s correlation coefficient was 0.75 (P=0.002) for HAL and 0.73 for 
ALA (P=0.002). In the arterioles that had relatively high PpIX fluorescence intensity in 
the vessel wall, vasoconstriction frequently was 100%. Lower PpIX fluorescence intensi-
ties correlated with various degrees of vasoconstriction. The two arterioles that dilated 
-indicated by the negative vasoconstriction values in figure 3b- were from one particular 
ALA mouse and in this mouse there was a very low PpIX fluorescence intensity in all ROIs 
(adipose tissue, vessel walls and vessel centres).
Spatial distribution of PpiX
PpIX fluorescence intensity for all regions of interest combined was higher for HAL than 
ALA (P=0.00083, two-sided student’s t-test). For the individual ROIs this difference was 
significant for the venule wall (P=0.0252) and venule centre (P=0.0029), but not for the 
arteriole wall (P=0.259) or adipose tissue (P=0.153). The PpIX fluorescence intensity for 
HAL and ALA in the different regions of interest is illustrated in figure 4.
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Figure 4. Mean PpIX fluorescence intensity in various tissue regions: HAL versus ALA. In the HAL group 
overall mean PpIX fluorescence intensity was higher than in the ALA group (P=0.00083). For the individual 
regions, PpIX fluorescence intensity was significantly higher in the venule wall (P=0.0252) and venule 
centre (P=0.0029) but the difference was not significant for the arteriole wall (P=0.259) and adipose tissue 
(P=0.153). Error bars indicate one standard deviation.
Confocal image example
Figure 5 shows a representative example of the images obtained using the confocal 
microscope. Figure 5a is a transmission image before PDT; figure 5b is the transmission 
image taken immediately after PDT; figure 5c is the transmission and 5d the fluorescein 
fluorescence image 20 minutes after PDT. These images illustrate that the arteriole (black 
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arrow in figure 5a) is completely constricted immediately and twenty minutes after PDT. 
The contour of the arteriole can still be seen in the fluorescein image indicating the pres-
ence of FITC-labelled albumin. This type of response was seen in most measurements.
a b 
c d 
Figure 5. Typical confocal images taken at different time points illustrating arteriole response. The 
transmission images before (a) and immediately after (b) PDT show complete vasoconstriction of the 
arteriole (black arrow) while the venule (white arrow) does not show any response. Twenty minutes after 
PDT (c) the arteriole is still constricted but vaguely visible in the fluorescein fluorescence image (d). Each 
image measures 0.9*0.9 mm, magnification 100x.
diSCuSSiOn
This study was designed to investigate the effects of topical HAL and ALA-PDT on the 
underlying vasculature in a mouse skin fold chamber, and to investigate the ability of 
the vessel wall to accumulate PpIX. Interestingly, HAL and ALA had similar effects in 
terms of both vascular response and PpIX distribution in the vessel wall. The vascular 
effect was very clear for the arterioles as nearly all of them showed vasoconstriction 
after PDT and in most cases this constriction was 100% and lasted at least 20 minutes. 
The extent of vasoconstriction strongly correlated with the PpIX fluorescence intensity 
in the arteriole wall. In contrast to the arterioles, the venules did not respond to PDT 
but two larger veins did. This may be explained by the relative inability of venules to 
constrict, whereas larger veins have some constrictive ability. Our findings are important 
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because they reveal so far unknown pharmacokinetic characteristics of PpIX after the 
topical administration of HAL. In contrast to what is commonly believed, the depth of 
penetration was no limitation in this mouse skin model for both HAL and ALA as these 
molecules penetrated the skin well into the subcutis. They were also capable of actually 
entering the subcutaneous vessel wall, leading to biologically relevant PpIX accumula-
tion. This has not been demonstrated in vivo for HAL, and is in accordance with a study 
that demonstrated PpIX formation in endothelial cells after HAL application in vitro 32. 
For ALA the results are comparable to a previous study from our group in which a similar 
mouse chamber model was used. ALA resulted in higher endothelial PpIX accumulation 
and more extensive vascular effects than methylaminolevulinate (MAL) 22. Our results 
also show that when the PpIX concentration in the endothelial cells is high enough, 
the arterioles will show complete vasoconstriction. As figure 4 shows, high PpIX fluo-
rescence intensities resulted in 100% vasoconstriction, whereas low PpIX fluorescence 
intensities resulted in no or partial vasoconstriction. This suggests a PpIX concentration 
threshold in the vessel wall that results in complete vasoconstriction.
The finding that arterioles show PpIX-dose dependent vasoconstriction is important for 
our understanding of topical PDT mechanisms and, as a result, possibly for the optimiza-
tion of future HAL or ALA-PDT protocols. Complete vasoconstriction especially can be 
of great relevance for PDT outcome. For instance when this happens early during the 
illumination, oxygen supply to the PDT site may be insufficient, resulting in an inefficient 
photodynamic effect. On the other hand, complete vasoconstriction could also be ben-
eficial to PDT outcome, especially when it occurs late or after PDT when most PpIX has 
already been bleached. Our finding indicate that in many cases, the constriction lasted 
at least 20 minutes after PDT. Such longer duration of ischemia could further damage 
and help destroy (tumor) cells that survived the oxidative damage of the PDT. Complete 
vasoconstriction may also be relevant to other uses for topical HAL or ALA PDT where the 
vasculature can be a potential target, such as port wine stains. One animal study clearly 
showed that tumor vasculature could be destroyed 18 using topical ALA-PDT. However, 
tumour cell photosensitization was a more important factor for tumor destruction than 
vascular photosensitization. This suggests that vascular effects are not primarily respon-
sible for tumor cell destruction but may be an important secondary factor.
When comparing our results with those from other investigators it is important to 
note that a relevant comparison cannot be made between topical and systemic ad-
ministration of porphyrin pre-cursors. The bio-distribution of PpIX after the systemic 
administration of ALA and HAL are known to be significantly different than after topical 
administration 35. We have therefore only compared our findings to others that have 
investigated vascular responses after topical HAL or ALA-PDT. The only study conducted 
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so far that investigated vascular effects after topical HAL-PDT in mice found no vasocon-
striction after 3 hours of HAL application, while 17 hours of HAL application resulted in 
complete vasoconstriction 24. The results of this study are in general agreement with our 
proposed dose dependent threshold mechanism, but their findings after 3 hours are 
different from ours. As these investigators used fluorescein angiography using a camera 
that imaged the skin from above, their experimental design was not sensitive enough to 
detect small arteriole constriction. It may well be that larger, deeper arteries were also 
imaged that constricted under very high PpIX circumstances, which occurred only after 
17 hours of HAL application. It is likely that after such a long application time HAL is 
distributed throughout the entire thickness of the skin, as longer application times lead 
to deeper penetration 36. In contrast, we measured only superficial arterioles directly 
and on a microscopic rather than a macroscopic scale, which allows for more detailed 
measurements.
Interestingly, the same group of investigators have also investigated the PDT response 
after topical HAL application in human skin, and found increased blood volume imme-
diately after PDT 25. That study used reflectance spectroscopy to assess the response 
over a time-period of two weeks in five healthy volunteers. Possible explanations for 
this could lie in the differences in structure between mouse and human skin. Maybe 
the HAL did not penetrate deep enough to result in high enough PpIX accumulation in 
the vessels. Another plausible explanation is that the diffuse reflectance spectroscopy 
used was measuring vasodilatation in deeper blood vessels. These deeper vessels may 
respond differently to PDT than superficial ones. This distinction between deep and su-
perficial blood vessels is relevant, because the superficial blood vessels directly supply 
the oxygen that is necessary for PDT. Larger, deeper blood vessels on the other hand 
may deliver blood to the surrounding skin area, and not to the skin that is immediately 
above it. Furthermore, techniques such as diffuse reflectance spectroscopy measure 
combined information from both arterioles and venules, which we have shown to 
respond completely different to PDT. The depth at which vessels are measured and the 
difference between macroscopic versus microscopic measurements are also important 
considerations when viewing our results against the background of studies that investi-
gated vascular effects of topical ALA-PDT.
One approach that has been used to measure vascular response after topical ALA-PDT 
is measuring the depletion of fluorescein fluorescence using a camera that is some 
distance away from the skin 21. A decrease in fluorescein signal is indicative of vasocon-
striction. Another approach is to measure blood flow using laser Doppler imaging 20, 37 
or diffuse correlation spectroscopy 19. As mentioned above, these type of approaches 
measure on a much larger scale and will be greatly influenced by signals from deeper 
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blood vessels. Two studies used a similar chamber model to investigate blood vessel 
response after topical ALA-PDT and concluded that topical ALA-PDT leads to distinct 
vasoconstriction responses 22, 23. In the first, a study performed by our own group 22, the 
vascular effects of high versus low fluence PDT was investigated for ALA and another 
ester of ALA, methylaminolevulinate (MAL). In addition to imaging the subcutaneous 
vessels directly, trans-epidermal images were also obtained which yielded less sensitive 
results. The extent of vascular damage for the high fluence ALA-PDT group was very 
similar to our results for ALA. In the second study, 23 a decrease in functional vessels and 
reduced blood flow for ALA was found using a hamster dorsal skin fold model. In the 
current study we investigated not only ALA, but also HAL. Furthermore, we also included 
the relationship between vascular response and PpIX concentration in the vessel wall.
There are of course some limitations to the present study. First, the results are based on a 
limited number of mice (5 in each group). To increase accuracy we measured 3 arterioles 
in each mice and performed statistics on these numbers, resulting in 15 arterioles in 
the HAL and 14 arterioles in the ALA group (in one mouse we could only image two 
arterioles instead of three explaining the difference). It may be argued whether or not 
the averaged results per mouse would be a better way to analyse the data, although 
this results in loss of information. Our choice is further supported by finding no different 
distribution of arteriole responses between individual mice for HAL, our primary group 
of interest (P=0.261, Kruskall Wallis independent samples test) and also for ALA (P=0.06) 
if the one mouse that hardly accumulated PpIX is excluded. A second drawback is that 
we did not measure tissue oxygenation during, or skin damage after PDT. Then it would 
have been possible to correlate vasoconstriction with tissue ischemia and with treat-
ment effect. Also, our setup only allowed us to measure vascular response after, but not 
during PDT. This means that we were unable to measure dynamic vascular responses 
during illumination that could help explain blood flow dynamics such as found by 
Becker et al 19. Temporal dynamics of vasoconstriction may be important because very 
high PpIX concentrations in the arteriole wall may lead to vasoconstriction very early in 
the PDT process, leading to insufficient oxygen availability and therefore inefficient or 
ineffective PDT. Therefore prolonged application times may not be the way to increase 
response, as vascular effects start to play an important limiting role.
Assuming that the extent of vasoconstriction depends on the PpIX concentration in the 
vessel wall it is not surprising that complete arteriole vasoconstriction occurred about 
as frequent for HAL (64%) as for ALA (60%) since there was no difference in PpIX con-
centration in the arteriole wall between the two. However, considering all our outcome 
measures it seems that HAL may be more potent than ALA in inducing vascular effects, 
even though we found no statistical differences between them. The HAL concentration 
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we used was lower than that of ALA, but the resulting PpIX concentration in tissue was 
generally higher. Also, the two larger veins that constricted partially were from the HAL 
group. Finally, more arterioles remained constricted twenty minutes after PDT in the 
HAL group than the ALA group. This last finding should be interpreted with caution 
since these measurements were only performed in a subset of arterioles. In this subset 
the measurements in the ALA group were greatly influenced by the one mouse in which 
PpIX concentration was very low and the arterioles actually dilated. Despite the differ-
ences between HAL and ALA, our results suggest a similar biological behaviour of HAL 
and ALA in terms of vascular response and distribution of PpIX in vessel walls.
This similarity in biological behaviour between HAL and ALA is especially interesting 
when compared with MAL. Several studies have shown that lower concentrations of 
HAL than of ALA and lower concentrations of ALA than of MAL are needed to reach the 
same PpIX concentrations in different models 38-42, although some investigators found 
contradictory results 43-45. The same holds true for PpIX concentration in the vascular 
endothelium, which was investigated in vitro 32 and in vivo 33, 46, resulting in more vaso-
constriction using ALA than MAL 22. These biological behavioural differences between 
ALA and MAL have also been suggested to play a role in the mechanism behind light 
fractionated PDT. A two hour dark interval followed by a second light fraction resulted 
in increased PDT effect for ALA 47 but not for MAL in normal mouse skin 48. Using this 
type of light fractionation for HAL has not been investigated yet. Our results indicate a 
similar behaviour of HAL and ALA, so it can be speculated that light fractionation may 
be valuable to increase effect of HAL PDT as well. In accordance with this speculation, 
a short light fractionation protocol was investigated for HAL-PDT in one animal study, 
increasing the response 49.
It should be noted that the translational step towards clinical use of HAL in relation to 
our results should be taken carefully (for both skin and other epithelial surfaces). Be-
sides obvious general differences between mouse and human biology, there are other 
specific considerations. Normal human skin is considerably thicker than mouse skin. 
This is of great relevance for the ability of HAL and ALA to penetrate into the dermis 
and into vessel walls. This may result in less PpIX accumulation in the vessel walls in 
thick human skin. If our proposed dose-dependent mechanism works for humans too, 
we would then expect less vasoconstriction in human skin. In addition to differences 
in thickness, the anatomy of normal mouse skin vasculature also differs from normal 
human skin, which has a superficial and a deep plexus. Furthermore, for skin lesions 
that are typically treated with PDT such as superficial basal cell carcinoma (BCC), the 
vasculature is in turn different from normal skin. Not only is the amount and diameter 
of blood vessels increased in BCC, they also tend to grow in a disorganized pattern and 
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may not have the same muscular power to constrict 50, 51. Finally, individual patients and 
lesions may vary in their vascular response to PDT, as was found for both BCC 19 and 
actinic keratosis 52. The vasodilatation found in HAL-PDT of normal human skin 25 versus 
the vasoconstriction that was found in ALA and MAL-PDT of BCC 37 illustrates that the 
vascular responses of PDT in human skin need further study.
In conclusion, arteriole vasoconstriction occurred frequently in both HAL and ALA based 
topical PDT in our mouse model, especially when relatively high PpIX concentrations in 
arteriole walls were reached. Venules in general did not respond. However, larger veins 
that have more constrictive ability may also constrict after PDT, since two of them did 
in this study. Overall PpIX concentration was higher in the HAL group than in the ALA 
group, but this difference was not significant for the arteriole walls. Vasoconstriction 
will likely influence PDT effect and should also be considered in studies on topical HAL 
and ALA-PDT in humans. Also, our results may redefine the vasculature as a potential 
secondary target for topical HAL and ALA based PDT.
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abSTraCT
Different distributions of hexyl-aminolevulinate (HAL), aminolevulinic acid (ALA) and 
methyl-aminolevulinate (MAL) in the superficial vasculature are not well studied but 
they are hypothesised to play an important role in topical photodynamic therapy (PDT). 
The colocalisation of fluorescent CD31 and protoporphyrin IX (PpIX) was calculated us-
ing confocal microscopy of mouse skin sections to investigate the vascular distribution 
after topical application. Vascular damage leads to disruption of the normal endothelial 
adherens junction complex, of which CD144 is an integral component. Therefore normal 
CD31 combined with loss of normal fluorescent CD144 staining was visually scored to 
assess vascular damage. Both the vascular PpIX concentration and the vascular damage 
were highest for HAL, then ALA and then MAL. Vascular damage in MAL was not differ-
ent from normal contralateral control skin. This pattern is consistent with literature data 
on vasoconstriction after PDT, and with the hypothesis that the vasculature plays a role 
in light fractionation that increases efficacy for HAL and ALA-PDT but not for MAL. These 
findings indicate that endothelial cells of superficial blood vessels synthesize biologi-
cally relevant PpIX concentrations, leading to vascular damage. Such vascular effects are 
expected to influence the oxygenation of tissue after PDT which can be important for 
treatment efficacy.
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inTrOduCTiOn
In skin photodynamic therapy (PDT) both aminolevulinic acid (ALA) and its methyl 
ester methylaminolevulinate (MAL) are being used worldwide for treating malignant 
and premalignant skin disease. Another ester derivative of ALA is hexylaminolevulinate 
(HAL). HAL ointment is registered for photodiagnosis of, and for margin establishment 
during surgery of bladder cancer but research is ongoing investigating its therapeutic 
use in the skin, cervix and bladder 1-6. HAL, ALA and MAL are porphyrin precursors that 
lead to intramitochondrial accumulation of protopophyrin IX, but they have different 
pharmacokinetic properties. These properties are in part related to the more lipophilic 
character of HAL and MAL compared to ALA, but are also related to known differences 
in cellular uptake mechanisms 7-9. This will lead to differences in penetration and bio-
distribution between them after topical application, which may account for otherwise 
unexplained differences in biological behaviour. In particular the biodistribution in the 
superficial vasculature could be important to account for these differences. It is known 
that prolonged topical ALA application results in systemic distribution of PpIX, whereas 
PpIX is restricted to the site of MAL application in mice 10, 11. Furthermore, subcutaneous 
arterioles completely constricted directly after topical HAL and ALA-PDT of mouse skin 
12, while this was less frequent for MAL-PDT 13. Related to this, in vitro data show that HAL 
is more potent than ALA, which in turn is more potent than MAL in photosensitising hu-
man endothelial cells 14. Also, there is more dermal oedema after light fractionated PDT 
in ALA than MAL: an indirect indication that leakage through the dermal vessel walls is 
an acute response to light fractionated ALA-PDT 15. These and other studies 15-17 have led 
our group to hypothesize that the vasculature also plays a critical role in the mechanism 
behind the response to light fractionation. Light fractionation involves delivery of a 
small first light fraction, followed by a dark interval of two hours and a larger second 
light fraction. It improves the preclinical and clinical response of ALA-PDT, but not of 
MAL-PDT in mouse skin 16, 18. Recent data suggest that light fractionation is also beneficial 
for HAL-PDT 19. We postulate that these differences in response to light fractionation are 
related to differences in vascular sensitization between the three porphyrin precursors.
However, there remain areas of ambiguity. First, it has not been studied if and to what 
extent the blood vessels in the superficial dermis accumulate PpIX. Second, it is unknown 
if PDT using porphyrin precursors damages these vessels, as opposed to causing transi-
tory vasoconstriction which subsequently recovers. For these reasons we conducted the 
present study, performed on normal mouse skin. The study has two parts: a study of 
the vascular distribution of PpIX in dermal blood vessels after topical HAL, ALA or MAL 
application (part A), and a study of the vascular damage for each porphyrin precursor 
after PDT (part B). For both part A and B the vasculature was visualized in frozen sections 
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of skin biopsies using fluorescent CD31 (platelet endothelial cell adhesion molecule) an-
tibodies, a commonly used marker for this purpose. Confocal microscopy images were 
subsequently analysed to calculate the co-localisation of PpIX and CD31 as a measure for 
the distribution of PpIX in endothelial cells (part A). To study the presence and the extent 
of vascular damage to these superficial blood vessels after light fractionated PDT (part 
B), a combination of fluorescent-labelled CD31 and CD144 antibodies were used. The 
integrity of the vasculature was imaged and scored using a confocal microscope. CD144 
-vascular endothelial cadherin- is an integral component of the endothelial adherens 
junction complex. Endothelial damage results in a disruption of the normal endothelial 
complex so that CD144 can no longer be stained along the plasma membrane. This ef-
fect is maximal after 24 hours, after which CD144 is slowly restored 20, 21.
MaTErialS and METhOdS
a: The vascular distribution of PpiX, 4 hours after the application of hal, 
ala or Mal (the time-point at which light fractionated PdT is performed as 
described in b).
Animals and drug delivery
A total of 20 SKH1-hr mice (Charles River, Someren, The Netherlands) were divided in 4 
groups of 5 mice. In the first 3 groups different porphyrin precursors were applied on a 
7mm skin area: 5% HAL ointment, 16% MAL cream or 20% ALA gel. The 4th group was 
the control group in which only the gel was applied. The HAL ointment and MAL cream 
were the standard commercially available products from Photocure (Oslo, Norway) and 
Galderma (Freiburg Germany) respectively. The ALA gels were freshly prepared by dis-
solving ALA (Fagron, Oud Beijerland, The Netherlands) in 3% carboxymethylcellulose in 
water with NaOH added to reach pH4.
Tissue sampling and imaging
After 4 hours occlusion a 5 mm punch biopsy was taken from the center of the applica-
tion area and snap frozen in liquid nitrogen. On the day before fluorescence imaging 3 
frozen sections (10 µm) from each biopsy were cut under subdued light conditions to 
prevent PpIX photobleaching. In order not to wash out the PpIX fluorescence we chose 
to minimize the staining procedure and to omit the fixation step. Sections were carefully 
washed with a few drops of PBS and incubated with rat anti-mouse CD31 conjugated 
with Alexa Fluor® 488 (BioLegend, Uithoorn, The Netherlands) diluted 1:200 in PBS over-
night at 4°C. Sections were re-washed carefully with PBS and covered with glycerol (1:3 
in PBS).
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The distributions of PpIX and AlexaFluor (CD31) in the dermis were imaged at a resolu-
tion of 512x512 pixels using a confocal microscope (Zeiss, LSM 510 Meta) in lambda 
mode at 400x magnification. PpIX was imaged first utilizing 405 nm excitation light and 
spectral detection between 582 and 753 nm. Immediately thereafter Alexa Fluor® 488 
was imaged under 488 nm excitation and a band pass filter (BP 530/600) or spectral 
detection between 493 and 753 nm. From each section 3 areas were imaged in which 
blood vessels were clearly visible, using a slice thickness of 5 µm. The images were ex-
ported and analyzed using ImageJ software (version 1.46, National Institute of Health, 
USA).
An important consideration in this type of approach is artefacts, normally termed bleed-
through/overlap, caused by a significant background contribution of each fluorophore 
in the emission band of the other fluorophore. Preliminary experiments using control 
samples and singularly stained sections showed that there is no influence from PpIX flu-
orescence in the detected emission band of AlexaFluor®488 (BP 530-600 nm) and a neg-
ligible influence of the tail of AlexFluor®488 fluorescence in the detected emission band 
of PpIX (620–710 nm) under 405 nm excitation. The contribution of autofluorescence in 
both emission bands was accounted for by performing a background subtraction based 
on an average uniform autofluorescence collected from control sections containing only 
PpIX or AlexFluor®488 from the region of interest within which colocalisation analyses 
were performed.
Colocalisation analysis
Our primary outcome was the colocalisation between PpIX and AlexaFluor in the vessel 
wall. To calculate the extent of colocalisation, regions of interest were drawn following 
all visible vessel walls. In these regions of interest the fluorescence intensities of PpIX 
and Alexa Fluor were measured. The colocalisation was calculated in two ways. First, the 
degree of correlation between theCD31 and PpIX fluorescence intensities for each pixel 
in the region of interest were calculated and expressed as the intensity Pearson’s cor-
relation coefficient. Second, Mander’s coefficients were calculated over the same region 
of interest, which are another measure for the degree of colocalisation 22. This analysis 
yields two outcomes: M1 and M2. M1 is the proportion of PpIX positive pixels that also 
contain a CD31 signal intensity larger than zero. M2 is the proportion of CD31 positive 
pixels that also contain a PpIX signal intensity larger than zero.
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b: Vascular damage after light fractionated hal, ala or Mal-PdT.
Animals, drug delivery and light fractionated PDT
A total of 12 SKH1 HR mice were divided into three groups of four animals. Either HAL 
ointment, MAL cream or ALA gel was applied to a 7 mm skin area and occluded for four 
hours. Then the area was illuminated using 532 nm laser light at a fluence rate of 89 
mWcm-2 to a dose at which 50% of PpIX was bleached (on average this was approximately 
3 J cm-2). The 89 mWcm-2 was calculated to be equivalent to delivery of 50 mWcm-2 at 514 
nm, which is what we used in most previous experiments. This calculation is based on 
the PpIX absorption and photon energy for these wavelengths. The rationale for the 50% 
photobleaching dose is explained in more detail elsewhere 23, 24. After a dark interval of 
two hours a second illumination was delivered to reach a total dose of 100 J cm-2.
Tissue sampling and imaging
At 24 hours after PDT, a 7 mm biopsy was taken from the treated area and from contra-
lateral control skin, sectioned, stained, imaged and analyzed. Both the staining method 
and the imaging analysis were different from the methods described in A. Frozen sec-
tions were fixated with acetone (20 min), cellular permeability was increased using 0.5% 
triton in 1% BSA in PBS (30 min) and non-specific staining was reduced using 5% BSA in 
PBS (60 min). The vessel wall was visualized by staining with anti CD31 conjugated with 
AlexaFluor®647 (BioLegend, San Diego, CA, USA) in 1% BSA in PBS. To determine damage 
to the vessel wall the sections were also stained with anti-CD144 conjugated with biotin 
in 1% BSA in PBS. Both CD31 and CD144 stainings were performed simultaneously at 4°C 
overnight, followed by biotin-specific staining with streptavidin efluor 570 in 1% BSA in 
PBS (both from eBioscience, Vienna, Austria) the next morning.
Scoring of vascular damage
In each section three 400x images were scored for the presence of vascular damage 
which was our primary outcome for this part of the study. Vascular damage was defined 
as the absence of an identifiable blood vessel in the CD144 staining while there was a 
blood vessel visible in the CD31 staining. This scoring method was applied to both the 
PDT treated skin and the contralateral control skin. This resulted in 9 scores of vascular 
damage (yes/no) per mouse for the PDT skin sections and another 9 for the control skin. 
The investigator was blinded from the treatment groups.
Drug application, taking the biopsies and performing PDT were all performed under 
general anesthesia. The experiments were approved by the local animal experiments 
committee.
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Part a: PpiX colocalisation with Cd31
There was clear PpIX fluorescence in the epidermis and in hair follicles for all three 
groups (HAL, ALA, MAL). In the dermis there was much less PpIX signal. Some of the 
dermal PpIX was visible as spindle shaped fluorescence throughout the interstitial up-
per dermis, corresponding to dermal fibroblasts. In many cases the PpIX fluorescence 
was visibly located in the wall of a superficial blood vessel, which was also positively 
stained with CD31 (Figure 1).
Figure 1. Illustrative example of a PpIX fluorescence image (upper) and the corresponding 
Alexafluor®488-conjugated CD31 fluorescence image (lower). Note the presence of PpIX in the epidermis 
(black arrow) and in the endothelium of a dermal blood vessel (white arrows). There was also some none-
specific CD31 staining in the epidermis. Magnification 400x.
Such colocalisation of PpIX with CD31 was variable per mouse in all groups. On aver-
age the highest colocalisation was observed in the HAL group, less in the ALA and MAL 
groups and the lowest in the control skin (Figure 2). Both the average correlation and 
M2 coefficients per mouse in the three groups (HAL, ALA and MAL) were significantly 
different from the control group (correlation coefficient: P=0.005; M2: P=0.002), but not 
different from each other (correlation coefficient: P=0.19; M2: P=0.29, Kruskall-Wallis 
test). The colocalisation was significantly higher in the HAL, ALA and MAL when indi-
vidually compared with the control group (P=0.008 for all comparisons except for the 
M2 coefficient of MAL versus control, P=0.16 Mann-Whitney U-test). The M1 coefficient 
was high (>0.95) for all groups.
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Figure 2. The extent of colocalisation between PpIX fluorescence and CD31 conjugated with 
AlexaFluor®488, represented as (a) the Pearson’s correlation coefficient between individual pixels; and (b) 
Mander’s M2 coefficient, which indicates the proportion of CD31 positive pixels that also contain PpIX 
fluorescence. Data shown are average values per mouse (n=5) for each group. The value for each mouse 
was calculated from a total of 9 images taken in 3 microscopic tissue sections.
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CD144 
overlay 
Control PDT 
Figure 3. Confocal fluorescence images example of control skin (left) and HAL-PDT-treated skin (right) 
of the same mouse. The upper images are the CD31 and the corresponding CD144 stainings. The lower 
image is the overlay of the upper images, showing overlap of CD31/CD144 in the control skin, but not in 
the PDT skin. In the PDT-treated skin the CD144 no longer stained along the plasma membrane, indicating 
vascular damage. Magnification 400x, zoom 5.3x.
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Part b: vascular damage.
In all three groups (HAL, ALA and MAL) focal loss of normal fluorescent CD144 located 
along the vascular endothelium was observed. Instead, the CD144 was relocated into 
the immediate surroundings of the vessel, indicating disruption of the endothelium. 
Such a response was scored as vascular damage and an example of this is shown in 
Figure 3.
This type of loss of identifiable vessel in the CD144 staining was also observed in 400x 
images of normal skin (in 12/99 of total images), but much more often in the PDT-treated 
skin (in 33/99 of total images). The number of total images that was scored as vascular 
damage was highest in the HAL-PDT group (14/36), then in the ALA-PDT group (10/27) 
and lowest in the MAL-PDT group (9/36). When the data per mouse (instead of per im-
age) are considered, 3 of 4 mice in the HAL group showed more vascular damage in the 
PDT treated skin than in normal skin, which was 2 of 3 mice in the ALA group and 2 of 4 
mice in the MAL group.
The percentage of 400x images that was scored as vascular damage is illustrated in fig-
ure 4 for all three groups, including PDT treated and normal skin. One mouse in the ALA 
group died which is why there are fewer data in this group. In both the HAL and ALA-PDT 
treated skin the percentage in which vascular damage was scored in 400x images was 
statistically significantly higher than the combined data of all 99 control skin images 
(P=0.0005 and P=0.003 respectively). In the MAL group there was no significant differ-
ence between PDT treated skin and control skin (P=0.068, chi-square test). The number 
of vascular damage scores per 400x image was not different between the HAL, ALA and 
MAL groups (P=0.408 chi square test).
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Figure 4. Proportion of 400x images in which vascular damage was scored for the three PDT-treated 
groups (n=36 for HAL, n=27 for ALA, n=36 for MAL and n=99 for control). HAL and ALA groups were 
significantly different from control skin (P=0.0005 and 0.003 respectively, but MAL was not (P=0.068, Chi-
squared test).
diSCuSSiOn
In this study the distribution of PpIX in dermal blood vessels was investigated after either 
HAL, ALA or MAL application. In addition, we studied if fractionated PDT using HAL, ALA 
or MAL damages the vascular integrity of these vessels. We found that after application 
of all three porphyrin precursors, endothelial cells in the vessel walls synthesized PpIX. 
However, these PpIX concentrations (represented by the degree of colocalisation be-
tween PpIX and CD31) were highest in the HAL group, next in the ALA group and lowest 
in the MAL group. The same trend was seen for the vascular damage after PDT: highest 
vascular damage scores for HAL, followed by ALA and then MAL.
These combined findings indicate that the amount of PpIX synthesis in the vessel wall 
actually causes vascular damage and that this effect is the strongest for HAL. We previ-
ously reported more extensive constriction of subcutaneous arterioles for HAL than for 
ALA-PDT, which was correlated with PpIX concentration in the vessel wall 12 and more 
extensive arteriole constriction after PDT using ALA than MAL 13. In another study we 
observed more acute edema after ALA than MAL-PDT 15. From these studies and our 
current findings we can conclude that 5% HAL ointment leads to higher PpIX concentra-
tions in dermal and subcutaneous vessel walls than 20% ALA gel, which leads to higher 
PpIX concentrations than 16% MAL cream. As a logical result, the vascular constriction 
and vascular damage is increasingly extensive with this increasing potential to accumu-
late PpIX in vessel walls.
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From our current findings, which were performed on normal skin, it can be assumed 
that the vasculature is also damaged after topical HAL and ALA-PDT of cancer tissue. 
Obviously the aim here is to destroy all cancer cells while preserving normal tissue. This 
ratio may be dependent on the vascular response. When vessels constrict too much 
during PDT, this limits the oxygen supply to the PDT treated site. This type of response 
will decrease the potency of PDT to destroy tumor cells. On the other hand, if vasocon-
striction happens late during or after PDT or if vessels are damaged, local ischemia may 
help destroy cancer cells that would otherwise survive. However, when the ischemia 
becomes too extensive or long-lasting, normal tissue will die too which may result in 
an inferior cosmetic or functional outcome. This suggests that there may be a delicate 
balance between too much or too little vascular photosensitization to achieve optimal 
PDT effect. The phenomenon that the PDT outcome is related in a complex manner to 
vascular responses and oxygen supply has already been described for PDT using sys-
temic porphyrins in the 1980s 25-27. Our current results indicate that the extent of vascular 
constriction or damage may be important for the overall effect of topical PDT too.
In addition to enhanced tumor cell kill due to hypoxia from vascular damage, the vas-
cular responses may also be part of the mechanism behind the success of light fraction-
ated PDT. For ALA-PDT, light fractionation has proven beneficial in both preclinical 23, 28-30 
and clinical studies 18,  31. We hypothesize that the vascular endothelium synthesizes a 
small but relevant amount of PpIX which makes it vulnerable to a second illumination. 
Because the effect of light fractionation is stronger for relatively low PpIX concentrations 
17 the vascular endothelium is a potential target for fractionated PDT. In both in-vitro and 
in-vivo studies it has been shown that vascular endothelial cells can be photosensitized 
using ALA 14, 32. It could very well be however that a minimum PpIX concentration is nec-
essary to cause vascular damage. Because light fractionation does not increase efficacy 
of MAL-PDT in normal mouse skin 16, it may be that the endothelial PpIX concentration is 
too low which is in accordance with our current findings. Our current data are also in line 
with the expectation and recent evidence that light fractionation may also be beneficial 
for HAL-PDT 19, which could be relevant for clinical trials.
Before translating our findings to clinical implications however, we should bear in mind 
that such a step needs to be taken carefully. Apart from the obvious biological differences 
between humans and mice, a considerable difference lies in the increased thickness of 
human skin (and other epithelial surfaces such as those of the bladder and cervix). This 
is relevant with respect to penetration. Also, tumor tissue such as basal cell carcinoma is 
known to have a different vasculature than normal skin 33, 34 which potentially influences 
the ability of the endothelial cells to accumulate PpIX.
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Despite these differences between human and mouse tissues, our findings may be 
useful when designing clinical trials. It could very well be that vascular responses also 
play a role in clinical PDT, for which there is some evidence in the literature. Simulations 
of PpIX photobleaching kinetics and subsequent measurements have confirmed blood 
flow changes during ALA-PDT of basal cell carcinoma 35, 36 and blood volume and satura-
tion changes were observed in ALA-PDT of actinic keratosis 37. Also, after PDT for skin 
rejuvenation the number of telangiectasias in the face decreased after ALA-PDT 38, but 
not after MAL-PDT 39. This could reflect the increased ability to sensitize endothelial cells 
of ALA compared with MAL. ALA-PDT is also used off-label to treat port wine stains 40. 
It is questionable however if the vascular accumulation of PpIX in port wine stains will 
be sufficient to cause direct vascular damage, or that other mechanisms after PDT may 
play a role. The effect of ALA-PDT on port wine stains can however be considered an 
indication that the vasculature can also be a primary target of PDT, which suggests that 
other vascular tumors may theoretically also benefit from topical HAL or ALA-PDT.
There are some limitations to the current study which must be addressed. Most impor-
tantly we observed a loss of CD144 staining along the vessel wall also in the normal skin 
sections. Since the normal skin was taken from contralateral site is it extremely unlikely 
that this finding represents actual vascular damage. It may instead be associated with a 
background level of loss of CD144 staining that is also observed in other cellular studies 
41,  42. It can then be logically assumed that such a background level is also present in 
the PDT treated sections. Although this decreases the specificity of our scoring system, 
we did find a significantly larger loss of CD144 staining in the PDT treated skin than in 
normal skin using unpaired statistical testing. We are therefore confident in our conclu-
sion that our findings reflect the presence of vascular damage.
Another potential concern is the relatively low Pearson’s correlation coefficient, which 
can be explained by its sensitivity to background noise and to variable fluorescence 
intensities 22. The M2 coefficient however provides additional information on the degree 
of colocalisation that is less sensitive to noise and uneven PpIX intensity distributions 
in this case. Because our region of interest contains only the vessel wall, it is saturated 
with CD31 positive pixels. The high value of M2 (especially high for HAL) indicates that a 
large proportion of these CD31 positive pixels also contain PpIX signal, even if this signal 
is low. The level of noise is represented by the average M2 value in the control sections 
(0.28). This high noise level originates from the PpIX images. It explains why the M1 
coefficient is almost 1 for all groups as nearly all of the PpIX/noise pixels will colocalise 
with CD31 pixels in our region of interest. A way to reduce the signal to noise ratio in 
the future may be to increase the integration times during the PpIX image acquisition. 
Different vascular photosensitization and vascular damage in HAL, ALA and MAL-PDT 95
However, it should be noted that the rapid photobleaching rate of PpIX will limit the 
signal to noise ratio that is achievable.
It must also be noted that we did not include a functional test to study the functional 
consequences of the vascular damage, which would provide additional evidence for 
vascular damage. We previously observed more oedema after light fractionated ALA-
PDT than after MAL-PDT 15, which indicates increased permeability after PDT. To sup-
port the results of the present study we have performed additional in-vivo intra-vital 
microscopy investigating the distribution of fluorescein after fractionated ALA-PDT. In 
an extension of the mouse dorsal skin fold chamber model that we have previously 
used to investigate the vascular response during PDT with porphyrin pre-cursors 12 514 
nm light from the confocal microscope (ca 12 J cm-2) was used both for light delivery 
and for imaging through the epidermis. Immediately after PDT, fluorescein (FITC-BSA, 
Sigma) was injected intravenously at a dose of 0.2 mg/mouse. Trans-epidermal images 
were obtained and showed focal leakage of fluorescein into the perivascular space. An 
example image of this is shown in figure 5.
a b 
Figure 5. Trans-epidermal confocal images in a mouse skin fold chamber model. Immediately after 
fractionated ALA-PDT fluorescein was injected intravenously. On the left (a) is a transmission image 
before PDT and on the right (b) a fluorescence image after PDT showing leakage of fluorescein into the 
perivascular space (white arrow). The round dots in both images are hair follicle units. Image adapted 
from the thesis “New insights into photodynamic therapy using porphyrin precursors” by de Vijlder in 
2013 with permission.
Such focal fluorescein leakage is in accordance with our current finding of focal loss 
of CD144 staining. Increased permeability leads to stress fiber formation, followed 
by phosphorylation of RhoA, inhibiting CD144 formation 43. So the direct increase in 
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permeability is a functional measure of vascular dysfunction, which results in structural 
changes that can be detected as loss of normal CD144 staining 24 hours later.
A possible limitation could also be that we compared the ability of HAL, ALA and MAL to 
penetrate through the epidermis and synthesize PpIX in the vascular endothelium, but 
we used different concentrations and formulations. In several studies it has been shown 
that lower concentrations of HAL than ALA and lower concentrations of ALA than MAL 
are needed to reach the same PpIX concentration in different models 6,  44-46. Also, the 
vehicle can influence the penetration of the molecules 47, 48. To translate the relevance 
of our findings for clinical applications we considered it more useful to compare the 
standard available products which is why we chose to use these in the current study.
For future research it may be interesting to investigate if there are any differences in 
vascular damage after single versus light fractionated PDT. If our hypotheses are correct 
we can expect to see less vascular damage after a single illumination, but considering 
the presence of CD144 staining artifacts, the number of animals and/or sections needs 
to be larger to detect statistical differences. Another interesting future step would be to 
further investigate the benefit of light fractionated for HAL-PDT in vivo.
In conclusion we have now shown for the first time that there is vascular damage of 
dermal blood vessels after topical light fractionated HAL and ALA-PDT, which is related 
to the ability of the vessel wall to synthesize PpIX. In this and previous work we find a 
consistent trend that shows the highest vascular PpIX synthesis, vascular constriction 
and vascular damage for HAL, followed by ALA and then MAL. While the vascular con-
striction that we found in previous studies may be relevant for the oxygen supply during 
PDT, the vascular damage that we found in this study could also be relevant for the 
oxygen supply after light fractionated PDT. This potentially plays a role as an enhanced 
kill mechanism of light fractionated PDT for cancer cells that would otherwise survive. In 
addition, our findings suggest that topical fractionated HAL and ALA-PDT can be used to 
primarily target the vasculature. This could be an important aspect of PDT for cosmetic 
purposes, port wine stains and possibly other vascular tumors.
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abSTraCT
Background: Light fractionation with a two-hour dark interval increases the efficacy of 
topical aminolevulinic acid (ALA) photodynamic therapy (PDT). Hexyl-aminolevulinate 
(HAL) is the hexyl ester of ALA. Both HAL and ALA lead to protoporphyrin IX (PpIX) ac-
cumulation in endothelial cells and to vascular effects, which are important for light 
fractionation. We investigated light fractionation for HAL-PDT in a mouse skin model 
and compared this with ALA.
Methods: Three illumination schemes were studied: a) 100 Jcm-2 in a single illumination; 
b) 50+50 Jcm-2 in a two-fold illumination; c) a small first light fraction until 50% of PpIX 
was photobleached (ca. 3 Jcm-2), followed by 97 Jcm-2 two hours later. PpIX fluorescence 
was measured continuously during illumination. Efficacy was evaluated by daily visual 
skin damage scoring up to 7 days after PDT.
Results: Light fractionation showed a trend towards increased efficacy for HAL-PDT. Both 
the initial PpIX synthesis and the PpIX resynthesis during the dark interval were higher 
for ALA, but these were not correlated with efficacy. Single HAL-PDT was more effec-
tive than single ALA-PDT. Photobleaching rates of HAL and ALA were similar indicating 
similar biodistributions at depth.
Conclusion: Our results provide evidence to support that light fractionation may be ben-
eficial for HAL-PDT. We are cautious because we found only a non-significant increase in 
response. However, combining our results with literature data suggest that the illumina-
tion scheme may be further optimized for HAL-PDT to potentially enhance the effect of 
light fractionation.
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inTrOduCTiOn
Since 1990 aminolevulinic acid (ALA) is being used topically for photodynamic therapy 
(PDT)1. Later more lipophilic ALA-esters have been developed such as methyl-ami-
nolevulinate (MAL) and hexyl-aminolevulinate (HAL). All three lead to protoporphyrin 
IX (PpIX) accumulation in mitochondria. Our group has previously focused primarily on 
ALA and we have developed and optimized a protocol for light fractionated ALA-PDT. 
Fractionated ALA-PDT involves delivery of a small light fraction followed by a large light 
fraction, separated by a two-hour dark interval. This protocol improves clinical efficacy 
in ALA-PDT for human basal cell carcinoma 2, 3. It is based on a number of mouse studies 
in which, for different illumination schemes, the fluorescence kinetics and visual skin 
damage in normal skin were measured 4-7. This mouse model has proven to provide 
information on the subtleties of PpIX synthesis and PpIX photobleaching that has aided 
our understanding of underlying mechanisms.
Interestingly, light fractionation did not increase response for MAL-PDT using the same 
illumination scheme and mouse model 8. It was hypothesized that differences in vessel 
wall distribution and vascular response between ALA and MAL explain this difference in 
response. Further studies supported this hypothesis and showed that ALA application 
indeed leads to higher PpIX levels in the vessel wall than MAL9, 10, and that ALA-PDT leads 
to more vascular constriction than MAL-PDT 11.
Contrary to ALA and MAL, HAL is not used in dermatology. HAL ointment is registered for 
photodiagnosis of, and for margin establishment during surgery of bladder cancer but 
research is ongoing investigating its therapeutic use in the skin, cervix and bladder12-17. It 
is therefore useful to investigate if light fractionation also enhances the efficacy of HAL-
PDT. There are similarities between HAL and ALA that suggest that this approach would 
be beneficial. First, HAL also penetrates into endothelial cells in-vitro 18 and in vessel 
walls in-vivo 19. Second, HAL-PDT leads to a comparable vascular response as ALA-PDT 19.
For these reasons our goal was to investigate if our light fractionated protocol also 
increases HAL-PDT efficacy, measured as visual skin damage in the same mouse model 
as previously used for ALA and MAL. Three illumination schemes were studied for HAL 
and for ALA, which served as a control group. Furthermore, we measured PpIX fluores-
cence kinetics during PDT. It is well documented that the rate of PpIX photobleaching is 
related to the efficiency of the PDT process 20-22 and this information has also been used 
successfully to predict differences in (sub)cellular PpIX distribution 8.
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MaTErialS and METhOdS
animal model and porphyrin precursor application
The experiment was approved by the local animal ethical committee. We used 45 albino 
hairless mice (SKH1 HR), that had been on a chlorophyll free diet for two weeks and 
divided them in three groups of 15 animals. We applied either HAL ointment, or ALA 
gel on a 7 mm skin area under occlusion for 4 hours. The ALA gel was freshly prepared 
as follows: 20% ALA (Fagron, Oud Beijerland, The Netherlands) in 3% carboxymethylcel-
lulose in water with NaOH added to reach pH=4. HAL, 5% (100mg ointment: CeviraTM, 
Photocure Oslo, Norway) is the standard available product for the treatment of cervical 
intraepithelial neoplasia.
PdT light delivery and setup
The setup we used for PDT light delivery and fluorescence measurements (see section 
below) was similar as described earlier 22 (Figure 1). A relevant difference was that we 
now had to use a different laser. To deliver the same effective fluence rate as in previ-
ous experiments (50 mW cm-2 at 514 nm) we now delivered a measured fluence rate 
of 89 mW cm-2 at 532 nm. Using the same calculation as in a previous study 11 this was 
considered as the equivalent effective fluence rate, based on the PpIX absorption and 
photon energy for these wavelengths.
 
532 nm laser 
Dichroic mirror 
mimimirror 
> 570 nm filter 
CCD-camera 
Figure 1. Setup. Laser light is delivered on the treatment area on mouse skin, while the fluorescence 
images are collected by a CCD camera.
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In both groups (n=15 per group) all animals received a total light dose of 100 J cm-2, but 
we used three different illumination schemes (n=5 animals per scheme). In one scheme 
100 J cm-2 was delivered in a single illumination. In the second scheme an initial dose 
of 50 J cm-2 was delivered, followed by a dark interval of two hours and delivery of an 
additional 50 J cm-2. In the third scheme the duration of the first light fraction was based 
on the extent of PpIX fluorescence photobleaching measured during PDT in individual 
animals (see fluorescence measurements section below). In this scheme the first il-
lumination was stopped when approximately 50% of initial PpIX was photobleached. 
This was considered as the optimal photobleaching percentage for ALA in a previous 
experiment using the same mouse model and 50 mW cm-2 at 514 nm7. The dose of this 
first light fractions was on average in the order of 3 J cm-2. The remaining fluence was 
delivered in the second light fraction to reach 100 J cm-2 in total.
Fluorescence measurements
Light from the 532 nm laser was focused on a 7mm treatment area and fluorescence im-
ages were taken using a CCD camera (ORCA-ER, Hamamatsu, Japan) which was also used 
to focus and to relocate the treatment area. Scattered excitation light was blocked from the 
spectrograph using a 570 nm long-pass filter. Fluorescence images were taken at regular 
time-intervals during illumination, without interrupting PDT light delivery. Protoporphy-
rin IX (PpIX) fluorescence intensity was used as a measure for the PpIX concentration and 
the extent of PpIX photobleaching. The images were corrected for the dark background 
signal and for a factor to account for the contribution from skin autofluorescence, which 
was measured in each animal before the administration of ALA or HAL.
damage score
Damage scoring was performed daily up to seven days after PDT. A previously described 
visual scoring system was used with a scale from zero to five: 0 = no damage; 1 = minimal 
erythema; 2 = moderate erythema; 3 = severe erythema or a blister; 4 = thin crust and 5 
= thick haemorrhagic crust 22. Within the total treated area the damage score of smaller 
areas contributed to the total damage score based on their size relative to the total area.
data analysis and statistics
To compare damages between groups and illumination schemes the cumulative dam-
age score was calculated as the area under the curve (AUC) of the daily damage scores 
seven days after PDT. An ANOVA was used to test for differences in AUC between the 
illumination schemes within each group (HAL or ALA) using 0.05 as a significance level. To 
compare differences in rate of photobleaching and PpIX resynthesis during the dark inter-
val the fluorescence was normalized by dividing the PpIX fluorescence intensity it by its 
initial value before the first illumination. This normalisation step was performed to correct 
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for variations in these starting intensities. Differences in PpIX resynthesis and initial PpIX 
fluorescence intensity between the three groups were tested by means of independent 
samples T-test. Correlations between initial fluorescence intensity or PpIX resynthesis and 
cumulative skin damage (AUC) were calculated as Pearson’s correlation coefficient.
rESulTS
Visual skin damage score
The daily visual skin damage in the days after PDT typically showed blister formation, 
followed by crust formation and healing of the treated skin. The general pattern was 
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Figure 2. Visual skin damage score after PDT. The mean daily damage scores up to 7 days after PDT for each 
illumination scheme in the HAL(a) and ALA(b) groups. Scheme “100” refers to delivery of a 100 J cm-2 in a 
single illumination; “50+50” to delivery of 50 and 50 J cm-2; and “3+97” to delivery of a small first light fraction 
in the order of 3 J cm-2, followed by a second light fraction to deliver 100 J cm-2 in total. For clarity standard 
deviations are not shown, but they average at 0.53 (range 0.04-1.19) and are similar for ALA and HAL.
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similar for HAL and ALA (Figure 2). The three lines in this figure represent the three dif-
ferent illumination schemes, which overlap in the HAL group. In both the HAL and ALA 
groups the single illumination line (100 J cm-2) is generally lower than the fractionated 
group lines (50+50 and 3+97 J cm-2), but this is much more clearly visible in the ALA 
group. Also, only in the ALA group there was a significant difference in the calculated 
AUC between the illumination schemes (Figure 3, ANOVA, P=0.039). In the HAL ointment 
group however there was a trend towards increased damage for light fractionation 
(highest damage in the 3+97 group and lowest in the single illumination group), but 
this trend was not significant (P=0.157, linear regression).
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Figure 3. Cumulative visual skin damage per group and illumination scheme, presented as the area under 
the curve (AUC) of daily damage score up to 7 days after PDT. Scheme “100” refers to delivery of a 100 J 
cm-2 in a single illumination; “50+50” to delivery of 50 and 50 J cm-2; and “3+97” to delivery of a small first 
light fraction in the order of 3 J cm-2, followed by a second light fraction to deliver 100 J cm-2 in total. Error 
bars indicate one standard deviation.
Protoporphyrin iX fluorescence measurements
There was large variation in starting PpIX fluorescence intensity (i.e. just before the first 
illumination) for both ALA and HAL. The starting fluorescence was significantly higher 
in the ALA group than in the HAL group (respectively mean 1760 a.u., SD 628 and mean 
1125 a.u., SD 564, P=0.006). This starting fluorescence intensity was not correlated with 
the cumulative skin damage (Pearson’s correlation coefficient = -0.16).
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The PpIX resynthesis during the dark interval, which was defined as the increase in nor-
malized PpIX fluorescence was also higher for ALA than for HAL, but this difference was 
not significant (respectively mean 66%, SD 24% and mean 44%, SD 25%, P=0.06). This 
PpIX resynthesis percentage was also not correlated with the cumulative skin damage 
(Pearson’s correlation coefficient =-0.08). The variability in starting fluorescence, PpIX 
resynthesis and photobleaching is illustrated for the 50+50 illumination schemes in 
figure 4.
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Figure 4. Examples of PpIX kinetics during illumination in the 50+50 J cm-2 illumination scheme for 
(a): HAL and (b) ALA. Shown are PpIX fluorescence intensities normalized to the starting intensity for 
individual mice. Note the variability in photobleaching rate (slope of the curve) between individual 
animals, and in PpIX resynthesis percentage between HAL and ALA during the two-hour dark interval at 
50 J cm-2.
The rate of PpIX photobleaching (the slope of the curve) varied between individual 
animals. For each animal this rate was fastest in the beginning of the illumination and 
decreased with increasing fluence. Although individual animals showed variation in 
photobleaching rate, there was no systematic difference between ALA and HAL, This 
photobleaching rate for HAL and ALA is illustrated in figure 5 for the first 2 J cm-2.
diSCuSSiOn
This study provides evidence to support that light fractionation may increase efficacy 
of HAL-PDT. For HAL the skin damage was highest in the scheme that received a low 
first dose of approximately 3 J cm-2, which is exactly the scheme in which we expected 
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the highest efficacy, based on results from previous dose-finding studies with ALA 6, 7, 22. 
However, the difference in skin damage between the illumination schemes was not 
significant and a single illumination was already more effective for HAL than ALA. As 
briefly mentioned in the introduction it is important to keep in mind the mechanism be-
hind increased efficacy for light fractionated ALA-PDT. Previous studies showed that for 
ALA the biodistribution in the vasculature is an important factor behind the increased 
PDT effect of light fractionation 8-10,  23. Because the vascular distribution and vascular 
effects are similar for HAL and ALA 19, we expected light fractionation to also significantly 
increase efficacy for HAL-PDT, but we found only a trend towards this result.
Before fully considering this finding it is interesting to first consider the higher initial 
PpIX synthesis for ALA than HAL. Note that the different PpIX concentrations should be 
interpreted carefully, because we used different concentrations of HAL than ALA (5% ver-
sus 20% respectively), which are both standard concentrations. Previous studies found 
that similar to up to 18 times lower concentrations of HAL than ALA are needed to yield 
similar PpIX concentrations 17,  19,  24-26. Taken into account the variability of tissue types 
and measurement methods used in these studies, our ratio of HAL/ALA concentration 
related to the PpIX concentration is somewhere in the middle of what is described in the 
literature. When interpreting our PpIX fluorescence findings it is crucial to realize that 
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Figure 5. Photobleaching rate during first 2 J cm-2 for HAL ALA. For each group the data represent the 
averages of the normalized PpIX fluorescence intensity in all mice of all illumination schemes (n=15 per 
group). Standard deviations were 8% on average, but are not presented for graphical clarity.
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we used a surface fluorescence measurement. Since the epidermal PpIX dominates the 
signal from surface fluorescence measurements, the method we used now is insensitive 
to differences in PpIX distributions or concentrations at depth. From our findings it can 
therefore be concluded that 20% ALA leads to higher epidermal PpIX concentrations 
than 5% HAL, but that deeper PpIX concentrations could not be measured.
The higher epidermal PpIX concentration for ALA is interesting because more PpIX leads 
to more singlet oxygen formation during PDT. It would therefore be logical to also expect 
higher damage scores in the ALA groups. However, we found no correlation between 
the initial PpIX synthesis and the skin damage, and also not between the amount of 
PpIX resynthesis and the skin damage. This indicates that the total amount of epidermal 
PpIX is not important for the effect of light fractionation. Instead, differences in PpIX 
distribution at depth such as in endothelial cells - resulting in different site of PDT dam-
age- apparently play a more important role in the response to single and fractionated 
PDT for both HAL and ALA. This conclusion is in accordance with the conclusions from 
a previous study 8.
When considering the effect of light fractionation on HAL-PDT, we found highest damage 
in the 3+97 group (mean AUC=21.5) and lowest in the single illumination group (mean 
AUC=18.3), which is as expected. This difference is relatively small however compared to 
what we found previously for ALA 7, 8, 22, and is also not statistically different. Whether or 
not this may still be a biologically relevant difference is not immediately clear. In figure 
3 can be seen that the main reason that the additional effect of light fractionation was 
relatively small for HAL, is that a single illumination was already quite effective in induc-
ing skin damage. Despite this, it is arguable that light fractionation may still provide 
additional benefit for HAL-PDT. The reasons for this are as follows.
First, for light fractionation to be most effective, the PDT dose of the first illumination 
needs to be low 7, 23. Because we found that the effect of a single illumination lead to 
more damage for HAL than for ALA, it can be assumed that the first light fraction of a 
fractionated HAL scheme also does more damage. This in turn decreases the effect of 
light fractionation. Delivery of a smaller effective PDT dose in the first illumination may 
therefore be a logical and possible valuable improvement for light fractionated HAL-PDT.
Second, the other and possibly more important aspect in the mechanism behind light 
fractionation is the site of PDT damage. Even though our current PpIX fluorescence mea-
surement method is insensitive to differences in PpIX distribution at depth, we did find a 
similar rate of photobleaching for HAL and ALA. In a comparable study that investigated 
the use of light fractionated MAL, it was found that the rate of photobleaching was 
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significantly slower for MAL than for ALA. It was hypothesized that this was due to a dif-
ferent distribution at depth, resulting in a different site of PDT damage. This hypothesis 
was further tested and confirmed in follow-up studies 10, 11. Our current findings that the 
rate of photobleaching was the same for HAL and ALA may also indicate a similar distri-
bution at depth of HAL and ALA. This is in accordance with previous findings that HAL 
and ALA share an ability to accumulate in endothelial cells, unlike MAL. This similarity 
in localisation and rate of photobleaching probably accounts for the tendency towards 
increased response for light fractionated HAL-PDT.
Third, our visual skin damage model may not be sensitive enough to measure a statisti-
cal increase when the efficacy is already high for a single illumination. The maximum 
score in our model is limited so every step towards higher PDT damage will tend to 
result in smaller increases in measured total cumulative skin damage. Eventually a maxi-
mum damage score plateau will be reached. The decreasing standard deviation with 
increasing cumulative skin damage for HAL could be an indication of the onset of this 
effect. To detect a statistically significant effect for smaller differences in efficacy may 
require more animals than the numbers that we have used in the present study. This 
may explain why we found a trend towards increased efficacy for light fractionation of 
HAL-PDT but no statistically significant difference. Although the scoring system can be 
considered a limitation of the current study, our model previously proved to be a good 
translational model, ultimately leading to increased clinical effect 3.
Finally, it is important to realize that the light fractionation scheme we used in this study 
was extensively investigated and optimized for ALA, but not for HAL. It may well be that 
for HAL the optimal illumination scheme is somewhat different. As mentioned above, an 
interesting option would be to lower the effective PDT dose of the first illumination. This 
can be achieved by delivering the first illumination sooner (e.g. after two instead of four 
hours application) or by lowering the dose (e.g. 30% photobleaching instead of 50%) to 
decrease the amount of damage in this first light fraction. Possibly other illumination 
schemes, light doses or fluence rates may be better suitable for HAL.
Since the biodistribution of HAL, ALA and MAL plays an important role for the effect of 
light fractionation it is useful to realize that these molecules are similar to each other but 
differ in some important biological properties. The two main factors are differences in 
lipophilicity and in cellular uptake mechanisms. The lipophilicity is mainly relevant for 
the potential to penetrate through epithelial tissues. The uptake of ALA uptake depends 
on BETA transporters 27, 28, whereas the ALA esters are taken up through PEPT1 or PEPT2 
transporters 29 although other differences and also similarities in uptake mechanisms 
have been described 30. Different uptake mechanisms may result in differences in spatial 
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distribution of ALA, HAL, MAL and PpIX, which could play a role in the light fractionation 
process. However, our current setup was not designed and therefore not very sensitive 
to detect such differences.
Before coming to conclusions we need to address some limitations of the current study. 
One limitation is that our findings for our control group ALA were slightly different from 
what was expected. Although we could again show increased effect of light fraction-
ation for ALA-PDT, we expected the damage to be highest in the 3+97 group instead of 
the 50+50 group. This expectation is based on previous study results in which slightly 
higher AUC scores (of around 22) were found in the 3+97 group using the same scoring 
model 6, 7, 22. Since no abnormalities occurred and PpIX photobleaching kinetics and the 
shape of daily damage response curves were as expected, we do not have an adequate 
explanation for this.
Another limitation is that our normal mouse skin model does not measure the effect 
of light fractionation in tumor tissue, but in healthy tissue only. Because tumor tissue 
is known to have a different vasculature and because the vasculature is believed to 
play a role in light fractionation we cannot exclude a potentially increased benefit of 
fractionation for HAL-PDT in tumor tissue. Similarly, other tissue types such as bladder 
or cervix may respond differently to light fractionation than skin. It would therefore be 
interesting to also study the effect of fractionated HAL-PDT in these tissues and in tumor 
models.
Unfortunately, to our knowledge there are no further studies on the effect of light 
fractionation on topical HAL-PDT in any tissue. It is therefore not easy to see our results 
against the background of existing literature. In this respect it should be noted that the 
rationale for a short light fractionated scheme such as used in two other studies 31,  32 
is completely different from our light fractionation scheme. A repeated on/off cycle 
of light delivery in short light fractionation utilises available oxygen more efficiently, 
similar to lowering the fluence rate. Instead, our light fractionation scheme makes cells 
sensitive to a large second illumination after delivery of a short first illumination and a 
dark interval of at least two hours. Such short light fractionation schemes can therefore 
not be compared with our results. Nevertheless, use of short light fractionation schemes 
or low fluence rate PDT may be a very interesting option to decrease pain, which is a 
common problem in human skin 33.
In summary we have evidence to support that light fractionation may be beneficial for 
HAL-PDT. Since we did not see a statistically significant benefit we need to be cautious 
with this conclusion. We found that initial epidermal PpIX concentration and resynthesis 
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during the dark interval are irrelevant for the effect of light fractionation. Rather, the 
PpIX distribution at depth plays an important role. The same PpIX photobleaching rate 
of HAL and ALA may indicate a similar distribution which is in accordance with findings 
of similar PpIX distributions in previous studies. The light fractionated protocol for HAL 
can potentially be further optimized by delivery of a lower first light dose or by shorten-
ing the application time. The main rationale behind this option is to decrease the PDT 
damage of the first illumination. Also, the important role of the vasculature for light 
fractionation makes it interesting to also investigate fractionated HAL-PDT in tumour 
tissue which in general have more blood vessels. Such possibilities combined with the 
trend towards increased efficacy suggest that light fractionated HAL-PDT continues to 
be an interesting research topic to optimize PDT effect.
114 Chapter 6
rEFErEnCES
 1. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: 
basic principles and present clinical experience. J Photochem Photobiol B. 1990;6(1-2):143-8.
 2. de Haas ER, Kruijt B, Sterenborg HJ, Martino Neumann HA, Robinson DJ. Fractionated illumina-
tion significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid 
photodynamic therapy. J Invest Dermatol. 2006;126(12):2679-86. Epub 006 Jul 13.
 3. de Vijlder HC, Sterenborg HJ, Neumann HA, Robinson DJ, de Haas ER. Light fractionation sig-
nificantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid pho-
todynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Derm Venereol. 
2012;92(6):641-7. doi: 10.2340/00015555-1448.
 4. Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR, Brown SB, Star WM. Fluorescence pho-
tobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless 
mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photochem 
Photobiol. 1998;67(1):140-9.
 5. Robinson DJ, de Bruijn HS, de Wolf WJ, Sterenborg HJ, Star WM. Topical 5-aminolevulinic acid-
photodynamic therapy of hairless mouse skin using two-fold illumination schemes: PpIX fluores-
cence kinetics, photobleaching and biological effect. Photochem Photobiol. 2000;72(6):794-802.
 6. Robinson DJ, de Bruijn HS, Star WM, Sterenborg HJ. Dose and timing of the first light fraction 
in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless 
mouse skin. Photochem Photobiol. 2003;77(3):319-23.
 7. de Bruijn HS, van der Ploeg-van den Heuvel A, Sterenborg HJ, Robinson DJ. Fractionated illu-
mination after topical application of 5-aminolevulinic acid on normal skin of hairless mice: the 
influence of the dark interval. J Photochem Photobiol B. 2006;85(3):184-90. Epub 2006 Sep 1.
 8. de Bruijn HS, de Haas ER, Hebeda KM, van der Ploeg-van den Heuvel A, Sterenborg HJ, Neumann 
HA, et al. Light fractionation does not enhance the efficacy of methyl 5-aminolevulinate medi-
ated photodynamic therapy in normal mouse skin. Photochem Photobiol Sci. 2007;6(12):1325-
31. Epub 2007 Aug 28.
 9. de Bruijn HS, Meijers C, van der Ploeg-van den Heuvel A, Sterenborg HJ, Robinson DJ. Microscopic 
localisation of protoporphyrin IX in normal mouse skin after topical application of 5-aminolevu-
linic acid or methyl 5-aminolevulinate. J Photochem Photobiol B. 2008;92(2):91-7. doi: 10.1016/j.
jphotobiol.2008.05.005. Epub May 15.
 10. de Vijlder H, de Bruijn H, van der Ploeg-van den Heuvel A, Sterenborg H, Neumann H, de Haas E, 
et al. Differences in protoporphyrin IX localisation in dermal vasculature after topical application 
of 5-aminolevulinic acid and methyl-5 aminolevulinate. Submitted to: Journal of photochemistry 
and photobiology. 2013.
 11. de Vijlder H, de Bruijn H, van der Ploeg-van den Heuvel A, van Zaane F, Schipper D, ten Hagen T, et 
al. Acute vascular responses during photodynamic therapy using topically administred porphyrin 
precursors. Photochem Photobiol Sci 2013 in press. 2013.
Light fractionated HAL-PDT in normal mouse skin 115
 12. Soergel P, Wang X, Stepp H, Hertel H, Hillemanns P. Photodynamic therapy of cervical intraepi-
thelial neoplasia with hexaminolevulinate. Lasers Surg Med. 2008;40(9):611-5. doi: 10.1002/
lsm.20686.
 13. Soergel P, Makowski L, Makowski E, Schippert C, Hertel H, Hillemanns P. Treatment of high grade 
cervical intraepithelial neoplasia by photodynamic therapy using hexylaminolevulinate may be 
costeffective compared to conisation procedures due to decreased pregnancy-related morbidity. 
Lasers Surg Med. 2011;43(7):713-20. doi: 10.1002/lsm.21072.
 14. Soergel P, Dahl GF, Onsrud M, Hillemanns P. Photodynamic therapy of cervical intraepithe-
lial neoplasia 1-3 and human papilloma virus (HMV) infection with methylaminolevulinate and 
hexaminolevulinate—a double-blind, dose-finding study. Lasers Surg Med. 2012;44(6):468-74. 
doi: 10.1002/lsm.22041. Epub 2012 Jun 12.
 15. Juzeniene A, Nielsen KP, Zhao L, Ryzhikov GA, Biryulina MS, Stamnes JJ, et al. Changes in human 
skin after topical PDT with hexyl aminolevulinate. Photodiagnosis Photodyn Ther. 2008;5(3):176-
81. Epub 2008 Aug 28.
 16. Bader MJ, Stepp H, Beyer W, Pongratz T, Sroka R, Kriegmair M, et al. Photodynamic Therapy of 
Bladder Cancer - A Phase I Study Using Hexaminolevulinate (HAL). Urol Oncol. 2012;20:20.
 17. Dognitz N, Salomon D, Zellweger M, Ballini JP, Gabrecht T, Lange N, et al. Comparison of ALA- 
and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma. J Photochem 
Photobiol B. 2008;93(3):140-8. Epub 2008 Aug 17.
 18. Rodriguez L, de Bruijn HS, Di Venosa G, Mamone L, Robinson DJ, Juarranz A, et al. Porphyrin syn-
thesis from aminolevulinic acid esters in endothelial cells and its role in photodynamic therapy. J 
Photochem Photobiol B. 2009;96(3):249-54. Epub 2009 Jul 5.
 19. Middelburg T, De Bruijn H, Tettero L, Van der Ploeg van den Heuvel A, Neumann H, De Haas E, 
et al. Topical Hexylaminolevulinate and Aminolevulinic Acid Photodynamic Therapy: Complete 
Arteriole Vasoconstriction Occurs Frequently and Depends on Protoporphyrin IX Concentration 
in Vessel Wall. Journal of photochemistry and photobiology B: Biology. 2013;Accepted for publi-
cation.
 20. Langmack K, Mehta R, Twyman P, Norris P. Topical photodynamic therapy at low fluence rates—
theory and practice. J Photochem Photobiol B. 2001;60(1):37-43.
 21. Finlay JC, Mitra S, Patterson MS, Foster TH. Photobleaching kinetics of Photofrin in vivo and in 
multicell tumour spheroids indicate two simultaneous bleaching mechanisms. Phys Med Biol. 
2004;49(21):4837-60.
 22. Middelburg TA, Van Zaane F, De Bruijn HS, Van Der Ploeg-van den Heuvel A, Sterenborg HJ, 
Neumann HA, et al. Fractionated illumination at low fluence rate photodynamic therapy in mice. 
Photochem Photobiol. 2010;86(5):1140-6. doi: 10.11/j.751-097.2010.00760.x.
 23. de Bruijn HS, Casas AG, Di Venosa G, Gandara L, Sterenborg HJ, Batlle A, et al. Light fractionated 
ALA-PDT enhances therapeutic efficacy in vitro; the influence of PpIX concentration and illumina-
tion parameters. Photochem Photobiol Sci. 2013;12(2):241-5. doi: 10.1039/c2pp25287b. Epub 
2012 Oct 29.
116 Chapter 6
 24. Marti A, Jichlinski P, Lange N, Ballini JP, Guillou L, Leisinger HJ, et al. Comparison of aminolevulinic 
acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder 
cancer. J Urol. 2003;170(2 Pt 1):428-32.
 25. Endlicher E, Rummele P, Hausmann F, Krieg R, Knuchel R, Rath HC, et al. Protoporphyrin IX dis-
tribution following local application of 5-aminolevulinic acid and its esterified derivatives in the 
tissue layers of the normal rat colon. Br J Cancer. 2001;85(10):1572-6.
 26. Casas A, Perotti C, Fukuda H, Rogers L, Butler AR, Batlle A. ALA and ALA hexyl ester-induced por-
phyrin synthesis in chemically induced skin tumours: the role of different vehicles on improving 
photosensitization. Br J Cancer. 2001;85(11):1794-800.
 27. Rud E, Gederaas O, Hogset A, Berg K. 5-aminolevulinic acid, but not 5-aminolevulinic acid esters, 
is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol. 
2000;71(5):640-7.
 28. Rodriguez L, Batlle A, Di Venosa G, Battah S, Dobbin P, Macrobert AJ, et al. Mechanisms of 5-ami-
nolevulinic acid ester uptake in mammalian cells. Br J Pharmacol. 2006;147(7):825-33.
 29. Rodriguez L, Batlle A, Di Venosa G, MacRobert AJ, Battah S, Daniel H, et al. Study of the mecha-
nisms of uptake of 5-aminolevulinic acid derivatives by PEPT1 and PEPT2 transporters as a tool to 
improve photodynamic therapy of tumours. Int J Biochem Cell Biol. 2006;38(9):1530-9. Epub 2006 
Mar 18.
 30. Schulten R, Novak B, Schmitz B, Lubbert H. Comparison of the uptake of 5-aminolevulinic 
acid and its methyl ester in keratinocytes and skin. Naunyn Schmiedebergs Arch Pharmacol. 
2012;385(10):969-79. doi: 10.1007/s00210-012-0777-4. Epub 2012 Jul 17.
 31. Ascencio M, Estevez JP, Delemer M, Farine MO, Collinet P, Mordon S. Comparison of continuous 
and fractionated illumination during hexaminolaevulinate-photodynamic therapy. Photodiag-
nosis Photodyn Ther. 2008;5(3):210-6. Epub 2008 Oct 19.
 32. Estevez JP, Ascencio M, Colin P, Farine MO, Collinet P, Mordon S. Continuous or fractionated 
photodynamic therapy? Comparison of three PDT schemes for ovarian peritoneal micrometas-
tasis treatment in a rat model. Photodiagnosis Photodyn Ther. 2010;7(4):251-7. doi: 10.1016/j.
pdpdt.2010.07.007. Epub Aug 14.
 33. Mikolajewska P. Pain during topical photodynamic therapy [www document]. 2011;https://www.
duo.uio.no/handle/10852/11075?locale-attribute=en [accessed on 12 March 2013].
7
Monitoring blood volume and 
saturation using superficial fibre 
optic reflectance spectroscopy 
during PDT of actinic keratosis.
Tom Middelburg
Chad Kanick
Ellen de Haas
Dick Sterenborg
Arjen Amelink
Martino Neumann
Dominic Robinson
J Biophotonics. 2011;4(10):721-30.
118 Chapter 7
abSTraCT
Optically monitoring the vascular physiology during photodynamic therapy (PDT) may 
help understand patient-specific treatment outcome. However, diffuse optical tech-
niques have failed to observe changes herein, probably by optically sampling too deep. 
Therefore, we investigated using differential path-length spectroscopy (DPS) to obtain 
superficial measurements of vascular physiology in actinic keratosis (AK). The AK-specific 
DPS interrogation depth was chosen up to 400 microns in depth, based on the thickness 
of AK histology samples. During light fractionated aminolevulinic acid-PDT, reflectance 
spectra were analyzed to yield quantitative estimates of blood volume and saturation. 
Blood volume showed significant lesion-specific changes during PDT without a general 
trend for all lesions and saturation remained high during PDT. This study shows that DPS 
allows optically monitoring the superficial blood volume and saturation during skin PDT. 
The patient-specific variability supports the need for dosimetric measurements. In DPS, 
the lesion-specific optimal interrogation depth can be varied based on lesion thickness.
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inTrOduCTiOn
In photodynamic therapy (PDT) a photosensitizer mediates the transfer of light energy 
to oxygen, which results in the formation of reactive oxygen species, notably singlet 
oxygen. This leads to cellular damage and to vascular and immunologic responses that 
can destroy dysplastic tissue. PDT has been applied in various organs including the skin, 
in which PDT using porphyrin precursors such as aminolevulinic acid (ALA) is being used 
worldwide. One of the indications for PDT is actinic keratosis (AK), an intraepithelial 
dysplasia that may progress into squamous cell carcinoma. PDT for AK is painful but 
usually effective, although recurrence rates are around 20%. In these recurrent lesions, 
there must be a reason why they respond insufficiently to PDT. The response of tissue to 
PDT is influenced by three important parameters: the concentrations of oxygen, of the 
photosensitizer, and the local light fluence. These vary significantly due to the use of 
different light treatment schedules and light sources and due to patient- and/or tumor-
specific biological variations. These variations result in differences in effective PDT doses 
and therefore are likely to be responsible for incomplete responses. They may also be 
related to adverse events such as pain during treatment. To date, several studies have 
revealed the importance of using techniques that monitor these parameters during PDT 
to optimize individual patient dosimetry. 1-7.
As one of these techniques, reflectance spectroscopy is capable of measuring changes 
in tissue optical properties that provide information on the oxygen supply during 
PDT by measuring blood saturation and blood volume. Several different methods of 
reflectance spectroscopy exist that involve measuring reflectance over a broad range 
of wavelengths. The major differences between them are the optically interrogated vol-
ume and the uncertainty about the photon path length in tissue. To quantify the data of 
reflectance spectroscopy, mathematical models have been developed that incorporate 
Mie and Raleigh scattering mechanisms and the effects of main absorbing components 
of skin (i.e. hemoglobin, deoxyhemoglobin, melanin, and water) 8-11.
Although it is clearly important to measure blood oxygenation during PDT, two stud-
ies illustrate the complexity of using reflectance spectroscopy for this purpose. In one 
study diffuse reflectance spectroscopy (DRS) was used to measure reflectance spectra 
before and after PDT of mouse skin but no differences between the spectra were found 
12. Also, in basal cell carcinoma Cottrell et al did not observe changes in spectra before 
and after PDT using DRS 13. In both studies DRS is likely to be not sensitive enough to 
detect changes in blood flow and oxygenation during PDT. This is because the oxygen 
that is involved in the PDT process is supplied by blood located in superficial dermal 
capillaries, while DRS measurements are strongly influenced by reflectance signals 
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from deeper blood vessels. It is however very unlikely that there are no true changes in 
blood volume and oxygenation because porphyrins have been known to have vascular 
effects, for which it is used in treating for example ocular neovascularization. As vascular 
endothelial cells accumulate PpIX also after topical ALA application, vascular effects are 
also expected in topical ALA-PDT.
To further study the tissue oxygenation effects during ALA-PDT while overcoming 
the problems occurring in DRS, we used a technique termed differential path-length 
spectroscopy (DPS) in this study and introduced its use in human skin. In principle, DPS 
allows for much more accurate reflectance measurements in the relevant superficial vol-
ume. DPS is based on two optical fibers that are in contact with the measured medium. 
One fiber is used for delivery and collection of light and one is used for collection only. 
The delivery-and-collection fiber measures superficially scattered light, while light that 
is scattered deeper in the tissue is collected by both fibers. Subtracting the two signals 
provides the DPS signal and by choosing different fiber diameters, the interrogation 
volume can be accurately determined. Additionally, model-based analysis of the DPS 
signals provides quantitative descriptions of vascular physiology that are independent 
of background tissue optical properties 10, 14-16.
In the present study we investigated the use of DPS in patients undergoing light fraction-
ated ALA-PDT for AK. Since this is the first study using DPS to acquire reflectance spectra 
in human skin and in AK, its architecture had to be first considered in order to choose 
a probe with the correct optical interrogation volume. AK has a thicker epidermis than 
normal skin and since the relevant capillaries are situated directly under the epidermis 
we needed to measure the thickness of AK in skin biopsies and to design a probe based 
on these measurements.
Our goal was to investigate if DPS can be used to derive quantitative data of the super-
ficial blood volume and oxygenation in human skin and if these would change during 
ALA-PDT for actinic keratosis. This will add to our understanding of PDT and support the 
attempts to optimize dosimetry aimed at improving the tolerability and/or efficacy of 
ALA-PDT.
MaTErialS and METhOdS
Patients and procedures
The epidermal thickness of AK excision biopsies from twenty patients was measured (see 
below). All lesions were located on the face and diagnosis was confirmed by a trained 
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pathologist. Nine other patients with a total of nine lesions received standard fraction-
ated ALA-PDT for facial AK in which two illuminations (20 and 80 Jcm-2 at 80 mW cm-2 
using an Omnilux® Waldmann LED device centered at 633 ± 20 nm) are delivered 4 and 6 
hours after topical application of ALA cream (Fagron®, Oud Beijerland, The Netherlands). 
The two illuminations were separated by a two-hour dark interval. In these nine patients 
DPS spectra were acquired by gently bringing the DPS probe into contact with the skin 
immediately before and after each illumination; these time points will be referred to as 
[Pre1, Post1, Pre2, Post2] throughout this manuscript. We took three repeated measure-
ments, by removing and replacing the probe, from the centre and from the margin of the 
lesion and, as a control, from normal appearing skin from the contra-lateral side. A single 
measurement took approximately 3 seconds and all measurements were performed by 
one investigator (T.M.) to minimize inter-individual differences in pressure.
Epidermal thickness
In the paraffin-embedded and haematoxylin and eosin stained sections the epidermal 
thickness was measured from the granular to the basal layer, using a light microscope 
and a calibrated 2 mm long liner with intervals of 10 microns. Multiple sections of each 
lesion were scanned to locate the thickest and thinnest dysplastic area. In addition, a 
visual overall average thickness was estimated. Table 1 shows the findings of these mea-
surements. The minimum thickness ranged from 30 to 360 microns (mean 120, median 
100) and the maximum thickness ranged from 80 to 1000 microns (mean 510, median 
550). The mean visually estimated thickness was 310 (SD 200). Patients mean age was 79 
years (range 57-94) and maximum vessel diameter averaged 70 microns (range 30-100).
Table 1: Histologically measured thickness of twenty actinic keratosis sections.
  Thinnest dysplastic area Thickest dysplastic area Visual average age
Range 30 - 360 80 - 1000 60 - 720 57 - 94
Mean (SD) 122 (77) 514 (306) 313 (199) 79 (10)
Median (IQR) 95 (75-148) 550 (228-763) 280 (158-425) 81 (74-86)
The range, mean, standard deviation (SD), median and interquartile ranges (IQR) for the thinnest and 
thickest dysplastic area in each section are presented; as well as for the age and the visual average 
thickness.
dPS probe design
Based on these findings we chose to use an 800 microns diameter DPS probe that 
enabled us to obtain a DPS signal 400 microns deep 16. This depth contains the whole 
epidermis (310 microns) and a fraction of papillary dermis (90 microns) where the blood 
vessels are located that oxygenate the dysplastic tissue during PDT. A DPS probe con-
tains two optical fibers (Ocean Optics) of which one is used for delivery and collection 
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(dc) of light and the other adjacent fiber is used for light collection only (c), see Figure 
1. Light from a tungsten halogen lamp (Avantes HL-2000) was coupled to one arm of an 
800-µm bifurcated fiber (Ocean Optics). A second arm was connected to a dual-channel 
spectrograph with a notch filter inserted so that the system could be used for fluores-
cence measurements in other monitoring applications.
Delivery and 
Collection Fiber 
Collection fiber 
White Light 
Source 
Notch filter 
1st Channel 2nd Channel 
Spectrograph 
Skin Rdc 
Rc RDPS = Rdc - Rc 
 
Figure 1. DPS experimental setup. During measurement light is delivered to the tissue by the dc-fiber 
and light remitted from the tissue is collected by both the delivery and collection (dc)-fiber and collection 
(c)-fiber and sent to a spectrograph. The dc-fiber collects both superficially and deeply scattered light, 
while the c-fiber collects only deeply scattered light. Subtraction of the two signals yields the superficially 
localized DPS signal.
Both the spectrograph and lamp were controlled by a custom made LabView program 
(National Instruments LabView 7.1) on a notebook computer. The other ends of the 
fibers, used for skin contact, were polished to an angle of 15o to minimize the collection 
of specularly reflected light at the probe-skin interface. Superficially scattered light was 
collected by the dc fiber, while light that was scattered deeper in the tissue was collected 
by both fibers. Subtracting these signals provides the superficial DPS signal.
To calibrate the setup we measured spectra from black and white Spectralon standards 
(Labsphere SRS-99 and SRS-02) in air and in a water-filled dark container. The difference 
in black and white measurement was used to correct for variations in lamp output and 
fiber-specific transmission properties while the air versus water measurement was used 
to correct for internal reflections 17.
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data analysis
To derive quantitative information on amount and saturation of blood within the 
optically sampled tissue volume, all spectra were fitted using a Levenberg-Marquardt 
least squares fitting routine that uses the standard deviations of the binned data points 
calculated from 4 neighbouring pixels as weight factors. Background scattering and 
tissue absorption were incorporated using the models to calculate reflectance as first 
described by Amelink et al 17 and later optimized by adding an extra Rayleigh scattering 
component 18, 19. The absorption coefficient of skin μa was described by:
μa = BVF • (StO2 • μHbO2a  (λ) + (1 – StO2) • μHba  (λ)) • Ccorr (λ) + Mel • μ Mela
where  μ Mela  = p1 λ
p2
a
and where BVF is the blood volume fraction of the sampled tissue, StO2 is the micro-
vascular blood oxygen saturation, μ HbO2a and μ Hba are the absorption coefficients of fully 
oxygenated and deoxygenated blood respectively, and Ccorr is a correction factor that 
depends on vessel diameter and accounts for the inhomogeneous distribution of blood 
in tissue20. Mel is the concentration of melanin and the contribution of melanin to the 
tissue absorption is calculated by using the specific absorption coefficient μ Mela , where p1 
and p2 were estimated using the method described by Jacques
21. The tissue reflectance 
(RDPS) can be described by applying a Beer-Lambert description of absorption to the 
background scattering model, as:
RDPS = a1  a2 
λ-b
λ0
 + (1 – a2) 
λ-4
λ0
  exp (μa • <L>)
The term in brackets represents a background scattering model composed of Mie and 
Rayleigh components. The fractional contributions of Mie and Rayleigh components are 
estimated by fitting the parameter a2 (which occupied values in the range 0-1), and the 
respective wavelength dependencies of the components are given as λ-b and λ-4, where b 
is a fitted parameter. The fitted parameter a1 corrects for changes in the absolute ampli-
tude of the measured reflectance intensity; the value of a1 is dependent on the distance 
between probe and Spectralon during calibration measurements and does not inform 
estimates of tissue scattering properties. The DPS photon path length -given as <L>- is 
insensitive to scattering effects in skin, as it is expected to fall within the range of 5-50 
mm-1. However, it can in part depend on the absorption coefficients, especially for the 
probe diameter d fiber utilized in this study. We accounted for this dependence by using 
an empirical expression described previously by Kaspers et al 14, given as;
<L> = 1.08d fiber
1 + 1n(1 + 0.71 μad fiber)
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Statistics
Differences were statistically analysed using a paired Wilcoxon test, using P<0.05 for 
significance.
rESulTS
Spectral fitting and a representative single lesion example
Figure 2a shows a representative example of the variations in measured BVF and StO2 
from one lesion during the course of light fractionated PDT. Each point represents the 
mean, weighted by the standard deviation of three measurements taken at the centre 
of a single lesion; there was little variation between these three measurements as is 
a 
b c 
Figure 2. (a) Variations in BVF (black line) and StO2 (grey line) from one representative lesion at different 
time points during the course of light fractionated PDT. Each data point represents the average value 
weighted by the standard deviations of three measurements taken from the centre of the lesion. (b) 
and (c) DPS reflectance spectra acquired before the first illumination (b, Pre1) and before the second 
illumination (c, Pre2) of the same lesion. Measured spectra are given as the grey data points and model 
fit is given as the black line. Model analysis yielded estimates of BVF and StO2. The residual line (given as 
Resid) below the spectra in both figures represents the percentage deviation between the model fit and 
the measured data.
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illustrated by the relatively small 95% confidence intervals. During PDT of this lesion, 
the StO2 increased after the first illumination and remained high before and after the 
second illumination; whereas the BVF decreased during the first illumination, increased 
considerably in the dark interval and decreased slightly during the second illumination. 
Note that the lines connecting the points are drawn only to illustrate the changes in the 
vascular physiology; they do not suggest linearity. Figures 2b and 2c show spectra cor-
responding to individual measurements acquired before the first and before the second 
illumination respectively. The model fit (solid line) of the blue data points illustrates the 
quality of the fitting procedure. The double dip in the 500-600 nm wavelength region in 
figure 2c indicates the characteristic presence of blood, in this case oxygenated haemo-
globin, whereas in figure 2b the spectrum showed the presence of a much lower blood 
volume. Note the variability in the data points around 650 nm, which was caused by the 
notch filter but did not affect quality of the fit. High quality fitting was achieved in over 
90% of measurements, also in the case of low blood volumes. Spectra that did not fit 
were excluded based on the presence of observable features in the residual between 
the model fit and the data 22. The poor quality of some individual measurements was 
due to probe and/or patient movement and incomplete contact between the probe and 
the skin surface.
average saturation and blood volume fraction during light fractionated PdT
While the average StO2 of individual lesions varied between 40-100%, the saturation 
was generally high and there was no consistent pattern in the StO2 changes between 
patients. This is illustrated for the measurements obtained from the centres of the 
lesions in figure 3a. The BVF showed high variability between lesions, between the dif-
ferent time point measurements during PDT, but not between the three measurements 
of the same lesion as is illustrated for the centres of the lesions in figure 3b. There was 
no consistent pattern in BVF change during the course of light fractionated PDT for the 
group of lesions as a whole. However, for patients showing a low initial BVF (less than 
0.5%), a trend was observed that the BVF relative to its starting value increased between 
time points Pre1 and Pre2 (bold lines in figure 3b). In figures 4a and 4b data points 
represent the mean relative BVF measured at each location (lesion centre, margin, and 
normal skin) at each sampled time point; each data point is relative to the value at the 
initial time point Pre1 (measured pre-treatment). For the subset of patients that had an 
initial BVF < 0.5% in the centre of the lesion, the median BVF increased by a factor of 
2.9 (P=0.06), following the dark interval and prior to the second illumination (figure 4a). 
Interestingly, these patients show no such trend immediately after the 1st illumination; 
instead they showed increased variability immediately following treatment illumination 
as evidenced by the large interquartile ranges. The trend observed in Figure 4a was not 
observed at the margin or normal measurement locations. Moreover, patients that had 
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an initial BVF > 0.5% did not exhibit the trend shown in Figure 4a, instead showing an 
increasing inter-patient variability in BVF changes in response to treatment, illustrated 
by increasing inter-quartile ranges (Figure 4b).
a b 
Figure 3. (a) StO2 and (b) BVF measured in all lesions at each sampled time point during the course of 
light fractionated PDT. Each line represents one lesion and each data point represents the average StO2 
weighted by the standard deviation of three measurements taken from the center. On panel (b) the * 
mark indicates lesion 5; see text for details.
a b 
Figure 4. Relative BVF, expressed as a percentage of the measured value at time Pre1, at each sampled 
location (lesion center, lesion margin, and normal skin), and at each time point during the course of light 
fractionated PDT. Panel (a) shows relative BVF for patients with BVF < 0.5 % at the initial measurement 
(Pre1) in the center of the lesion. Panel (b) shows relative BVF for patients with BVF > 0.5 % at the initial 
measurement (Pre1) in the center of the lesion. Each data point represents the median relative BVF and 
the error bars represent interquartile ranges for all patients within the subgroup.
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diSCuSSiOn
This study is the first to describe the use of DPS in human skin and it shows that DPS 
enables measurement of blood volume and saturation very superficially, and that it can 
be used to monitor changes herein during PDT for actinic keratosis. This is in contrast to 
what others have tried before when using other optical techniques such as DRS that are 
influenced by deeper signals. Our study also demonstrates the importance of choosing 
a probe diameter –and thus the interrogation depth- based on tissue properties, e.g. 
the histological thickness of AK. Ideally one would choose the fiber diameter based on 
a patient’s individual histological thickness. We measured an average thickness that was 
310 microns and showed a considerable variation (range 30 to 1000 microns). This is 
an important finding because in PDT the penetration of both drug and light is affected 
mainly by the epidermal thickness. In all our measurements we were able to measure 
the presence of blood, indicating that the diameter of our DPS probe of 800 microns 
was indeed appropriately chosen, measuring up to 400 microns in depth. The measure-
ment of AK thickness was not only necessary for our probe design, but was also another 
relatively new feature to our study as this has not been studied well in the literature. One 
study found a mean maximum AK thickness of 110 ± 10 microns in 10 patients, which is 
included in our interrogation volume. 23.
When considering the DPS spectra, our mathematical model resulted in good quality fits 
of the data, indicating that the results are reliable as is illustrated in figures 2b and 2c. 
Figure 2a also shows that single measurements were precise because they were repeat-
able with only small variations between them. The observed blood volume and satura-
tion in this particular lesion is very interesting, because these changed considerably 
during PDT. For example: during the first illumination the saturation increased while the 
blood volume decreased. Since PDT consumes oxygen, this can only be explained by 
another factor such as increased blood flow, which we have not measured but a rapid 
increase in blood flow was recently demonstrated in a study on ALA-PDT for basal cell 
carcinoma 24. Another feature in this lesion is that during the dark interval the blood 
volume increased as much as fourfold. Apparently the blood vessels have dilated in that 
lesion after the first illumination. PDT is known to induce an inflammatory response and 
the increase could be explained by vasoactive cytokine release. Since ALA-PDT induces 
immediate vasoconstriction, another explanation might be a compensatory vasodilata-
tion. It is reasonable to expect that the photodynamic process in this particular lesion is 
influenced by these changes, possibly influencing clinical outcome.
Not all lesions showed this pattern however. Especially for the blood volume there were 
large differences between lesions. In lesion five for example, represented by the dashed 
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purple line and marked with a * in figure 3b, the blood volume showed a completely 
different pattern. In that lesion the starting blood volume was much higher and it de-
creased during the first illumination and the dark interval to increase again during the 
second illumination. It is clear that these changes affect the PDT process in this lesion 
in a completely different way than the lesion illustrated in figure 1. These observations 
indicate that individual lesions and patients show changes that are important for the 
PDT effect, but that it is not possible to draw any general predictive conclusions. The 
clinical implication is that care should be taken when treatment schemes are applied to 
all patients or lesions while they may respond differently to treatment.
When considering the blood volume data of all patients, we noticed a pattern that in 
the center of lesions the blood volume increased during the dark interval in those le-
sions that had low initial starting values, whereas this was not the case in lesions that 
started with high blood volumes (figure 4). This increase in blood volume before the 
second illumination relative to the starting value was borderline statistically significant 
(p=0.06). This may be a real effect or it may be explained by regression to the mean or 
possibly because the blood vessels were already maximally stretched initially. It might 
mean however that these patients need an alternative approach, for which further study 
is needed.
Since this is the first time we used DPS in human skin, it is important to put our find-
ings in perspective to other measurement techniques and to the PDT process in whole. 
Although we did not find a general trend or pattern for the blood volume and satura-
tion, we did find different effects for different lesions. Other techniques previously also 
showed no overall changes but more importantly: they also showed no difference 
between lesions 13. As explained in the introduction these techniques may not be sensi-
tive for very superficial tissue volumes, where the PDT process takes place. Although we 
did not compare these techniques directly in this study, arguably DPS is more sensitive 
for superficial measurements. Using DPS, we have now shown that individual lesions 
respond differently to PDT with respect to blood volume and saturation. This highlights 
the fact that lesions need to be treated differently based on its individual properties. 
With respect to the PDT process as a whole it is immediately clear that we have not yet 
attempted to measure a critical parameter: the amount of PpIX within the lesion. It is 
very likely that the amount of PpIX within AK has a direct impact on the physiological 
responses that we observe. It is well known that local superficial quantitative measure-
ments of tissue fluorescence are challenging and can be strongly influenced by the 
light delivery, tissue optical properties and collection geometries. The combination of 
superficial reflectance and photosensitizer fluorescence spectroscopy will be reported 
in a future study.
Monitoring blood volume and saturation in ALA-PDT of actinic keratosis using DPS 129
Before drawing conclusions from our study it is important to consider some limitations. 
First, to demonstrate the possible use of DPS in human skin we needed only a few pa-
tients, but to discover statistically significant changes in blood volume and saturation 
the power may have been too low. Second, we measured blood volume and microvascu-
lar saturation as a proxy measure for tissue oxygenation, not taking the time for oxygen 
to diffuse to the tissue into account. Related to this, the third limitation was the speed of 
measurements. Dynamic vascular effects such as a sudden increase in blood flow may not 
be detected during the ten seconds needed to perform the three measurements taken 
at each time-point. In general, the blood flow in capillaries is relatively slow however 
and we found no systematic difference in blood volume in time between these three 
measurements, indicating that neither speed of measurements nor pressure had a ma-
jor impact. Time and speed of measurement remain important considerations though. 
It may be interesting to take a reflection spectrum during the second illumination at 
the time-point where 20 J cm-2 was delivered, which is equal to the total dose during 
the first illumination. At the end of the second illumination only a small amount of PpIX 
remains that may not be sufficient to have a significant effect on the microvasculature. 
A fourth limitation is that lesion-specific variability in thickness may explain the starting 
variability of blood volume between patients. The variability in response in individual 
lesions however, cannot be caused by this. Also, possible changes in lesion thickness 
due to edema formation during the dark interval were not accounted for. The effect of 
this is expected to be small but it could be interesting to test this using small and large 
fibre diameter probes and compare the difference. Finally, we had to exclude about 10% 
of the spectra from our data analysis because of unsuccessful fits. Possible explanations 
for this are movement of the probe during the measurement, a bad contact with the 
skin or possible ambient light or the presence of other chromophores. For future use 
of this technique it would be useful to identify these failed measurements during the 
acquisition procedure.
In conclusion we showed that DPS can be used to measure blood volume and saturation 
in human skin. We also showed that individual lesions behave differently in ALA-PDT 
with respect to blood volume and saturation, which has not been shown using other 
techniques. This means that the current approach of treating all lesions with the same 
light dose may need to be reconsidered. It also means that DPS may be advantageous 
to other techniques such as diffuse reflectance spectroscopy to monitor blood volume 
and saturation in skin PDT. Our data show the need to monitor patient-specific vascular 
physiology during PDT. Moreover, incorporating fluorescence measurements using DPS 
would allow monitoring photosensitizer concentration; this will be incorporated in 
future studies.
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abSTraCT
Background and objective: Fluorescence measurements in the skin are very much af-
fected by absorption and scattering but existing methods to correct for this are not 
applicable to superficial skin measurements.
Study design/materials and methods: The first use of multiple-diameter single fiber re-
flectance (MDSFR) and single fiber fluorescence (SFF) spectroscopy in human skin was 
investigated. MDSFR spectroscopy allows a quantification of the full optical properties 
in superficial skin (µa, µs’ and γ), which can next be used to retrieve the corrected -in-
trinsic- fluorescence of a fluorophore Qµfax. Our goal was to investigate the importance 
of such correction for individual patients. We studied this in 22 patients undergoing 
photodynamic therapy (PDT) for actinic keratosis.
Results: The magnitude of correction of fluorescence was around 4 (for both autofluo-
rescence and protoporphyrin IX). Moreover, it was variable between patients, but also 
within patients over the course of fractionated aminolevulinic acid PDT (range 2.7-7.5). 
Patients also varied in the amount of protoporphyrin IX synthesis, photobleaching 
percentages and resynthesis (>100x difference between the lowest and highest PpIX 
synthesis). The autofluorescence was lower in actinic keratosis than contralateral normal 
skin (0.0032 versus 0.0052; P<0.0005), and decreased further to 0.0021 after aminolevu-
linic acid application (P=0.01).
Conclusions: Our results clearly demonstrate how important it is to correct fluorescence 
for optical properties, because these vary considerably between individual patients and 
also during PDT. The autofluorescence can be relevant for diagnostic use in the skin, 
but also for studies investigating its association with several internal diseases such as 
diabetes. Protoporphyrin IX synthesis and photobleaching kinetics allow monitoring 
clinical PDT which facilitates individual-based PDT dosing and improvement of clinical 
treatment protocols.
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inTrOduCTiOn
Fluorescence spectroscopy can be used to measure the concentration of common 
fluorophores in the skin such as NAD(H), collagen, elastin, keratin, and advanced gly-
cation end-products (1-4). The combined emission of these fluorophores constitutes 
the skin autofluorescence, which has gained considerable attention because higher 
autofluorescence intensities have been described to be correlated with cardiovascular 
events, diabetes mellitus, chronic pulmonary disease, renal disease, liver cirrhosis and 
inflammatory diseases (5-11). Fluorescence spectroscopy can also be used to measure 
for example the protoporphyrin IX (PpIX) concentration during photodynamic therapy 
(PDT). Such measurements are important because it is well documented that PpIX 
fluorescence kinetics can help predict PDT outcome (12-17). However, the problem with 
these fluorescence measurements is that the detected fluorescence signals are critically 
dependent on the tissue optical properties, but these are not taken into account (18-20).
When obtaining a fluorescence signal, both the excitation and emission light are ab-
sorbed and scattered and, as a result, raw fluorescence signals will underestimate the 
fluorophore concentration. It is obvious that individual lesions and patients will differ in 
their physical and biochemical properties and thus also in their optical properties. Fur-
thermore, in the case of PDT, these optical properties may be changing in time during 
the course of treatment. Such variations in optical properties will result in differences 
in measured fluorescence intensity even if the fluorophore concentration is the same. 
Therefore, a crucial step to measure the intrinsic fluorescence in tissue is to correct it 
for the optical properties of that tissue. These must be quantified first to perform this 
correction accurately.
Measuring the optical properties in a superficial sampling volume such as in the human 
epidermis and upper dermis poses a significant challenge. Several techniques have 
been deployed that can be used, but these are either limited to a narrow wavelength 
range and/or are only valid for certain tissue optical properties (21-24). When using any 
optical instrument, knowledge of the photon path-length is necessary to quantify the 
optical properties of tissue. A solution therefore is to make use of an optical technique 
in which the path-length of light can be controlled. One such optical technique is single 
fibre reflectance (SFR) spectroscopy, which has recently been developed by our group 
(25-29). In SFR white light is emitted through a single fibre that is in contact with the skin. 
The same fiber also collects the reflected light and can be used to acquire a reflectance 
spectrum over a broad range of visible and near infrared wavelengths. This reflectance 
spectrum contains the combined information on how much light has been absorbed and 
scattered. From such a reflectance spectrum the tissue absorption coefficient, µa [mm
-1] 
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can be accurately quantified without prior knowledge of the scattering properties (28). 
Decomposition of µa into the constituent spectra of known tissue chromophores yields 
accurate measurements of the blood volume fraction, microvascular saturation, mean 
vessel diameter and of the melanin, bilirubin and beta-carotene content. To determine 
the tissue scattering properties however, a single SFR measurement does not suffice.
The geometry in SFR allows superficial measurements with relatively short photon path-
lengths. As a result, the number of scattering events is also relatively small. This means 
that the angle in which the light is scattered becomes increasingly important for the 
amount of reflected light. This scattering angle follows a probability distribution that 
is described by the (unknown) tissue phase function. Because the reflectance in SFR 
is highly dependent on this phase function it is necessary to characterize it in order to 
measure the reduced scattering coefficient µs’[mm
-1]. We have recently demonstrated 
that successive SFR measurements using two or more carefully chosen fiber diameters 
in a single optical probe enables to solve this problem, allowing quantification of both 
the phase function parameter γ [-] and of µs’ (30-32). This technique is termed multiple 
diameter single fiber reflectance (MDSFR) spectroscopy. The mathematical model to 
extract the optical properties from a measured spectrum has been validated using 
tissue-mimicking phantoms and in computer simulations that used a range of biologi-
cally possible optical properties (31, 32).
The optical properties that are measured using MDSFR can next be used to correct 
a subsequent fluorescence measurement (33). We have developed a model to ac-
curately quantitate the fluorescence by correcting for the tissue absorption and scat-
tering properties at both the excitation and emission wavelengths (34). This corrected 
-intrinsic- fluorescence is dependent on both the ability of the fluorophore to absorb the 
excitation light and its efficiency to emit light. Specifically, it is given as the product of 
the absorption coefficient of the fluorophore for the excitation wavelength µ fa,x and the 
quantum efficiency of the fluorophore across the emission spectrum Q [-]. This method 
is termed single fiber fluorescence (SFF) spectroscopy and this has recently been applied 
for the measurement of intrinsic fluorescence in pre-clinical models (35).
In this study we describe for the first time the use of MDSFR and SFF spectroscopy in 
human skin. Our goal was to investigate the importance of correcting fluorescence sig-
nals for optical properties in individual patients. We studied this in patients undergoing 
fractionated aminolevulinic acid (ALA) PDT for actinic keratosis or Bowen’s disease. This 
patient selection allowed us to measure both skin autofluorescence and ALA-induced 
PpIX fluorescence. Because optical properties are expected to change during PDT (36-
39), we also studied the magnitude of the effect of variations in optical properties on 
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fluorescence signals. This was done by measuring protoporphyrin IX fluorescence at 
various time-points during PDT.
MaTErialS and METhOdS
MdSFr and SFF setup
To obtain a reflectance spectrum, light from a tungsten halogen lamp was directed on 
the skin through a probe containing 2 single fibers with diameters of 0.4 and 0.8 mm. 
This choice is related to the fact that the photon path length -and thus the sampling 
volume- is on the order of the fiber diameter (29, 40). This means that when using these 
fiber diameters, normally both the epidermis and superficial dermis will be sampled in 
normal skin and actinic keratosis lesions (37). Another rationale for our choice is that 
it was shown that the accuracy of the MDSFR technique works best for relatively large 
fiber diameters and that the diameters of the two fibers should be relatively close so that 
they are measuring the same optical properties (31). After these sequential reflectance 
measurements, a SSF fluorescence spectrum was taken using the 0.8 mm fiber by il-
luminating the skin with 405 nm laser light. The reflectance and fluorescence spectra 
were detected by three spectrometers, one for each fiber to measure reflectance and 
one to measure fluorescence with a filter blocking the laser light by a 435 nm long-pass 
filter (Figure 1). The spectrometers and light sources were controlled by a custom made 
White Light 
Source Spectrometers 
Single Fiber, d = 0.4 mm 
Single Fiber, d = 0.8 mm 
405 nm Laser 
Figure 1. Schematic representation of the measurement setup. White light reflectance and fluorescence 
(405 nm laser excitation light) spectra were acquired using a single probe that contained two fibres of 0.4 
and 0.8 mm. The 0.8 mm fiber was used for both fluorescence and reflectance spectroscopy while the 0.4 
mm fiber performed reflectance spectroscopy only.
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LabView program (National Instruments LabView 7.1) on a notebook computer. A single 
combined MDSFR/SFF measurement took approximately 3 seconds. The ends of the 
fibers, used for skin contact, were polished to an angle of 15o to minimize the collection 
of specularly reflected light at the probe-skin interface. Figure 2 shows an example of 
the MDSFR spectra acquired by the 0.4 and 0.8 mm fibers. In this figure the percentage 
of incident light collected by each optical fiber is plotted as a function of wavelength 
(grey dots and their standard deviations) with the MDSFR model fit to the data (black 
lines). For both fibers the overall shape of the SFR signal is characterized by a signal that 
decreases with wavelength (grey line) that is attributable to the background scattering. 
Note that the reflectance is higher for the 0.8 mm fiber diameter, because the collection 
area is larger.
Figure 2. Example of an MDSFR spectrum for both the 0.4 and 0.8 mm fiber diameters. The characteristic 
wavelength-dependent features of haemoglobin are best seen in the 0.8 mm fiber in the 400 nm and 500 
to 600 nm regions (“dips” in the black line).
reflectance spectral analysis
To retrieve quantitative data on the tissue optical properties and the intrinsic fluorescence 
spectral analysis was performed using the same fitting model for the data described 
previously. For a detailed description of this model and the underlying mathematics, we 
refer to these articles (30-32, 35, 41). A simplified stepwise summary of our approach is 
described below.
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First the tissue absorption properties are calculated, which are defined by the absorp-
tion coefficient μa [mm
-1]. For each wavelength this is the sum of the known absorption 
coefficients of (de)oxygenized hemoglobin, melanin, bilirubin and beta-carotene. These 
result in the following measured parameters of the sampled volume: the blood volume 
fraction, the average vessel diameter, the saturation, and the melanin, bilirubin and 
beta-carotene concentrations. Next, the absorption-corrected spectra from both fiber 
diameters are simultaneously fitted to extract μs’ [mm
-1], and γ [-].
The melanin fitting routine is an important new addition to previous models, since this 
is the first study on human skin. Because the shape of the melanin absorption spectrum 
is similar to the scattering spectrum and the two properties have competing effects on 
the spectra, using melanin as an independent absorber can result in over-estimations of 
both melanin concentration and μs’. To address this, we assumed melanin to be confined 
predominantly to the basal membrane. This led us to model melanin as existing in a 
20 µm layer (40 µm photon round trip path length) within the measurement volume. 
It was also assumed that the melanin concentration observed by each fiber in the 20 
µm layer was the same, which allows simultaneous solution of the model equations for 
both fibers to produce an estimate of the melanin content. Another smaller addition 
to previous models was the inclusion of a new absorption spectrum for beta-carotene, 
based on a previous description of it in human skin (42).
Correction of fluorescence for absorption and scattering
To calculate the quantitative corrected intrinsic fluorescence, the raw fluorescence 
signals were corrected for the effects of absorption and scattering using the optical 
properties obtained from the MDSFR reflectance spectra. For a detailed mathematical 
description of the SFF model that was used we refer to earlier papers (33, 41). In short, 
the ratio of collected emission photons to delivered excitation photons at each wave-
length is first corrected for the average of the absorption coefficient at the excitation and 
emission wavelengths. Next, the absorption-corrected fluorescence ratio is corrected 
for the effects of scattering using the reduced scattering coefficients at both excitation 
and emission wavelengths. This step results in a calibrated and corrected fluorescence 
spectrum expressed as the wavelength-dependent intrinsic fluorescence, Q(λ)μ fa,x , 
where Q(•) is the quantum efficiency of the fluorophore at each emission wavelength. 
Lastly, the resulting wavelength-dependent intrinsic fluorescence is then integrated 
over the emission bandwidth of the fluorophore. This results in the intrinsic fluores-
cence of the fluorophore at the excitation wavelength, Qμ fa,x , where Q is now the total 
fluorescence quantum yield of the fluorophore. For the purposes of this manuscript, we 
wish to illustrate the effect of correction for optical properties. Therefore, here we define 
the “uncorrected fluorescence” as fluorescence spectra which undergo the correction 
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process using μa and μs’ values of zero. This ensures that the uncorrected and corrected 
fluorescence spectra have the same units.
Fluorescence spectral analysis
The fluorescence spectra, corrected for the influence of tissue optical properties, were 
then analyzed to determine the contribution from autofluorescence, PpIX and the PpIX 
fluorescent photoproducts. A skewed Gaussian was used to fit the autofluorescence 
while the basis spectra for PpIX and its photoproducts were isolated from spectra after 
subtraction of the autofluorescence (13)
Calibration of the MdSFr/SFF system
Before each set of measurements a careful calibration procedure was performed as 
described previously (30, 41) consisting of an integrating sphere calibration, a measure-
ment of a calibrated light source, and measurements in water in a dark container and 
in a liquid phantom containing 6.6% Intralipid-20% with a known reduced scattering 
coefficient (μs’ at 800 nm = 1.2 mm
-1). This procedure accounts for the output powers of 
the light sources and the spectral transmission and sensitivity of the system.
lesion selection
Spectra were obtained in 22 patients undergoing fractionated ALA-PDT for actinic 
keratosis (n=20) or Bowen’s disease (n=2). In fractionated PDT, which is the standard 
in our university hospital setting, two light fractions of 20 and 80 J cm-2 are delivered 
4 and 6 hours after ALA application, separated by a two-hour dark interval. All lesions 
were histologically confirmed. The study was performed within local written ethical 
guidelines and was in accordance with the declaration of Helsinki.
MdSFr/SFF measurements on skin
Both autofluorescence and PpIX fluorescence were measured in actinic keratosis or 
Bowen’s disease lesions. Spectra were obtained from the centre of the lesion at various 
time-points. Normal skin measurements were taken from normal contralateral skin. The 
first set of measurements (before and after gentle curettage) were acquired before ALA 
application. During PDT 3 individual measurements were taken by removing and replac-
ing the fiber probe at each of the following time-points: before and immediately after 
the first PDT illumination; and before and after the second illumination. All measure-
ments were performed by the same investigator to minimize inter-individual variations 
in applied pressure.
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data analysis
For each reflectance measurement, containing spectra from both the 0.4 and 0.8 mm fi-
bers, the goodness of the fit for the reflectance spectrum was calculated over the whole 
wavelength region using χ2 = ∑(Rmodel (λi) – Rmeasured (λi))2/ σ(λi)2 as an indicator of fit quality. 
Rejection criteria were: (1) a χ2 value larger than 1.6(10)5 for either fiber diameter, which 
was set empirically from the fitted data, (2) a maximum residual between the fit and 
the data exceeding 25% at any part of the spectrum, (3) crossing of the 0.8 and 0.4 mm 
spectra, or (4) if an imaginary component resulted from the fit. The spectra failing any 
of these rejection criteria were not used for further analysis. This lead to 418 of a total of 
572 spectra being included. All successful reflectance and fluorescence spectra lead to 
values for corrected fluorescence that included a 95% confidence interval, based on the 
model fitting as described previously (43).
For each set of three measurements per time-point, averages of these measurements 
were calculated when it was clear that individual measurements of the same lesion 
showed very little variation. For the same reason of consistency in measurements at the 
same spot, lesional measurements before and after gentle curettage were also grouped 
together. Similarly, actinic keratosis and Bowen’s disease were grouped as “lesional skin” 
and referred to as such throughout the rest of the manuscript.
The magnitude of correcting the autofluorescence and PpIX fluorescence signals for 
measured tissue optical properties was defined by dividing the average corrected by the 
average uncorrected values. This is referred to as “the correction factor” throughout the 
manuscript. We evaluated the effect of fluctuations in optical properties during PDT on 
the magnitude of the correction factor by comparing autofluorescence and PpIX fluo-
rescence intensities over time during PDT. In addition, the variation between patients in 
corrected PpIX synthesis 4 hours after ALA application and PpIX photobleaching during 
PDT was investigated. Finally, differences in the corrected autofluorescence intensities 
between normal and lesional skin were compared, as well as the lesional autofluores-
cence signals before and 4 hours after ALA application.
rESulTS
The effect of correction for optical properties on individual spectra
Figure 3 illustrates how individual spectra were affected by correcting for the tissue 
optical properties. It shows a typical spectrum from an actinic keratosis lesion 4 hours 
after ALA application. The broad peak centered around 480 nm is due to the combined 
autofluorescence signal from a number of common fluorophores such as collagen, elas-
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tin, keratin and NADH. The characteristic emission of PpIX is recognizable by its main 
peak around 635 nm. Note how the corrected fluorescence is about 4 times higher than 
the uncorrected (dashed line).
Figure 3. Example of corrected versus uncorrected (dashed line) spectra of actinic keratosis 4 hours after 
ALA application, showing the typical emission features of the skin autofluorescence below 600 nm and of 
PpIX fluorescence with a main peak at 635 nm. The corrected Qμ fa,x  values are about 4 times higher than 
the uncorrected.
Magnitude of the correction factor on autofluorescence for individual patients
The autofluorescence was variable between patients for both normal and lesional skin 
(Fig. 4a and b respectively). Note the two scales of the Y-axis, showing that values for 
the corrected Qμfa,x are always higher than the uncorrected. Taken in to account this 
different scale the corrected vales are in some cases below and in some cases above the 
uncorrected values in this figure, indicating variability of their ratio. The magnitude of 
this correction factor was 3.7 on average (range = 2.4-6.3) for normal skin. For lesional 
skin the correction factor was higher with a wider range (mean = 4.9, range = 2.7 – 7.5).
TEMPOral ChangES in OPTiCal PrOPErTiES during PdT and ThEir 
EFFECT On ThE auTOFluOrESCEnCE
Figure 5 illustrates the effect of temporal changes in optical properties on the auto-
fluorescence of (a) normal and (b) lesional skin. For both normal and lesional skin the 
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corrected autofluorescence was variable for the four time-points during PDT (before 
and after the first and second illumination), but there was no systematic increase or de-
crease. For normal skin the correction factor remained fairly constant over time, which 
is illustrated by the same shape of the corrected and uncorrected lines that connect the 
four time-points in figure 5a. In contrast, this was not the case for lesional skin (Fig 5b), 
in which the correction factor, and thus the optical properties varied during the time-
course of PDT. An example of a parameter that changed considerably during PDT is the 
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Figure 4. Corrected () and uncorrected () average values of individual measurements for the 
autofluorescence of (a) normal and (b) lesional skin. Shown are values at each of the four time-points 
before and after the first and second illumination for individual patients. The left y-axis is scaled to the 
corrected values and the right y-axis to the uncorrected.
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blood volume fraction. Compared to the initial value before PDT, the change in blood 
volume fraction ranged from a 7.7x decrease to a 4.9x increase. For individual patient the 
increase and decrease in blood volume fraction exhibited very variable patterns.
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Figure 5. The average corrected () versus uncorrected () autofluorescence during the four time-points 
during PDT for (a) normal and (b) lesional skin. For graphical clarity only 4 patient are shown. The pattern 
of variability was the same for normal skin, but not for lesional skin, indicated by the different shapes of 
the lines connecting the time-points. The left y-axis is scaled to the corrected values and the right y-axis to 
the uncorrected.
The relation between optical properties and the magnitude of the correction 
factor
Figure 6 illustrates the effect of variations in (a) absorption and (b) scattering properties 
of the skin on the magnitude of the correction factor for the autofluorescence. In this 
figure the blood volume fraction and the scattering coefficient are used as illustrative 
examples for the effects of respectively absorption and scattering. Higher blood content 
showed a positive correlation with the correction factor (Pearson’s correlation coefficient 
0.68, P<0.0001), and μs’ showed a moderate negative correlation (correlation coefficient 
-0.44, P<0.0001). The average value for μs’ (at 800 nm) was 1.32 mm
-1 for lesional skin and 
1.96 mm-1 for normal skin.
PpiX synthesis and photobleaching for individual patients
Individual patients showed considerable variation in the amount of synthesized PpIX 4 
hours after ALA application (figure 7). The corrected values were on average 4.4 times 
higher, but the magnitude of this correction factor was variable for individual patients, 
ranging from 3.3 – 5.9. This is graphically presented in figure 7 by the variable distance 
between corrected and uncorrected bars. Two patients synthesized minimal PpIX (8 and 
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20). For these patients not only the uncorrected but also the corrected PpIX values were 
very low (for patient 20 this was a factor 113 times lower than the highest measured 
PpIX fluorescence in patient 22). Note that the confidence intervals in this figure appear 
much larger for the corrected values than the uncorrected. However, when these are 
normalized to the magnitude of the fluorescence they are on average 28% of the total 
for the corrected and 25% for the uncorrected values.
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Figure 6. The effects of (a) absorption of blood and (b) the scattering coefficient μs’ (at 800 nm) on the 
magnitude of the correction factor for autofluorescence. Shown are average lesional values of all time-
points during PDT.
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per patient. There was a large variation between individual patients. The corrected values were on average 
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three repeated measurements, weighted by the confidence interval of their fit.
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During PDT we observed PpIX photobleaching to 19% (SD 9%), followed by variable PpIX 
resynthesis during the two hour dark interval to 76% (SD 36%) and further photobleach-
ing to 6% (SD 5%) remaining PpIX during the second illumination. These are averages 
of corrected PpIX fluorescence intensity values at these four time-points, normalized to 
the intitial PpIX synthesis 4 hours after ALA application for all patients except patient 20 
(who synthesized almost no PpIX at all).
difference in autofluorescence between normal and lesional skin
The autofluorescence in lesional skin was significantly lower than in normal skin (Fig. 8; 
median = 0.0032 versus 0.0052; P<0.0005, related samples Wilcoxon signed rank test). 
It was lower in 16 of the 18 patients in which we had successful sets of measurements 
for both normal and lesional skin. There was also an effect of ALA application on the 
autofluorescence in lesional skin. It decreased in 13/18 patients, which represented a 
statistical difference (median = 0.0032 versus 0.0021, P=0.01, related samples Wilxocon 
signed rank test).
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Figure 8. Significant lower average corrected autofluorescence in lesional compared with normal skin 
(P<0.0005, related samples Wilcoxon signed rank test). Error bar represent the 95% confidence interval 
weighted by the goodness of the fit of individual measurements.
diSCuSSiOn
In this study we report on the first use of MDSFR and SFF spectroscopy to quantify the 
intrinsic fluorescence in the epidermis and superficial dermis of human skin. Our find-
ing that the magnitude of the correction factor varied from 2.4 to 7.5 clearly illustrates 
how important it is to correct fluorescence signals for the tissue optical properties. This 
variability of the correction factor is a direct reflection of the heterogeneity in optical 
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properties of individual patients. Because of such heterogeneity it is crucial to first 
quantify the optical properties in individual patients and use these to correct the raw 
fluorescence signal of each measurement.
Effect of absorption and scattering on collected fluorescence
The way the fluorescence signal is affected by absorption and scattering is illustrated 
by the finding that the correction factor correlates with both the blood volume fraction 
and with µs’ (figures 6a and b). Higher blood volumes will lead to higher absorption and 
thus to lower collected raw fluorescence signals. This explains why the correction factor 
increases with increasing blood volume fraction. However, to explaining the negative 
correlation between the correction factor and µs’ necessitates a more detailed descrip-
tion of the empirical model used to correct fluorescence signals. This model is based on 
a recent publication on the underlying mechanisms associated with the influence of 
scattering and absorption properties on the fluorescence intensity collected by a single 
optical fiber (34). We have shown, based on Monte Carlo simulations, that for a single fi-
ber the measured fluorescence is proportional to the fiber diameter. We have also shown 
that the collected fluorescence rapidly decreases from a constant value in the absence 
of scattering (µs’ = 0) to reach a minimum at µs’ of around 0.5 mm
-1, and then increases 
with increasing scattering. This biphasic dependence is explained by two competing 
effects: superficially scattered photons tend to increase the collected fluorescence, 
whereas photons that are scattered deeper in the tissue are more likely to be scattered 
away from the fiber tip and thus decrease the collected fluorescence. At higher values 
for µs’ more photons are scattered superficially (resulting in a relatively small sampling 
depth). The net effect is that the increase in collected fluorescence caused by superficial 
scattering starts to outweigh the decrease caused by deeper scattering. In our study 
the average value for µs’ of lesional skin was 1.32 (range 0.48-3.28), which is of similar 
magnitude as previously reported (44). In this range of values for µs’ (i.e. higher than 
around 0.5 mm-1) increasing values for µs’ lead to an increase in collected fluorescence. 
This explains the negative correlation between µs’ and the correction factor.
Quantitative PpiX measurements during PdT: implications of our findings
When applying MDSFR with SFF measurements for the purpose of recovering the intrin-
sic PpIX fluorescence during PDT a few relevant findings can be highlighted. The first is 
that the optical properties in the sampled volume of lesional skin change during the 
course of PDT and these changes are different for individual patients. This is clear for 
example from the variable blood volume fraction over time during PDT, but can also be 
concluded from figures 5a and 5b. Figure 5a shows how the magnitude of the correction 
factor for the autofluorescence remained relatively constant over time for normal skin. 
In contrast, for lesional skin this correction factor varied over the time course of PDT 
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(figure 5b). This demonstrates that the optical properties in lesional skin change during 
PDT as a consequence of performing PDT. This again highlights the importance of cor-
recting for these varying optical properties during PDT.
A second important implication for the purpose of PpIX fluorescence measurements in 
PDT, is that the intrinsic PpIX fluorescence –and thus the synthesized PpIX concentration 
– is very variable between patients (figure 7). Because of the quantitative nature of our 
measurement, PpIX fluorescence values close to zero (patients 8 and 20) really mean that 
very little PpIX is synthesized. Because lack of PpIX synthesis will be related to decreased 
treatment effect, a benefit of quantitative PpIX fluorescence measurements would be 
to better predict individual treatment effect. Without correcting for optical properties, 
this could previously have been attributed for example by a lot of blood present in the 
sampling volume or by scattering effects. How such an uncorrected measurement can 
be very misleading can again be concluded from the variability of the correction factor 
for PpIX fluorescence measurements (which varied from 2.8-5.9).
A third potentially relevant implication of our findings for PDT is that quantitative PpIX 
fluorescence measurements can be used to estimate the effective PDT dose. This can be 
very useful for the individual dosing of the first illumination in light fractionated PDT; 
an approach that we have successfully adopted in mice (45, 46). Because previously we 
had no way of quantifying the intrinsic fluorescence in human skin, changes in optical 
properties during PDT make it impossible to reliably measure PpIX photobleaching 
percentages and resynthesis in the dark interval. Now that we can, this opens up new 
possibilities for the clinic. The current clinical light treatment parameters (20 Jcm-2 fol-
lowed by 80 Jcm-2 two hours later) were based on several preclinical studies. In these 
studies it was shown that the first light fraction needs to be small and larger first light 
fractions decrease efficacy (47). It was found that the optimal effective dose for the first 
illumination is to bleach circa 50% of PpIX . In our current study the PpIX photobleaching 
percentages during the first illumination were 81% on average. This suggests that the 
effective dose of the first illumination is too high. Possibly lower light doses will further 
increase efficacy. When we take a closer look at what our correction method may mean 
for an individual patient we see how use of a correction method changes the measured 
PpIX photobleaching kinetics. These are important because they have been related to 
PDT outcome in the past (48, 49). In patient 18 for example the uncorrected measured 
PpIX fluorescence at the four time-points during PDT is 100-15-73-8 %, whereas the cor-
rected values are 100-3-106-11%. This difference illustrates how correcting for optical 
properties can be important for a personalized approach to PDT. While quantitative PpIX 
fluorescence measurements are important for PDT studies, our measurements of the 
intrinsic skin autofluorescence can also be relevant for very different purposes.
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Quantitative skin autofluorescence measurements: implications of our findings
First, the different autofluorescence of normal and lesional skin (figure 9) points towards 
a diagnostic potential of intrinsic autofluorescence measurements. Again, it must be 
stressed that this is impossible unless a proper correction method is available. Several 
studies using different fluorescence spectroscopy techniques have described the poten-
tial value of the autofluorescence to differentiate between normal and neoplastic skin 
(50-52). To further explain why the autofluorescence is different for neoplastic skin it will 
be helpful to distinguish between the individual fluorophores that constitute the com-
bined autofluorescence signal, but our method currently does not allow this. Therefore 
a lower autofluorescence signal in lesional skin could simply reflect sampling less fluo-
rescent collagen in the dermis due to thicker epidermis of lesional skin, although one 
study reported that the epidermal thickness was not related to the autofluorescence 
(19). Another explanation may be that in lesional skin the mitochondrial function or 
redox state is somehow altered, which has been reported to affect the autofluorescence 
(4, 53). Future research that focuses on separating out the individual components in 
the autofluorescence signals are needed such as use of different excitation light (54) or 
phasor analysis of multiphoton spectral imaging (2).
A second potential benefit of quantifying the skin autofluorescence is that the autofluo-
rescence is considered a risk factor for a range of conditions that are related to increased 
cumulative metabolic stress. Currently a spectroscopic device called the AGE reader 
is commonly used to perform autofluorescence measurements (1, 5-8, 55), which are 
related to reference values for different age categories of normal Caucasian skin (56). 
Although these measurements are used for example to assess the risk for cardiovas-
cular complications in diabetes patients, they do not involve any correction for optical 
properties and thus may be off by a factor of around 6. This value may actually be even 
higher. This is because our measurements were also preceded by a careful calibration 
procedure. This way both the uncorrected and corrected outcomes were already cor-
rected for the variable output powers of the light sources and the spectral transmission 
and sensitivity of the system. Apart from this comparison with the AGE-reader it is inter-
esting to also compare our method with other methods that have attempted to correct 
raw fluorescence for optical properties.
Comparison with other methods to retrieve intrinsic fluorescence
A range of investigators have developed methods to correct fluorescence for optical 
properties in various biological tissues and tissue mimicking phantoms. However, these 
are often based on diffuse measurements with large source-detector separations (21, 
57). The correction methods associated with these measurements are often based on 
diffusion theory, which is useful for the measurements of larger volumes but not for 
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superficial measurements in the skin. Equally a number of groups have developed 
specific probe geometries for superficial fluorescence measurements (21, 24, 58-60) 
and combined these with more complicated models of light transport in tissue. Many of 
these approaches lead to substantial errors in recovered intrinsic fluorescence (61), or 
are restricted by specific ranges of optical properties over which the recovery of intrinsic 
fluorescence is valid (24). Some have also used single optical fiber fluorescence spectros-
copy (62, 63), but they have had to make assumptions about the scattering properties. 
Because we are using multiple fibers we can measure them (both µs’ and γ) to correct 
fluorescence for each individual measurement. This is an important difference because 
the phase function has been shown to have a great impact on the collected reflectance 
(64-66) and thus also on the corrected fluorescence signal (33).
From PpiX fluorescence to PpiX concentration
Given that we have measured Qμ fa,x  of PpIX in actinic keratosis and Bowen’s disease 
it is interesting to consider if we can use this to estimate the concentration of PpIX. 
Clearly such an estimation requires some assumptions that are difficult to verify in-vivo 
without a thorough investigation of the relationship between the intrinsic fluorescence 
and the concentration of PpIX determined by chemical extraction. However, we can use 
a representative extinction spectrum of PpIX (67) to assume the extinction of PpIX at 405 
nm in vivo to be 14000 L. M-1mm-1. Next we can adopt a fluorescence quantum yield of 
0.5%, which is recently reported using diffuse optical tomography (57, 68). Under these 
assumptions the average PpIX concentration before PDT in actinic keratosis and Bowen’s 
disease is 2.25 nmol ml-1 [range 0.38 – 6.81]. These values are comparable with values 
reported in the literature using chemical extraction of PpIX from biopsies of basal cell 
carcinoma (69) and actinic keratosis (70).
It is also interesting to consider the detection limit of our technique. Using the integra-
tion times utilized in the present study we were able to accurately fit (i.e. with a 95% 
confidence interval <10% of the measured value) the very low PpIX fluorescence after 
the therapeutic illumination, which corresponded to a PpIX concentration of 0.06 nmol 
ml-1.
A way to further investigate if the assumed value of Q for PpIX in tissue is correct, would 
be to measure PpIX fluorescence in tissue with known pH. The decrease in autofluores-
cence after ALA application that we found is an example of how the pH can affect the 
quantum efficiency of a fluorophore. This is likely due to the acidity of ALA, decreasing 
the pH. This also indicates that the moment during PDT at which autofluorescence is 
measured is critical, which can be relevant for example when the skin autofluorescence 
is measured to perform a crude correction for the PpIX fluorescence.
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limitations
Some limitations of this study must also be addressed. The main limitation of our method 
is that the model is based on the assumption that the two optical fibers measure the 
same optical properties. This may not necessarily be the case because they are seeing 
different volumes due to different diameters and due to the side-by-side placement of 
the fibers within the probe. In this study this problem is partly solved by our strict rejec-
tion criteria. As described in the methods section spectra were excluded for a number of 
reasons, including crossing of the spectra of the two fibers. This is an indication that the 
scattering properties are not truly consistent between the two fiber diameters due to 
differences in sampled volume. Apart from using this rejection of spectra we have been 
working on improvements of the technique to overcome this problem. One option has 
been to use a single fiber with variable diameter using a coherent bundle and a series of 
pinholes to control the effective fiber diameter (71). This has recently been updated to 
a 19-core fiber bundle that is quicker and that simulates a variable-diameter solid-core 
fiber while there is no disturbance by free-space optical components (41). A solid-core 
fiber with variable diameters may be the optimal solution for the future, but is challeng-
ing to construct. An additional benefit of these improvements is also that measurements 
can be tailored to the desired sampling depth, which greatly increases the applicability 
of the system for various research questions.
The number of spectra that were rejected can also be considered a limitation of this 
study. As described above, some were attributable to either crossing of spectra. A small 
number of spectra were also rejected because the nonlinear regression routine could 
not fit the spectra without generating imaginary components to the fit parameters. Most 
rejected spectra were however attributable to experimental errors such as movement 
artifacts and cream remnants that contained unknown chromophores. These errors can 
be largely avoided in future MDSFR/SFF use by instructing the patients to keep still dur-
ing the measurement and by more thorough cleaning of the sampled skin.
A further but minor limitation is that Qμ fa,x  is still not a direct measure of the concen-
tration. To calculate this the extinction coefficient of PpIX is also needed, but this is 
unknown. This coefficient will depend on the pH, which is assumed to be fairly constant 
at the inside of the mitochondrial membrane even in the presence of ALA.
Summary
In summary, in this study the optical properties of the epidermis and superficial dermis 
in human skin were successfully quantified and used to correct fluorescence measure-
ments. For both the autofluorescence and the PpIX fluorescence we demonstrated how 
important such corrections are to obtain quantitative results. We showed that optical 
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properties change during PDT and that for this reason fluorescence measurements at 
different time-points are needed to correct for these temporal changes. The resulting 
PpIX fluorescence kinetics can be useful to predict efficacy and optimize clinical PDT 
illumination protocols. A quantitative measurement of the skin autofluorescence on the 
other hand has the potential to differentiate between neoplastic and normal skin. It 
can also provide important information on the concentration of advanced glycation end 
products, which are related to several internal diseases and are considered important 
risk factors for cardiovascular complications. This study illustrates how a combination of 
MDSFR and SFF spectroscopy opens up new possibilities for future research that involve 
measurements of intrinsic fluorescence in the skin.
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diSCuSSiOn
This thesis is focused on three main topics that are closely related to a more fundamental 
understanding of PDT in the skin:
1) The distribution of PpIX in the skin and how this relates to vascular effects during 
PDT.
2) The measurement of PpIX fluorescence during PDT. This enables monitoring PpIX 
synthesis and photobleaching and it provides information on oxygen consumption 
and singlet oxygen formation.
3) The use of optical techniques that allow superficial measurements of optical proper-
ties in the skin. These measurements provide information on the blood supply during 
PDT and presence of other chromophores, while they can also be used to measure 
scattering properties and correct detected fluorescence signals.
These topics are critically important for the optimization of current treatment protocols, 
and show how approaches to personalize PDT could be applied in future studies. The 
importance of the need to improve PDT is illustrated by lack of long term complete 
responses in some patients 1-4 and by the considerable pain associated with PDT using 
porphyrin pre-cursors 5, 6.
distribution of PpiX in the skin and vascular effects
The results presented in chapters 4-6 clearly illustrate the magnitude of the vascular 
effects associated with topical HAL and ALA-PDT. These effects include arteriole vaso-
constriction during and after PDT, and damage to the endothelial membrane of dermal 
blood vessels. It is demonstrated how vascular effects are related to PpIX concentration 
in the vasculature. The consistent trend is that HAL is more potent than ALA, which is 
more potent than MAL in photosensitizing the superficial vasculature. This leads to most 
extensive vascular constriction and vascular damage during PDT for HAL, then ALA, then 
MAL. It is important to realize that it is not immediately clear whether such vascular 
effects are beneficial to PDT outcome or not. Since PDT requires oxygen, vasoconstric-
tion of the superficial vessels that supply this oxygen can lead to insufficient oxygen 
availability during PDT. This in turn can harm the efficiency and the effectiveness of 
PDT. When the vasoconstriction is long-lasting or if the vasculature is damaged, this 
can lead to ischemia post-PDT. When such ischemia is extensive, too many normal cells 
may die too. This can lead to an inferior cosmetic or functional outcome. However, some 
ischemia may be beneficial because it can give a final blow to already damaged tumour 
cells, increasing effectiveness of PDT.
While the clinical relevance of this delicate balance between inducing too extensive 
or too little vascular effects needs to be further investigated, its importance can be il-
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lustrated by the response to light fractionated PDT. The idea behind the increased effect 
of light fractionation is that a small first light fraction makes cells sensitive to a larger 
second light fraction. It has been shown that light fractionation works best for lower 
concentrations of PpIX 7, and that it is critical that the effective dose of the first light frac-
tion is low 8. Because in topical PDT endothelial cells synthesize low concentrations of 
PpIX (compared with keratinocytes) these are considered the target of light fractionation 
9, leading to vascular damage after PDT and increased PDT efficacy. The fractionated 
illumination protocol used in this thesis has been developed and optimized for ALA-PDT. 
When these same illumination parameters are used for MAL-PDT however, it appears 
that the vascular PpIX concentrations are too low to lead to biologically relevant effects. 
Similarly, for HAL-PDT the vascular PpIX concentrations may be a little too high, leading 
to too much damage in the first illumination. This explains why light fractionation works 
best for ALA, appears to work for HAL but does not work for MAL-PDT 10. Potential solu-
tions are to lengthen the first illumination for MAL or to shorten it for light fractionated 
HAL-PDT. This illustrates how future fractionated illumination protocols for different 
porphyrin precursors (e.g. HAL or MAL) may need to be optimized based on their ability 
to photosensitize the vasculature and the resulting vascular effects.
Importantly, this ability may be different in human skin than in mouse skin due to poten-
tially lower penetration of porphyrin precursors. It is commonly believed that ALA is too 
hydrophilic to penetrate the human epidermis well. However, the physiological changes 
that we measured with DPS and MDSFR during light fractionated ALA-PDT (chapters 7 
and 8) indicate otherwise. Since we have shown that the vascular response in mice is 
strongly dependent on the PpIX concentration in the vessel wall, it is logical to assume 
that this will be true also in human skin. This in turn means that the superficial vessels 
in human skin also synthesize biologically relevant amount of PpIX in ALA-PDT. This is 
important because then a logical conclusion is that ALA does penetrate well through 
the epidermis and that its hydrophilic nature is not a limitation. How the vascular distri-
bution of ALA compares to that of HAL and MAL after topical application in human skin 
is unknown, but may provide useful information that can be related to vascular effects 
in human skin.
PpiX fluorescence measurements
Monitoring PpIX fluorescence during PDT has the potential to be a powerful tool because 
it provides a wealth of relevant information about the PDT process. This includes the PpIX 
synthesis and resynthesis (which is important in light fractionated PDT), the kinetics of 
PpIX photobleaching, the availability of oxygen and the rate of singlet oxygen forma-
tion. It thus also informs on the effective deposited PDT dose. Another way in which 
PpIX fluorescence can be used to help understand fundamental processes involved in 
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PDT, is illustrated by its measurement in histological sections and in the mouse skin fold 
chamber model (chapters 4 and 5). These measurements are hardly affected by scat-
tering and absorption because of the minimal volume of the examined tissue, but they 
are invasive methods. A surface measurement (using imaging or spectroscopy) has the 
advantage that it is a non-invasive method that can be applied during PDT illumination. 
However, as we have shown, the accuracy of such measurements is critically dependent 
on the effects of both light absorption and light scattering within the measured tissue. 
It is only when fluorescence is corrected for these optical properties that the power of 
measuring PpIX fluorescence can be used to its full extent in PDT. This is why throughout 
this thesis particular attention has been paid to try and optimize optical measurements 
on human skin.
Optical measurements on human skin
The first crucial consideration when optically sampling skin is the realisation that the 
epidermis and superficial part of the dermis are the volume of interest. This is where 
most PpIX is located and where the blood vessels are that directly supply oxygen during 
PDT. Furthermore, this is where many skin diseases will differ most in their optical prop-
erties. The second crucial consideration is that for spectroscopic techniques it is only 
possible to say something sensible about the collected light if you know what happens 
to the light in the tissue. This is why it is important to apply appropriate theories about 
light propagation in biological tissue to such spectroscopic measurements. It must be 
stressed that diffusion theory, widely employed for large volumes of tissue, is not valid 
for superficial spectroscopic measurements of µs’ or fluorescence in skin. The reason for 
this is that light propagation is not diffuse at short source-detector separations that 
are necessary for superficial measurements 11. In such superficial measurements the 
proportion of wide-angle backscattering effects significantly affects the amount of light 
collected in a reflectance measurement 12,  13. DPS is already a step forward because it 
samples from a superficial volume (chapter 7). However, it can only be used to measure 
the absorption but not the scattering properties. Because of this, it has been essential 
to develop a new model on light scattering that incorporates theory about the tissue 
phase function, which describes the distribution of the angle in which the light is scat-
tered. This theoretical model was developed and the technique validated in computer 
simulations and in tissue-mimicking phantoms 14-16. This has led to the development of 
MDSFR and SFF spectroscopy 17-23, which is being applied for the first time on human 
tissue in this thesis. This is an important step forward in biomedical optics. These types 
of measurements are not only valuable for PDT, but potentially also for applications that 
are beyond PDT and/or beyond the skin.
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Potential value of MSdFr and SFF spectroscopy for PdT
For PDT the primary value of MDSFR and SFF spectroscopy is that it can be used to 
quantify PpIX fluorescence in human skin. The synthesis and photobleaching kinetics 
of PpIX in turn can be related to patient-specific PDT outcome in clinical studies. Fur-
thermore, as we have shown to be possible in mice, MDSFR/SFF spectroscopy has the 
potential to control the effective deposited PDT dose in human skin. An example of this 
potential is to measure PpIX photobleaching and resynthesis during the dark interval 
in light fractionated PDT to optimize clinical treatment protocols. Again it is important 
to stress that this is not possible unless changes in optical properties during PDT are 
corrected for. While MDSFR/SFF spectroscopy enables to measure these changes in 
order to adequately correct PpIX fluorescence, it also allows to monitor changes in the 
vascular physiology during PDT of human skin. While such changes are likely to affect 
PDT outcome, clinical follow-up studies investigating this are needed.
Potential value of MSdFr and SFF spectroscopy for diagnostics (in the skin)
A closely related subject is the potential for using MDSFR and SFF spectroscopy to dif-
ferentiate between skin diseases. Although this is not directly related to PDT it is worth 
paying particular attention to, because this diagnostic potential may be an important 
additional asset of MDFSR/SFF spectroscopy. As we have shown, the skin autofluores-
cence is significantly lower in actinic keratosis than in normal skin, for reasons that are 
however not immediately clear. This may be related to the thicker epidermis in actinic 
keratosis but possibly also to differences in the redox state between dysplastic and nor-
mal keratinocytes 24, 25. In addition to the autofluorescence measured with MDSFR/SFF, 
it is interesting to also consider the potential diagnostic value of the reflectance mea-
surements. After all, with this approach it is possible to quantify the optical properties 
in a superficial volume of the skin. Importantly, this is the region in which most skin 
diseases will differ most in their histological and thus also in their optical characteristics. 
These different characteristics can be picked up by our innate optimal instruments –the 
eye– to distinguish between different skin diseases. Our eyes are however very limited 
optical instruments that are easily fooled by variable optical properties, which is why we 
perceive for example melanin and blood as blue when they are located deeper in the 
skin. Because MDSFR is an optical technique that is able to quantify the optical proper-
ties in the skin, it conceivable that such an approach may improve the differentiation 
between skin diseases. The optical properties that can be quantitated with MDSFR and 
SFF spectroscopy can be divided into the: (1) scattering, (2) absorption and (3) auto-
fluorescence. Each of these may have diagnostic value, and it is important to make a 
distinction between them and their separate diagnostic potential.
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Scattering
When we consider the scattering properties of skin, it needs to be realized that these can 
be altered by nanoscale morphological changes that occur during early carcinogenesis 
in cells 26-29. Because earlier cancer detection increases cure rates, scattering spectroscopy 
is a potentially valuable non-invasive diagnostic tool. With MDSFR spectroscopy it is now 
possible to quantify µs’ in a superficial sampling volume that includes only the epidermis 
or the epidermis and a part of the dermis (depending on the choice of fiber diameters). 
The values of µs’ have not yet been systematically investigated, because it has not been 
possible to quantify these in a superficial volume. Previous attempts to measure µs’ have 
been based on diffuse, deep measurements that basically inform on an average of the 
scattering properties over a large sampling volume. Obviously, scattering properties are 
not homogeneously distributed throughout the thickness of the skin. This makes diffuse 
measurements insensitive to detection of superficial scattering changes that may be im-
portant in diagnostics. In addition to quantifying µs’, MDSFR spectroscopy also enables 
a measurement of the scattering power a2. This is considered an indicator of the relative 
size of scattering particles and has yet unclear potential value for diagnostics. Moreover, 
MDSFR allows the measurement of the phase function parameter γ. Gamma is believed 
to be related to the tissue ultrastructure 30. Differences in tissue ultrastructure such as 
cytoskeleton alterations in early cancer may be reflected by changes in γ. It is important 
to note that the diagnostic potential of phase function parameters such as γ are at the 
forefront of research in biomedical optics and their potential value are therefore still 
largely unexplored.
Absorption
The quantification of the absorption coefficient µa with MDSFR spectroscopy yields in-
formation on the vascular parameters (i.e. blood volume fraction, mean vessel diameter 
and saturation). These may be diagnostically valuable because cancer tissue is known 
for its alterations in the local microvasculature. From µa it is also possible to calculate 
the local concentration of other chromophores, such as melanin, bilirubin and beta-
carotene. These parameters may also be different for different skin conditions, but their 
measurement needs further validation in the skin.
Autofluorescence
Finally, the quantification of the intrinsic autofluorescence may also be diagnostically 
valuable. Several studies using different fluorescence spectroscopic techniques have de-
scribed the potential value of the autofluorescence to differentiate between normal and 
neoplastic skin 31-33. Obviously, it is necessary to correct the fluorescence for the optical 
properties of the sampled volume to obtain quantitative results. It is also important to 
improve our ability to differentiate between the individual fluorophores that constitute 
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the combined autofluorescence signal. Finally, in-vivo spectroscopic measurements 
need to be validated for example by comparing the fluorescence with chemical extrac-
tion of the fluorophores in skin biopsies.
While the potential diagnostic value of MDSFR and SFF spectroscopy will be further 
investigated in the near future, it is nevertheless interesting to take a closer look at our 
measurements of chapter 8. When we compare our MDSFR measurements of actinic 
keratosis before ALA application with those acquired from contralateral normal skin dur-
ing PDT (chapter 8) we see some interesting differences between them. It is important 
to again stress that these measurements need to be validated. Table 1 gives an overview 
of the absorption, scattering and autofluorescence parameters that were measured with 
MDSFR spectroscopy. Even though these data are based on relatively few patients, three 
parameters were significantly different after correction for multiple comparisons: the 
blood volume fraction, the bilirubin content, and the autofluorescence.
Table 1. Overview of the absorption and scattering parameters measured with MDSFR and SFF 
spectroscopy in normal and lesional skin (actinic keratosis or Bowen’s disease).
Measured parameter (unit)
lesional skin
median (¼ - ¾ iQr)
normal skin
median (¼ - ¾ iQr)
Magnitude of 
median difference 
(lesional/normal)
P-value (paired 
Wilcoxon signed 
rank test)
Saturation (%) 60 (38-75) 48 (32-65) 1.2 0.27
Blood volume fraction (%) 0.61 (0.34-0.75) 0.33 (0.18-0.42) 1.9 <0.005
Mean vessel diameter (mm) 0.013 (0.008-0.022) 0.014 (0.010-0.020) 0.89 0.85
Melanin (µM) 15 (2.3-38) 27 (16-50) 0.54 0.16
Beta carotene (µM) 0.047 (0.011-0.082) 0.022 (0.013-0.041) 2.1 0.03
Bilirubin (a.u.) 3.4 (2.5-5.4) 0.92 (0.52-2.36) 3.7 <0.0005
γ at 800nm (-) 1.6 (1.5-1.7) 1.6 (1.5-1.7) 1.0 0.81
µs’ 800nm (mm
-1) 1.4 (1.2-1.6) 1.6 (1.1-2.6) 0.85 0.08
a2 800nm (mm-1 nm-1) 1.0 (0.9-1.3) 1.4 (1.1-1.7) 0.71 0.09
Autofluorescence (mm-1) 0.003 (0.002-0.004) 0.005 (0.005-0.006) 0.61 <0.0005
In italic are the parameters that were significantly different after correction for multiple comparisons (i.e. 
P-value < 0.005). IQR=interquartile range.
While the higher blood volume is in accordance with the clinical reddish appearance 
of actinic keratosis, our eyes cannot see the difference between vasodilation in inflam-
mation and neovascularisation in (pre)malignant change. In our MDSFR measurements 
the blood volume fraction was higher for actinic keratosis than normal skin but the 
vessel diameter was not, which indicates that neovascularisation (and not inflammatory 
vasodilation is primarily responsible for the red appearance of actinic keratosis. Such 
information can be useful for diagnostics in the skin and other organs.
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The higher bilirubin content in lesional skin is interesting but without a full valida-
tion is difficult to explain. Bilirubin is a breakdown product of haemoglobin, and this 
breakdown process occurs in macrophages. Since actinic keratosis in accompanied 
by a macrophage containing infiltrate, the higher bilirubin content in actinic keratosis 
may be a reflection of increased local breakdown of haemoglobin. Note that bilirubin 
is also absorbed in the same spectral regions in which melanin and haemoglobin are 
well absorbed, making bilirubin measurements less precise. However, this may not be 
problematic because the magnitude of the difference was large (3.7x) and this finding 
was very consistent between patients (in 89% of patients the bilirubin was higher in 
lesional than in normal skin).
Although the scattering properties were not significantly different in this studied ex-
ample, it can be expected that morphological changes of neoplastic cells will result in 
differences in scattering properties as explained above. The magnitude of the difference 
in µs’ and a2 suggest that MDSFR may allow the detection of such differences. Obviously 
our dataset was small and not powered to detect any statistical difference properly. A 
larger follow up study is needed that is better powered and thus also allows for multi-
variate regression analysis to detect combinations of measured parameters that can be 
considered predictors of disease. Upon histology, actinic keratosis exhibits a more or 
less characteristic combination of visible features and here a single histologic feature 
(e.g. acanthosis) is not disease-specific and thus not a good predictor for the diagnosis. 
Likewise, individual optical parameters may also be not a good predictor on their own, 
but specific combinations for actinic keratosis may exist that are good predictors for a 
diagnosis. The combination of blood volume fraction and vessel diameter is an example 
of such a combination. In conclusion, the full potential of the predictive value of MDSFR 
spectroscopy for diagnostics in the skin needs further study. It is promising however 
that we can already detect statistical differences in optical properties between actinic 
keratosis and normal skin in a small sample of patients.
Potential value of MSdFr and SFF spectroscopy beyond PdT and beyond the 
skin
It is interesting to also consider the potential applications of MDSFR/SFF spectroscopy 
other than for PDT or diagnostics in the skin. First, MDSFR/SFF is not limited to being 
applied solely in the skin. In principle, it can also aid the diagnosis of diseases in various 
organs in which superficial changes in optical properties are likely to be characteristic 
of disease. As such it may be used in the epithelia of the oral cavity, the gastrointes-
tinal tract, the bladder, the cervix or the lung. The small diameters of the probes may 
even allow them to be incorporated in fine-needle aspiration which may also aid the 
diagnostic process. Because MDSFR/SFF spectroscopy enables measurements of local 
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fluorophore or chromophore concentrations, it may also be helpful to detect certain 
internal diseases. These can be liver diseases accompanied with high bilirubin levels, 
porphyrias accompanied by porphyrin accumulation in the blood, or metabolic storage 
diseases in which several molecules can accumulate in tissue such as the skin. Further, 
the quantification of the autofluorescence from advanced glycation end products us-
ing MDSFR and SFF spectroscopy can be very valuable for risk assessment in a range 
of diseases associated with cumulative metabolic stress. The list of associations with 
high skin autofluorescence is long: cardiovascular complications, glucose intolerance 
in diabetes, chronic obstructive pulmonary disease, postsurgical complications, renal 
insufficiency, liver cirrhosis, leg ulceration, advanced age and more 25, 34-43. It cannot be 
stressed strongly enough that it is crucial to correct any skin fluorescence measurement 
for the tissue optical properties. In the studies investigating these associations a dif-
fuse, deep optical measurement was taken and this was not corrected for absorption, 
scattering or variability in for example lamp output or light transmission within the 
system. This can result in a patient being treated for assumed high cardiovascular risk 
based on high skin autofluorescence that does not represent high fluorescence from 
advanced glycation end-products at all, but simply increased backscattering or reduced 
absorption that has no relation to the risk of cardiovascular events. This illustrates that 
studies relating skin autofluorescence to any of the mentioned conditions can benefit 
enormously from MDSFR and SFF spectroscopy. This is especially true when the aim is 
to derive meaningful information about an autofluorescence measurement in a single 
patient. When fluorescence is measured in a large number of patients, correlations (if 
present) will be found also with non-quantitative measurements. However, the likeli-
hood of a single measurement in a single patient to be a good predictor (for example for 
cardiovascular events) is a lot better for accurate than for inaccurate measurements. In 
other words: accurate, quantitative autofluorescence measurements can provide useful 
information on risk assessment on a personalized level, while non-quantitative and inac-
curate measurements cannot.
This thesis and personalized PdT
It is now time to consider how this thesis contributes to an improved and more per-
sonalized approach to PDT. One important contribution is related to the potential of 
PpIX photobleaching kinetics to monitor and control the effective deposited PDT dose 
for individual mice (chapters 3 and 6). Now that we have the ability to quantitate PpIX 
fluorescence in human skin using MDSFR and SFF spectroscopy, this kind of approach 
can also be applied to human PDT. It can be used to control the effective PDT dose 
of the illuminations in light fractionated PDT. PpIX fluorescence measurements can be 
performed on an individual basis to optimize PDT on a personalized level. Moreover, 
monitoring PDT with MDSFR/SFF spectroscopy will allow for pain-free and effective 
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PDT. This can be achieved by applying low fluence rate, light fractionated PDT. During 
illumination, the effective PDT dose for each individual patient can be monitored based 
on the PpIX photobleaching kinetics to ensure effectiveness.
Another potential contribution to personalize PDT is that when the PpIX concentration 
before the (first) PDT illumination turns out to be too low, it may be best to not perform 
PDT at that time for that particular patient. Potentially the peak in PpIX synthesis in 
some patients requires a longer application time of the porphyrin precursor. The optimal 
time-point for illumination can be based on such individual differences, because the 
PpIX fluorescence can now be quantified with MDSFR/SFF spectroscopy. This can help 
to improve PDT effectiveness on a personal basis.
Finally, it is now possible to accurately monitor changes in the physiology of the super-
ficial vasculature in individual patients. Such changes can influence the oxygen supply 
that is required for PDT. Therefore, extensive vasoconstriction during PDT can decrease 
its efficiency and effectiveness. In this respect, it is interesting that lowering the fluence 
rate will likely result in less vasoconstriction. This can be explained by the apparent 
threshold for arteriole vasoconstriction which is related to the PpIX concentration in 
the arteriole wall (chapter 3). It can be assumed that this threshold is not in fact directly 
and causally related to this PpIX concentration. Instead, it makes biologically more sense 
that it is related to the rate of singlet oxygen formation, which is higher for higher PpIX 
concentrations. As a result, the threshold for vasoconstriction will be reached quicker at 
high PpIX concentration and at high photobleaching rates. A solution would therefore 
be to use a lower fluence rate, which leads to lower photobleaching and singlet oxygen 
formation rates. It may be that at low fluence rate PDT, the rate of singlet oxygen produc-
tion will be lower than the threshold that leads to vasoconstriction.
Future perspectives
When using MDSFR and SFF spectroscopy to monitor PDT, this is ideally performed 
continuously during illumination while providing immediate feedback during illumina-
tion. Currently this is limited due to the computation time of analysing the spectra. 
Advances in computation speed can be combined with the development of software 
that automatically generates graphical or other types of feedback on measured param-
eters. However, when continuous measurements are taken, then the MDSFR/SFF probe 
would be in the way of the PDT illumination light, which is an obvious problem. A way to 
overcome this problem would be to adapt the system so that it uses red (~635 nm) light 
to excite PpIX while emitted PpIX fluorescence is detected at longer wavelengths (PpIX 
has another emission peak centred at 705 nm). This ensures that the probed area will 
receive the same amount of excitation light as the rest of the treated area.
170 Chapter 9
Another important future perspective that is however not related to PDT is the use of 
MDSFR spectroscopy for diagnostics in the skin. A significant improvement of the MS-
DFR/SFF system used in this thesis is the recent development of a 19-fiber optical probe 
20. This allows tailoring the sampling volume to the desired depth, which will increase 
sensitivity for depth-dependent parameters that have diagnostic value. Skin diseases 
are expected to have more or less characteristic combinations of optical properties, 
similar to them having more or less characteristics histological features under light 
microscopy. By now, many books have been written about which patterns of histological 
features fit best with a particular diagnosis. In a similar fashion it may be advantageous 
to build a database that contains the typical pattern of optical properties of skin dis-
eases for a range of optical sampling depths. It will then be theoretically possible to 
construct an algorithm that automatically generates an optical differential diagnosis of 
a single MDSFR measurement which would significantly aid the clinical and histological 
diagnostic process.
Conclusion
This thesis is focused on the identification and measurement of parameters that con-
tribute to an improved understanding of fundamental PDT processes. It is shown how 
this type of approach can improve and personalize PDT, and control side effects. I’d 
like to conclude with two expressions of Lord Kelvin from the 19th century that seem 
particularly applicable to this thesis and to science in general: “When you can measure 
what you are speaking about, and express it in numbers, you know something about it , 
and “If you cannot measure it, you cannot improve it”.
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Chapter 1 is the introduction of this thesis. The quantum mechanics and general ap-
plications of PDT are introduced, followed by the specific use of PDT in the skin using 
porphyrin precursors. It is described how the combination of light, oxygen and PpIX 
leads to a range of biological effects that include cellular, immunological and vascular 
responses leading to cell death. Limitations of PDT in the skin are discussed and it is 
highlighted how an individual approach may benefit our understanding of treatment 
failures and side effects. Potentially relevant measurable parameters that may contrib-
ute to such an approach are discussed while some are considered more relevant than 
others. The importance of the distribution of PpIX in tissue is emphasized, as well as 
monitoring its fluorescence during PDT, which provides information on the concentra-
tion of PpIX photosensitizer, the rate of its photobleaching process and the related oxy-
gen consumption. It is explained how fluorescence measurements are affected by tissue 
optical properties which are determined by absorption and scattering of light in the tis-
sue. Several techniques that attempt to measure these optical properties are described 
and the limitations explained. New techniques that are more suitable for superficial skin 
measurements are introduced. These techniques may be used for diagnostic purposes, 
to measure physiological parameters such as oxygenation during PDT and to quantify 
skin fluorescence measurements by correcting for the measured optical properties. The 
chapter concludes with the outline of this thesis.
Chapter 2 describes a study on one of the main limitations of PDT: pain. Many risk 
factors for pain have already been described in the literature but the clinical relevance 
is often hard to interpret. Severe pain was scored as a clinically relevant outcome in a 
patient group treated with PDT for an area of actinic field cancerisation of at least 25 
cm2. In addition, patient satisfaction was scored using a validated questionnaire. Severe, 
sometimes intolerable, pain was a frequently reported outcome (in 28 of 48 patients), 
necessitating infiltrative or nerve block anaesthesia. When identifying predictors for 
patients to experience severe pain only the size of the treated area size was statistically 
significant, and it was associated with patient dissatisfaction. The patients included in 
the study are in principle ideal candidates for PDT field treatment. However, because of 
the high risk for severe pain the applicability of PDT is limited for this patient group. The 
study illustrates that there is need for methods to control pain during PDT other than 
using infiltrative anesthesia.
In Chapter 3 an approach to decrease pain during PDT is studied: the use of low fluence 
rate. A lower fluence rate will also lead to more efficient PDT due to more efficient use 
of available oxygen. PpIX fluorescence measurements were used to optically monitor 
PDT efficiency and control the deposited effective PDT dose in mice. Several single and 
fractionated illumination protocols were studied, in which a total dose of 50 or 100 J 
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cm-2 was delivered at fluence rates of either 20 mW cm-2 (“low”) or at 50 mW cm-2 (“high”) 
fluence rate. Outcome was cumulative daily visual skin damage 7 days after PDT. The 
fractionated delivery of 100 J cm-2 was equally effective at low and high fluence rates. 
At low fluence rate PDT was more efficient, but the average total treatment time was 
considerably longer (80 versus 33 minutes). Possibly the most promising light delivery 
protocol for clinical purposes was the one in which initially low fluence rate light was 
delivered, followed by a high fluence rate. An important consideration for this illumi-
nation scheme is that increasing the fluence rate when there is little PpIX remaining 
has been documented not to cause pain. In this group efficacy was maintained but the 
total illumination time was reduced to 58 minutes. This type of illumination scheme is 
therefore expected to lead to effective, more efficient PDT with less pain at acceptable il-
lumination times. It is concluded that low fluence rate is an interesting option for clinical 
investigation, stressing the importance of PpIX fluorescence measurements to monitor 
PDT dose and ensure effectiveness.
In chapters 4, 5 and 6 three papers are presented that share a central theme: the spatial 
distribution of PpIX and the related vascular effects of PDT with a focus on the use of HAL, 
the hexyl ester of ALA. Vascular responses to PDT may influence the availability of oxy-
gen during PDT and the extent of tumor destruction after PDT. In chapter 4 the vascular 
constrictive response of HAL and ALA-PDT and the relationship with PpIX distribution in 
the vessel walls were studied in a mouse skin fold chamber model. This geometry allows 
to directly visualize the subcutaneous blood vessels underlying the treated area and 
measure PpIX fluorescence intensity without being disturbed by absorption and scat-
tering effects of overlying tissue. Vessel diameters were measured before and after PDT. 
The results were similar between HAL and ALA. Most (>60%) arterioles were completely 
constricted immediately after PDT and many remained constricted 20 minutes later. 
Venules generally did not respond. The extend of arteriole vasoconstriction was strongly 
correlated with the PpIX fluorescence intensity in the arteriole wall. It is concluded that 
such vasoconstrictive effects during topical HAL and ALA- PDT may have important ef-
fects on the oxygen supply necessary for PDT, and that prolonged vasoconstriction after 
PDT could result in increased cell death of both normal and malignant cells. In chapter 5 
the microscopic distribution of PpIX in dermal blood vessels of mouse skin after topical 
application of HAL, MAL (the methyl ester of ALA) or ALA is investigated first, followed 
by a study of the potential of topical PDT to induce vascular damage to these vessels. 
Fluorescent-labeled CD31 antibodies were used to visualize the vessels in microscopic 
sections of skin biopsies. To measure the vascular distribution of PpIX the colocalisation 
of CD31 and PpIX fluorescence was calculated using confocal microscopy imaging. The 
vascular damage after PDT was scored by visual interpretation of fluorescent CD31 and 
CD144 confocal images. Vascular damage results in a loss of normal CD144 staining 
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along the plasma membrane, while CD31 staining is unaffected. The PpIX concentration 
within the vessel wall was highest in the HAL group, followed by the ALA and then the 
MAL group. Similarly, vascular damage was highest for HAL, then ALA and then MAL. It is 
concluded that the dermal vasculature synthesizes biologically relevant concentrations 
of PpIX and that topical PDT can lead to vascular damage. These effects appear to be 
causally related and are therefore most pronounced for HAL. The study shows that the 
vasculature can be a potential target of PDT and it supports the hypothesis that vascular 
responses are important for the increased effect of light fractionation. in chapter 6 
this idea is utilized to study the effect of light fractionation for HAL-PDT in a mouse 
model. Visual skin damage was scored after PDT and PpIX photobleaching kinetics were 
measured during PDT. A single illumination and two light fractionation schemes were 
studied for both HAL and ALA. For both precursors light fractionation increased visual 
skin damage, but the effect was not statistically significant for HAL. Photobleaching 
rates were similar for HAL and ALA and PpIX fluorescence intensity was higher for ALA 
than for HAL. This PpIX fluorescence intensity is mainly dependent on the epidermal 
PpIX synthesis. Because it was not correlated with efficacy, this indicates that other fac-
tors such as superficial vascular responses may play an important role. The potential 
use of light fractionation HAL-PDT is discussed as well as methods to potentially further 
improve fractionated HAL-PDT.
In chapter 7 the use of a newly developed technique termed DPS (differential path-
length spectroscopy) is described. DPS allows optical monitoring of the vascular physi-
ology during PDT in human skin and this was studied in 9 patients undergoing PDT for 
actinic keratosis. DPS is a spectroscopic technique that combines the reflectance signals 
from two optical fibers to determine the absorption characteristics of a superficial col-
lection volume. This is opposed to diffuse measurements in which signals from deeper 
in the skin greatly influence the measured reflectance. The sampling depth was tailored 
to the average epidermal thickness of actinic keratosis, which was first measured in 
histologic sections. The vascular response to PDT was highly variable for individual 
patients, especially the blood volume fraction and to a lesser extend the saturation. This 
could not be demonstrated before using diffuse measurement techniques, stressing the 
importance of using optical monitoring techniques that allow superficial measurements. 
It is concluded that the patient-specific variability of the vascular physiological changes 
during PDT can be relevant for the oxygen supply during PDT for individual patients.
In Chapter 8 a study is presented in which another reflectance spectroscopic tech-
nique is introduced: multi-diameter single fiber reflectance (MDSFR) spectroscopy. 
This technique enables a complete determination of the optical properties, defined by 
the absorption and reduced scattering coefficient, in a superficially sampled volume 
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of skin. It has been recently developed and validated in computer simulations and 
tissue-mimicking phantoms and this is the first use in human skin. In this study MDSFR 
is specifically applied in combination with single fiber fluorescence (SFF) spectroscopy. 
This combination enables to quantify the fluorescence by correcting for the measured 
optical properties. To illustrate the importance of performing such correction, uncor-
rected and corrected values for PpIX and autofluorescence were compared. This was 
done at various time-points in 22 patients undergoing light fractionated ALA-PDT. 
Measurements were taken immediately before and after the two PDT illuminations. We 
found that the corrected values were higher than the uncorrected, varying from 2.4-7.5 
times higher. This variability reflects the heterogeneity in individual patients’ or lesions’ 
optical properties. Also, the optical properties changed during the course of PDT, and in 
a different way for different patients. Both the variability in optical properties between 
patients and the varying optical properties during PDT illustrate the importance of in-
dividually correcting for optical properties to obtain quantitative results. This is the first 
time quantitative fluorescence has been successfully measured in a superficial volume 
of skin. Our values are of the same magnitude as those obtained using chemical extrac-
tion of PpIX from tissue biopsies. This is a big step in biomedical optics, not only for PDT 
but also for applications beyond PDT and beyond the skin. With MDSFR/SFF it is now 
possible to correlate the intrinsic PpIX fluorescence with PDT outcome, and to use PpIX 
photobleaching kinetics as a method to individually dose PDT. In addition to the useful-
ness of quantifying PpIX fluorescence, the skin autofluorescence may also be valuable 
but for different purposes. First, it can be used as a diagnostic tool, as we have shown 
that the autofluorescence of actinic keratosis is significantly lower than of normal skin. It 
will also be interesting to include a comparison of the absorption and scattering proper-
ties measured with MDSFR between lesions, because these may also have diagnostic 
value. In many studies high autofluorescence has also been related to an increased risk 
for several internal diseases associated with cumulative metabolic stress. Quantitative 
MDSFR/SFF measurements in which the sampled volume can be tailored to the desired 
depth will greatly benefit such research.
Chapter 9 is the discussion of the thesis. It focuses on the distribution of PpIX and how 
this relates to vascular effects, on the importance of measuring PpIX fluorescence during 
PDT, and on optical techniques that allow superficial measurements in skin. It is de-
scribed how these topics are interrelated because of the complex interactions between 
light, oxygen, PpIX and the effects they have on the tissue and vice versa. For example: it 
may seem advantageous to have a lot of PpIX and light available, but this combination 
can lead to vascular constriction that limits the oxygen supply required for PDT. It is 
discussed how individual monitoring of relevant parameters can aid the optimization 
process of PDT, for which accurate measurements are necessary. The improvements in 
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optical measurement techniques contribute significantly to the potential of research on 
PDT in human skin. The translational step is made from our findings in mice and humans 
and how these can be combined to optimize clinical PDT protocols. The potential for 
personalized PDT is discussed as well as future perspectives of PDT and how optical 
monitoring can be incorporated to improve PDT with the aim to increase its efficacy 
while minimizing associated pain.
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hoofdstuk 1 is de algemene introductie van dit proefschrift. Eerst wordt de quantum 
mechanica waarop PDT is gebaseerd uitgelegd en daarna het gebruik van PDT in het 
algemeen en specifiek voor de huid waarbij porfyrine precursors gebruikt worden. 
Er wordt beschreven hoe de combinatie van licht, zuurstof en PpIX leidt tot diverse 
biologische effecten, waaronder cellulaire, immunologische en vasculaire responsen 
die resulteren in celdood. De beperkingen van PDT worden besproken en de nadruk 
wordt gelegd op het belang van een patiënt-specifieke aanpak om beter te begrijpen 
waarom PDT faalt of waarom bijwerkingen optreden bij individuele patiënten. Enkele 
parameters die tijdens PDT gemeten of gecontroleerd kunnen worden en die belangrijk 
zouden kunnen zijn voor het beter begrijpen van PDT worden geïntroduceerd. Er wordt 
benadrukt hoe belangrijk het meten van de distributie van PpIX is en hoe belangrijk 
het monitoren van de PpIX fluorescentie tijdens PDT is, omdat dit informatie verschaft 
over de PpIX concentratie, de mate van bleking en het hieraan gerelateerde zuurstofver-
bruik. Uitgelegd wordt hoe fluorescentiemetingen worden beïnvloed door de optische 
eigenschappen van het weefsel zoals absorptie en verstrooiing van licht. Verschillende 
technieken om deze optische eigenschappen te meten worden besproken, inclusief hun 
beperkingen. De nadruk ligt op het bespreken van nieuwe technieken die het mogelijk 
maken om nauwkeurige metingen te doen van oppervlakkige delen van de huid. Deze 
kunnen waardevol zijn als diagnostische toepassing, om bijvoorbeeld de bloedtoevoer 
en saturatie tijdens PDT te meten. Tevens maken ze het mogelijk om fluorescentie 
metingen te corrigeren voor de optische eigenschappen van het gemeten deel van de 
huid. De introductie sluit af met een beschrijving van de verschillende onderdelen van 
dit proefschrift.
hoofdstuk 2 beschrijft een studie waarin een van de belangrijkste beperkingen van 
PDT wordt onderzocht: pijn. In de literatuur zijn al diverse risicofactoren voor pijn tijdens 
PDT beschreven, maar de klinische relevantie hiervan is vaak moeilijk te interpreteren. 
In deze studie werd ernstige pijn als klinisch relevante uitkomstmaat onderzocht bij 
patiënten die behandeld werden met PDT voor actinische keratosen op een gebied van 
25 cm2 of meer. Tevens werd de patiënttevredenheid onderzocht met een gevalideerde 
vragenlijst. Het bleek dat ernstige pijn, waarvoor infiltratieve anesthesie noodzakelijk 
was, vaak voorkwam (in 28 van de 48 patiënten). Alleen de grootte van het behandelde 
gebied was een statistisch significante voorspeller van ernstige pijn en dit was tevens 
geassocieerd met ontevredenheid van patiënten over de behandeling. PDT is in principe 
een ideale behandeling om een groot gebied met actinische keratose te behandelen, 
maar de toepasbaarheid in de praktijk wordt dus beperkt door de pijn. De studie de-
monstreert dat pijn een relevant probleem is en dat er behoefte is aan andere methoden 
naast lokale anesthesie om de pijn te verminderen.
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In hoofdstuk 3 wordt een mogelijke oplossing voor het pijnprobleem tijdens PDT 
onderzocht: het gebruik van licht met een laag vermogen. Dit leidt tevens tot een ef-
ficiënter gebruik van zuurstof en dus tot efficiëntere PDT. PpIX fluorescentie metingen 
werden gebruikt om de efficiëntie te monitoren en om de geleverde effectieve PDT dosis 
te controleren in een muizenstudie. Diverse enkele en gefractioneerde belichtingssche-
ma’s werden onderzocht, waarin een totale dosis van 50 of 100 Jcm-2 werd gegeven bij 
een vermogen van ofwel 20 (“laag”) ofwel 50 (“hoog”) mW cm-2. De cumulatieve visuele 
huidschade gedurende 7 dagen na PDT werd gemeten als effectiviteitsmaat voor PDT. 
Een dosis van 100 Jcm-2 was even effectief voor laag als hoog vermogen belichting. 
Bij laag vermogen was PDT efficiënter, maar was de totale belichtingstijd aanzienlijk 
langer (80 versus 33 minuten). Het meest veelbelovend voor de kliniek is het geven 
van eerst laag, en later hoog vermogen belichting binnen een gefractioneerd schema. 
Het is beschreven dat wanneer er nog maar weinig PpIX over is, ook hoog vermogen 
PDT geen pijn doet bij mensen. In deze groep muizen die behandeld werden met dit 
schema was PDT effectief en de totale belichtingstijd was verkort naar 58 minuten. Het 
kan verwacht worden dat een dergelijk schema klinisch gebruikt kan worden voor effec-
tieve, efficiëntere PDT met minimale pijn. Geconcludeerd wordt dat laag vermogen PDT 
een veelbelovende behandeloptie is waarbij het belangrijk is om de PpIX fluorescentie 
tijdens PDT te meten om de geleverde dosis en daarmee de effectiviteit individueel te 
kunnen controleren.
In hoofdstukken 4, 5 en 6 worden drie studies gepresenteerd die een gezamenlijk 
thema hebben: de distributie van PpIX en de daaraan gerelateerde vasculaire effecten 
van PDT, met een focus op HAL, de hexyl ester van ALA. Vasculaire effecten kunnen de 
zuurstofvoorziening tijdens PDT belemmeren, maar ook de mate van tumor destruc-
tie na PDT beïnvloeden. In hoofdstuk 4 worden de resultaten van onderzoek in een 
kamertjesmodel op muizenhuid naar vasoconstrictie en de relatie met de hoeveelheid 
PpIX in de vaatwand beschreven. Dit kamertjesmodel maakt het mogelijk om de vaten 
die onder het behandelde gebied liggen direct te visualiseren en om fluorescentieme-
tingen te doen zonder last te hebben van absorptie of verstrooiing van het licht door 
tussenliggend weefsel. Vaatdiameters werden gemeten voor en na PDT. De resultaten 
waren vergelijkbaar tussen HAL en ALA. De meerderheid (>60%) van de arteriolen waren 
volledig vernauwd direct na PDT en dit bleef vaak zo wanneer er na 20 minuten opnieuw 
gemeten werd. De venules reageerden niet of nauwelijks. De mate van constrictie van 
arteriolen was sterk gecorreleerd met de PpIX concentratie in de vaatwand. Er wordt 
geconcludeerd dat de sterk vasoconstrictieve effecten van topicale HAL en ALA-PDT be-
langrijke gevolgen kunnen hebben voor de zuurstofvoorziening die nodig is voor PDT, 
en dat langdurige vasoconstrictie kan leiden tot ischemie en tot toegenomen celdood 
van zowel normale cellen als tumorcellen. In hoofdstuk 5 wordt eerst de microscopi-
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sche distributie van PpIX in dermaal gelegen vaten na topicale applicatie van HAL, MAL 
(de methyl ester van ALA) of ALA onderzocht, gevolgd door een studie naar de even-
tuele schade aan deze vaten na PDT. Fluorescerende antilichamen tegen CD31 werden 
gebruikt om de vaten te visualiseren. Om de PpIX distributie in de vaten te meten, werd 
de colokalisatie tussen CD31 en PpIX fluorescentie berekend met behulp van confocale 
microscopie. De vaatschade na PDT werd gescoord door visuele interpretatie van CD31 
en CD144 confocale opnamen. Vaatschade leidt tot verlies van normale kleuring van 
CD144 langs de plasma membraan, terwijl CD31 onveranderd zichtbaar blijft. De PpIX 
concentratie in de vaatwand was het hoogst voor HAL, daarna kwam ALA en MAL had 
de laagste concentratie. De vaatschade na PDT had hetzelfde patroon met de meeste 
vaatschade na HAL, daarna ALA en daarna MAL-PDT. Geconcludeerd wordt dat dermale 
vaten biologisch relevante hoeveelheden PpIX synthetiseren en dat dit resulteert in 
vaatschade na PDT. Deze effecten lijken met elkaar samen te hangen en zijn daarom 
het meest uitgesproken voor HAL. Deze studie illustreert dat de oppervlakkige vaten 
beschouwd kunnen worden als mogelijk target (primair of secundair) van PDT, en het 
ondersteunt de hypothese dat de vasculaire respons belangrijk is voor het toegenomen 
effect van gefractioneerde belichting. in hoofdstuk 6 wordt dit idee verder gebruikt om 
het effect van gefractioneerde belichting te onderzoeken voor HAL-PDT in een muizen-
model. Visuele huidschade na PDT en PpIX fluorescentie tijdens PDT werden gemeten. 
Drie belichtingsschema’s (één enkele belichting en twee gefractioneerde schema’s) 
werden vergeleken voor zowel HAL als ALA-PDT. Voor beide leidde fractioneren tot meer 
huidschade, hoewel dit effect niet statistisch significant was voor HAL. De snelheid van 
PpIX bleking was vergelijkbaar voor HAL en ALA, maar de initiële PpIX fluorescentie was 
hoger voor ALA dan voor HAL. De intensiteit van deze fluorescentiemeting wordt vooral 
wordt bepaald door de epidermale PpIX concentratie. Aangezien er geen relatie was 
tussen gemeten PpIX synthese en huidschade, lijken andere zaken zoals de vasculaire 
respons een belangrijke rol te spelen. Het potentieel van klinische HAL-PDT voor gy-
naecologische en urologische toepassingen wordt besproken alsmede methoden om 
fractionele HAL-PDT verder te verbeteren.
In hoofdstuk 7 wordt een nieuw ontworpen techniek genaamd DPS (differential 
path-length spectroscopy) besproken. Met DPS is het mogelijk om de vasculaire fy-
siologie tijdens PDT in menselijke huid te meten, en dit werd gedaan in 9 patiënten 
die behandeld werden met PDT voor actinische keratose. DPS is een spectroscopische 
techniek waarbij reflectiesignalen van twee optische fibers worden gecombineerd om 
de absorptie karakteristieken te kunnen meten in een oppervlakkig deel van de huid. 
Dit is in contrast met algemeen gebruikte diffuse metingen, waarbij signalen van dieper 
in de huid de gemeten reflectie sterk beïnvloeden. De diepte van de metingen werd 
afgestemd op de gemiddelde dikte van actinische keratose, hetgeen eerst onderzocht 
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werd in histologische coupes. De vasculaire respons tijdens PDT bleek sterk te verschil-
len voor individuele patiënten, met name de bloed volume fractie en in mindere mate 
de saturatie. Eerder kon dit niet worden aangetoond met de diffuse metingen, wat 
illustreert hoe belangrijk het is om optische technieken te gebruiken die betrouwbare 
oppervlakkige metingen toelaten. Er wordt geconcludeerd dat de patiënt-specifieke 
variabiliteit in veranderingen in de vasculaire fysiologie tijdens PDT belangrijk kan zijn 
voor de zuurstofvoorziening tijdens PDT voor individuele patiënten.
In hoofdstuk 8 wordt een studie gepresenteerd waarin een andere spectroscopische 
techniek wordt geïntroduceerd: multi-diameter single fiber reflectance (MDSFR) spec-
troscopie. Met deze techniek is het mogelijk om de volledige optische eigenschappen 
van een oppervlakkige meting in de huid te kwantificeren. Deze optische eigenschappen 
worden bepaald door de absorptiecoëfficiënt en de afgeleide verstrooiingscoëfficiënt. 
MDSFR spectroscopie is recent ontwikkeld en gevalideerd in computer simulaties en 
modellen waarin weefsel wordt nagebootst. In deze studie wordt MDSFR voor het eerst 
toegepast in mensenhuid en wordt specifiek gebruikt in combinatie met single fiber 
fluorescentie (SFF) spectroscopie. Deze combinatie maakt het mogelijk om oppervlak-
kige fluorescentiemetingen in de huid te kwantificeren door ze te corrigeren voor de 
optische eigenschappen van datzelfde oppervlakkige deel van de huid. Om het belang 
van een dergelijke correctie te illustreren werden gecorrigeerde en niet-gecorrigeerde 
waarden voor PpIX en autofluorescentie met elkaar vergeleken. Dit werd gedaan in 
22 patiënten die werden behandeld voor actinische keratose of de ziekte van Bowen 
met gefractioneerde ALA-PDT. Metingen werden genomen direct voor en direct na de 
eerste en tweede PDT belichting. Het bleek dat de gecorrigeerde waarden hoger waren 
dan de ongecorrigeerde en dat dit verschil varieerde van een factor 2,4 tot 7,5. Deze 
variabiliteit geeft de heterogeniteit van optische eigenschappen tussen individuele 
patiënten/laesies weer. Ook waren de optische eigenschappen van de huid onderhevig 
aan veranderingen tijdens PDT, en dit was weer verschillend voor individuele patiënten. 
Zowel de variabiliteit in optische eigenschappen tussen laesies als de veranderingen 
tijdens PDT illustreren het belang van de correctie hiervoor om kwantitatieve resultaten 
te verkrijgen. Dit is de eerste keer dat succesvolle kwantitatieve fluorescentie metingen 
werden verricht in een oppervlakkig deel van de huid, en onze waarden komen overeen 
met waarden die worden verkregen met chemische extractie van PpIX uit biopsieën. 
Dit is een grote stap voorwaarts in de biomedische toepassing van optische metingen. 
Niet alleen voor PDT, maar ook voor applicaties buiten PDT en ook buiten de huid. Met 
MDSFR/SFF is het nu mogelijk om de intrinsieke PpIX fluorescentie te correleren aan PDT 
uitkomst, en de PDT dosis individueel af te stemmen aan de hand van PpIX bleking tij-
dens PDT. Naast dit belang van PpIX fluorescentie, is ook de autofluorescentie mogelijk 
belangrijk voor diverse toepassingen. Ten eerste kan het als diagnostisch hulpmiddel 
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worden toegepast, aangezien de autofluorescentie van actinische keratose significant 
lager is dan die van normale huid. Een andere interessante toepassing van MDSFR/SFF is 
om de absorptie en verstrooiingseigenschappen tussen laesies te vergelijken aangezien 
deze ook mogelijk diagnostische waarde hebben. Ten tweede is de autofluorescentie in 
veel studies gerelateerd aan een verhoogd risico op verscheidene interne ziekten die 
geassocieerd zijn met cumulatieve metabole stress. Kwantitatieve MDSFR/SFF metingen 
waarbij het gesampelde volume nauwkeurig afgestemd kan worden naar de gewenste 
diepte kunnen van groot nut zijn voor dergelijk onderzoek.
hoofdstuk 9 is de discussie van het proefschrift. Er wordt gefocust op de distributie 
van PpIX en de relatie met vasculaire effecten, op het belang van het meten van PpIX 
fluorescentie tijdens PDT, en op optische technieken die oppervlakkige metingen 
mogelijk maken. Er wordt beschreven hoe deze onderwerpen nauw met elkaar samen-
hangen en elkaar beïnvloeden vanwege de complexe relatie tussen licht, zuurstof, PpIX 
en de effecten die zij hebben op het weefsel en andersom. Als voorbeeld: het lijkt op 
het eerste gezicht nuttig om veel PpIX en veel licht te hebben, maar dit leidt o.a. tot 
vasoconstrictie waardoor er misschien niet genoeg zuurstof beschikbaar is voor PDT. 
Er wordt besproken hoe het individueel monitoren van relevante parameters tijdens 
PDT kan bijdragen aan de optimalisering van PDT, en dat hiervoor accurate metingen 
nodig zijn. De recente verbeteringen in optische meettechnieken leveren een signifi-
cante bijdrage aan de mogelijkheden om PDT in mensenhuid verder te onderzoeken. De 
translationele stap tussen onze bevindingen in muizenhuid en die in mensenhuid wordt 
gemaakt en besproken wordt hoe deze kunnen worden gecombineerd om klinische 
behandelprotocollen te verbeteren. Het potentieel voor gepersonaliseerde PDT wordt 
besproken, alsmede de toekomstperspectieven van PDT en hoe het optisch monitoren 
kan bijdragen om de effectiviteit van PDT te verhogen en de pijn te verminderen.
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dankWOOrd
Promoveren doe je niet alleen. Ook ik heb dankbaar gebruik mogen maken van de hulp 
van velen die mij op diverse manieren hebben geholpen bij het tot stand komen van 
dit proefschrift. Van sommigen heb ik veel geleerd, anderen hebben mij geïnspireerd 
om nog meer mijn best te doen of hebben mij gemotiveerd om door te zetten. Weer 
anderen hebben me fysiek geholpen met het uitvoeren van de onderzoeken, of met de 
logistiek die ook komt kijken bij het doen van onderzoek. Tot slot zijn er nog diegenen 
die mij op enigerlei andere wijze hebben ondersteund. Ik wil bij deze iedereen van harte 
bedanken voor zijn of haar hulp. Een aantal mensen wil ik in het bijzonder bedanken.
Professor Neumann. Het is een eer om u als promotor en als opleider te hebben gehad. 
In beide functies hebt u altijd in mij geloofd en mij altijd in woord en daad gesteund, 
geïnspireerd en gemotiveerd. U bent degene die mijn promotie van begin tot eind 
mogelijk heeft gemaakt waarvoor ik u zeer dankbaar ben.
Dominic Robinson. Als co-promotor ben jij het nauwst betrokken geweest bij alles wat 
bij mijn promotie kwam kijken. Je hebt me altijd onvoorwaardelijk geholpen met de 
opzet van de studies, de uitvoering, het nadenken over de betekenis van de resultaten 
en met het uiteindelijke opschrijven en publiceren van de artikelen. Ik heb genoten 
van de geestdrift en het enthousiasme waarmee je mij keer op keer wilde uitleggen 
hoe het ook alweer zat met die quantummechanica of andere voor mij ingewikkelde 
natuurkundige fenomenen. Dank je voor je niet aflatende inzet gedurende al die jaren.
Riëtte de Bruijn en Angelique van der Ploeg-van den Heuvel. Zonder jullie toewijding en 
bekwaamheid in het uitvoeren van de dierexperimenten zou ik geen betrouwbare data 
hebben kunnen verkrijgen. Het is me altijd een genoegen geweest te mogen en kunnen 
vertrouwen in jullie kunde en kennis. Om nog maar te zwijgen van de extra vrije tijd in 
weekenden en vrije dagen die jullie hebben opgeofferd om bijvoorbeeld huidscores te 
verrichten. Allebei ontzettend bedankt voor alle hulp en steun.
Tamar Nijsten. Achter de schermen heb jij veel bijgedragen aan mijn wetenschappelijke 
inzicht, het nadenken over methoden en statistiek en het efficiënt schrijven. Je nam 
altijd de tijd voor een vraag van mij waarna jij in een periode van een half uur de essentie 
niet alleen begrepen had, maar ook de valkuilen had gezien en tevens oplossingen hier-
voor had bedacht plus nog wat overige verbeterpunten. Erg fijn dat je je op die manier 
belangeloos met mijn onderzoek hebt willen bemoeien.
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Loes Hollestein. Met meerdere artikelen heb jij me geholpen antwoord te vinden waar 
niemand anders antwoord op had: hoe de juiste statistiek op de juiste manier toe te 
passen. Dank je wel voor je bereidheid om me te willen helpen waarbij je altijd even 
enthousiast bent geweest om naar een oplossing te zoeken.
Ellen de Haas. Jij staat aan de basis van de samenwerking tussen de afdeling derma-
tologie en het Centrum voor Optische Diagnostiek en Therapie. Dankzij jouw inzet 
hiervoor heb ik de mogelijkheid gehad om deze samenwerking verder op te pakken en 
te continueren waardoor dit proefschrift mogelijk is geworden.
Alle overige co-auteurs van de artikelen wil ik bij deze nogmaals bedanken voor jullie 
bijdrage in de totstandkoming hiervan.
Alle mensen die hebben bijgedragen aan de inclusie van patiënten zowel in het Erasmus 
MC als in het Amphia ziekenhuis te Breda bedankt. En natuurlijk de patiënten zelf enorm 
bedankt dat jullie hebben willen meewerken.
Van degenen die in praktische zin hebben bijgedragen aan het behandelen/plannen 
van patiënten wil ik Jolanda, Jeanette, Elsbeth, Franka en Hilly uit Rotterdam en Ans uit 
Breda bedanken hiervoor.
Alle(oud-)collega AIOS, dermatologen en onderzoekers van de afdeling dermatologie 
in het Erasmus, bedankt voor de gezellige tijd die ik met jullie heb gehad tijdens mijn 
opleiding waarin ik ook het grootste deel van mijn onderzoek heb gedaan. In het 
bijzonder gaat mijn dank uit naar Willemijn, Renate, Petra, Rick, Ewout, Hanke, Suzan, 
Marlies, Anke, Michelle, Manon, Annette, Esmee, Hessel, Hilde, Enes, Lisette, Armanda, 
Emoke, Wendy, Gijs, Simone, Femke, Bing, Errol, Eric, Annik, Michael, Kai, Annieke, Tan-
nja, Barbera, Ria, Mimi en Rennie.
Mijn familie en dan vooral mijn ouders die aan de basis hebben gestaan van mijn leer-
gierigheid en onderzoekende aard en mij daarin altijd hebben gestimuleerd. Dank jullie 
wel hiervoor.
Lieve Marijke, jij beweert dat je me vrijwel niet hebt geholpen met mijn onderzoek. Je 
hebt het mis. Je hebt me geleerd om te gaan met de tegenslagen die horen bij het 
promoveren. Zonder jou zou ik wellicht niet het vertrouwen hebben gehad om door te 
gaan. Je hebt altijd voor me klaargestaan en altijd een luisterend oor gehad. Je hebt het 
meest in mij geloofd van iedereen. Daarom.
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Bij het bekijken van de cover van dit boekje denkt u misschien: “wat ziet die foto er gek 
uit”. Het klopt dat er iets ongewoons aan de hand is. Wat u ziet is niet gewoon een foto 
van kiezelsteentjes, maar er zit een patroon in verborgen in de vorm van een autoste-
reogram. Dit kunt u zichtbaar maken door als het ware “door de foto heen te kijken”. 
Zoek op de voorkant van het boekje naar een wat grotere steen in het midden van de 
foto. U zult zien dat ongeveer 3 cm naar links en rechts deze steen opnieuw te vinden 
is in een zichzelf repeterend patroon. Wanneer u focust op iets dat achter de foto ligt, 
kunt u twee stenen laten “samenvallen” zodat uw linkeroog de linker steen ziet en uw 
rechteroog de rechter. Dan verschijnt plotseling in 3-D het woord “EUREKA”. Dit autos-
tereogram staat symbool voor de wetenschap. Eerst is er het gevoel dat er meer aan de 
hand is met de foto. Deze verwondering prikkelt ons om te onderzoeken en ontdekken 
wat dat dan precies is. Dankzij ons menselijk vermogen om patronen te herkennen 
kunnen we uiteindelijk de ruis van de informatie scheiden. Wanneer dit lukt zouden 
we het zogenaamde “EUREKA moment” kunnen ervaren. Archimedes heeft dit naar 
verluidt geroepen terwijl hij naakt door de straten van Syracuse rende, nadat hij in bad 
de naar hem vernoemde wet bedacht had. In het geval van dit proefschrift is het vooral 
bedoeld als een ironische verwijzing naar stelling 10 die luidt: The most exciting phrase 
to hear in science, the one that heralds new discoveries, is not ‘Eureka!’ but ‘That’s funny...’ 
van Isaac Asimov. Tevens vormen de eerste letters EUR de afkorting van de Erasmus 
Universiteit Rotterdam. EKA kan van alles betekenen volgens Google. Overigens is 
de originele foto gemaakt aan het prachtige Lake Wakatipu in Queenstown op het 
Zuidereiland van Nieuw Zeeland. Tussen de vele steentjes kan men daar ook op zoek 
naar kiezels van het waardevolle gesteente nefriet jade. Hiervoor is trouwens wel weer 
een heel andere zoekstrategie nodig.
